TABLE OF CONTENTS
As filed with the Securities and Exchange Commission on November 14, 2024.
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Gyre Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| | | |
Delaware | | | 56-2020050 |
(State or other jurisdiction of
incorporation or organization) | | | (I.R.S. Employer
Identification Number) |
| | | |
12770 High Bluff Drive
Suite 150
San Diego, CA 92130
(Address, including zip code, and telephone number, including area code, of registrant’s
principal executive offices)
Han Ying, Ph.D.
Chief Executive Officer
Gyre Therapeutics, Inc.
12770 High Bluff Drive
Suite 150
San Diego, CA 92130
(858) 567-7770
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Ryan A. Murr
Branden C. Berns
Gibson, Dunn & Crutcher LLP
One Embarcadero Center, Suite 2600
San Francisco, CA 94111-3715
(415) 393-8200
Approximate date of commencement of proposed sale to the public: From time to time after this registration statement becomes effective.
If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☒
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐
If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | | | | | | | |
Large accelerated filer | | | ☐ | | | | | | Accelerated filer | | | ☐ |
Non-accelerated filer | | | ☒ | | | | | | Smaller reporting company | | | ☒ |
| | | | | | | | | Emerging growth company | | | ☐ |
| | | | | | | | | | | | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until this registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.
TABLE OF CONTENTS
The information in this prospectus is not complete and may be changed. We may not sell these securities or accept an offer to buy these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting offers to buy these securities in any jurisdiction where such offer or sale is not permitted.
SUBJECT TO COMPLETION, DATED NOVEMBER 14, 2024
PROSPECTUS
COMMON STOCK
PREFERRED STOCK
DEBT SECURITIES
WARRANTS
UNITS
From time to time, we may issue, in one or more series or classes, up to $150,000,000 in aggregate principal amount of our common stock, preferred stock, debt securities, warrants and/or units, at prices and on terms that we will determine at the time of the offering.
This prospectus provides you with a general description of the securities we may offer. Each time we offer securities, we will provide specific terms of the securities offered in a supplement to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. We may not sell any securities under this prospectus without delivery of the applicable prospectus supplement. If information in any prospectus supplement is inconsistent with the information in this prospectus, then the information in that prospectus supplement will apply and will supersede the information in this prospectus.
You should read this prospectus, the applicable prospectus supplement and any related free writing prospectus carefully, as well as any documents incorporated by reference, before you invest in any of the securities being offered.
A significant portion of our business is operated through our indirectly majority-owned subsidiary in the People’s Republic of China (the “PRC”), Beijing Continent Pharmaceutical Co., Ltd. (d/b/a Gyre Pharmaceuticals, Inc.) (“Gyre Pharmaceuticals”). Such structure involves unique legal and operational risks to investors in our common stock. In particular, the PRC government has significant authority to exert influence on the ability of a company with substantive operations in the PRC, such as us, to conduct its business, accept foreign investments or list on a U.S. or other foreign exchanges. For example, we face risks associated with regulatory approvals of offshore offerings, anti-monopoly regulatory actions, oversight on cybersecurity and data privacy. Such risks could result in a material change in our operations and/or the value of our common stock or could significantly limit or completely hinder our ability to offer or continue to offer our common stock to investors and cause the value of such common stock to significantly decline or become worthless. As we are a company with substantive business operations in the PRC, you should pay special attention to disclosures included in our most recent annual report on Form 10-K incorporated by reference in this prospectus and risk factors included herein.
In addition, our auditor is headquartered in mainland China, a jurisdiction where the Public Company Accounting Oversight Board (“PCAOB”) was unable to conduct inspections without the approval of the PRC authorities. Trading in our common stock on the Nasdaq or over-the-counter may be prohibited, and as a result, our common stock may be delisted under the Holding Foreign Companies Accountable Act (“HFCAA”) if the PCAOB determines that it has been unable to inspect or investigate completely our auditor located in the PRC for two consecutive years. On December 16, 2021, the PCAOB issued the HFCAA Determination Report to notify the Securities and Exchange Commission (the “SEC”) of its determinations that the PCAOB was unable to inspect or investigate completely registered public accounting firms headquartered in mainland China and Hong Kong, including our auditor. On December 15, 2022, the PCAOB issued a report that vacated its December 16, 2021 determination and removed mainland China and Hong Kong from the list of jurisdictions where it is unable to inspect or investigate completely registered public accounting firms. As a result, we were not identified as a “Commission-Identified Issuer” under the HFCAA upon filing of our annual report on Form 10-K for the year ended December 31, 2023. However, whether the PCAOB will continue to be able to satisfactorily conduct inspections and investigations of PCAOB-registered public accounting firms headquartered in mainland China and Hong Kong is subject to uncertainty and depends on a number of factors out of our, and our auditor’s, control, including positions taken by authorities of the PRC.
The PCAOB is expected to continue to demand complete access to inspections and investigations against accounting firms headquartered in mainland China and Hong Kong in the future. The PCAOB is required under the HFCAA to make its determination on an annual basis with regards to its ability to inspect and investigate completely accounting firms based in the mainland China and Hong Kong. The possibility of being a “Commission-Identified Issuer” and risk of delisting could continue to adversely affect the trading price of our securities. If the PCAOB determines in the future that it no longer has full access to inspect and investigate accounting firms headquartered in mainland China and Hong Kong and we continue to use such accounting firm to conduct audit work, we would be identified as a “Commission-Identified Issuer” under the HFCAA following the filing of the annual report for the relevant fiscal year, and if we were so identified for two consecutive years, trading in our securities on U.S. markets would be prohibited under the HFCAA.
The PRC government has oversight over the conduct of our business and its laws, regulations and policies may affect our operations. The PRC government has recently published new policies that affected certain industries with respect to matters such as cybersecurity, data privacy, antitrust and competition, foreign investments, and overseas listings, and we cannot rule out the possibility that it will in the future release regulations or policies regarding our industry that could adversely affect our business, financial condition and results of operations. Furthermore, the PRC regulatory authorities have recently issued new laws and regulations to exert more oversight and control over overseas securities offerings and other capital markets activities and foreign investment in PRC-based companies. Any such action, once taken by the PRC regulatory authorities, could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or in extreme cases, become worthless. For additional information, see “Risk Factors - Risks Related to Our Business Operations in the PRC” in our most recent annual report on Form 10-K incorporated by reference in this prospectus.
Our shares of common stock are listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “GYRE.” The last reported sale price of our common stock on Nasdaq on November 11, 2024 was $16.80 per share.
Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading “Risk Factors” contained in this prospectus beginning on page
8 and any applicable prospectus supplement, and under similar headings in the other documents that are incorporated by reference into this prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
Prospectus dated , 2024
TABLE OF CONTENTS
This prospectus is a part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission (the “SEC” or the “Commission”) utilizing a “shelf” registration process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one or more offerings up to a total dollar amount of $150,000,000. This prospectus provides you with a general description of the securities we may offer.
Each time we sell securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. You should carefully read both this prospectus and any prospectus supplement together with additional information under the headings “Where You Can Find More Information” and “Incorporation of Certain Information by Reference.”
We have not authorized anyone to provide you with any information other than that contained or incorporated by reference in this prospectus and any applicable prospectus supplement, along with the information contained in any free writing prospectuses we have authorized for use in connection with a specific offering. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. This prospectus, any applicable supplement to this prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, any applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.
You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date.
Unless the context otherwise requires, we use the terms “Gyre,” “company,” “we,” “us,” and “our” in this prospectus to refer to Gyre Therapeutics, Inc. and, where appropriate, our subsidiaries.
TABLE OF CONTENTS
CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
This prospectus, including the documents that we incorporate by reference, contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of historical facts contained in this prospectus, including statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, business trends and other information referred to in the section entitled “Risk Factors” in this prospectus and the sections entitled “Business,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2023, which is incorporated by reference herein, are forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan,” “anticipate,” “target,” “forecast,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. Forward-looking statements are not historical facts and reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements.
There are a number of risks, uncertainties and other important factors that could cause our actual results to differ materially from the forward-looking statements contained in this prospectus. Such risks, uncertainties and other important factors include, among others, the risks, uncertainties and factors set forth in “Risk Factors,” and the following risks, uncertainties and factors:
• | the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other positive results; |
• | our ability to develop a pipeline of product candidates to address unmet needs in the treatment of organ fibrosis and other inflammatory diseases; |
• | the timing, progress and results of clinical trials for F351 (Hydronidone) from the Phase 2 trial, F573 from the Phase 2 clinical trial, ETUARY from the Phase 2/3 clinical trial, and other product candidates we may develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the studies or trials will become available and research and development programs; |
• | the timing, scope and likelihood of regulatory filings and approvals, including timing of investigational new drugs (an “IND” or “INDs”) and final U.S. Food & Drug Administration approval of F351 for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis (“MASH”) and chronic hepatitis B (“CHB”), ETUARY for the treatment of dermatomyositis-related interstitial lung disease (“DM-ILD”) and sclerosis-related interstitial lung disease (“SSc-ILD”), F528 for the treatment of chronic obstructive pulmonary disease, F230 for the treatment of pulmonary arterial hypertension, and any other future product candidates; |
• | the timing, scope or likelihood of foreign regulatory filings and approvals; |
• | our expectations regarding the future pursuit of product development efforts, including whether we will pursue such efforts, estimates regarding the expenses, future revenue, timing of any future revenue, capital requirements and need for additional financing related to such efforts, the timing of and our ability to pursue such efforts and our plans to develop and, if approved, subsequently commercialize any product candidates resulting from such efforts; |
• | our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash and investments; |
• | our ability to develop and advance current product candidates and programs into, and successfully complete, clinical studies; |
• | our manufacturing, commercialization and marketing capabilities and strategy; |
• | plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy; |
TABLE OF CONTENTS
• | the need to hire additional personnel and our ability to attract and retain such personnel; |
• | the size of the market opportunity for our product candidates, including estimates of the number of patients who suffer from the diseases we are targeting; |
• | expectations regarding the approval and use of our product candidates in combination with other drugs; |
• | expectations regarding the potential for accelerated approval or other expedited regulatory designation; |
• | our competitive position and the success of competing therapies that are or may become available; |
• | estimates of the number of patients that we will enroll in our clinical trials; |
• | the beneficial characteristics and the potential safety, efficacy and therapeutic effects of our product candidates; |
• | our ability to obtain and maintain regulatory approval of our product candidates and our expectations regarding particular lines of therapy; |
• | plans relating to the further development of our product candidates, including additional indications we may pursue; |
• | existing regulations and regulatory developments in the PRC, the United States, Europe (the “EU”), and other jurisdictions; |
• | our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering ETUARY, F351, F573, F528, and F230, and other product candidates we may develop, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights; |
• | our continued reliance on third parties to conduct additional clinical trials of our product candidates and for the manufacture of our product candidates for clinical trials; |
• | our relationships with patient advocacy groups, key opinion leaders, regulators, the research community and payors; |
• | our ability to obtain and negotiate favorable terms of, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates; |
• | the pricing and reimbursement of ETUARY, F351, F573, F528, and F230, and other product candidates we may develop, if approved; |
• | the rate and degree of market acceptance and clinical utility of F351, and other product candidates the Company may develop; |
• | our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; |
• | our financial performance; |
• | the period over which we estimate our existing cash will be sufficient to fund our planned operating expenses and capital expenditure requirements; |
• | expectations about the continued listing of our common stock on Nasdaq; |
• | the impact of laws and regulations; and |
• | expectations regarding the period during which we will qualify as a smaller reporting company under the Exchange Act. |
There may be other factors that may cause our actual results to differ materially from the forward-looking statements, including factors disclosed in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, which are incorporated by reference herein. You should evaluate all forward-looking statements made in this prospectus in the context of these risks and uncertainties.
TABLE OF CONTENTS
These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this prospectus, any accompanying prospectus supplement, information incorporated by reference herein or therein, and any related free-writing prospectus. In addition, we cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. All forward-looking statements contained in this prospectus are made as of the date of hereof and we undertake no obligation to publicly update or review any forward-looking statements to reflect subsequent events or circumstances.
TABLE OF CONTENTS
We are a commercial-stage biotechnology company with a record of success in developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. Fibrotic diseases represent a large patient population with significant unmet medical needs. Fibrosis involves a complex, multi-stage process with multiple pathways. While there are numerous potential targets for anti-fibrotic therapy, both established and emerging, addressing a single molecular pathway may not be sufficient to prevent, halt, or reverse fibrosis.
Our strategy is to use our experience in the successful development and commercialization of ETUARY® (Pirfenidone) to expand into new indications and develop similar drug candidates. Pirfenidone, the first anti-fibrotic drug approved for idiopathic pulmonary fibrosis (“IPF”) in Japan, the European Union, the United States, and the PRC, is a small molecule drug that inhibits the synthesis of Transforming Growth Factor -ß1 (“TGF-ß1”), Tumor Necrosis Factor-α, and other fibrosis and inflammation modulators. We have obtained approval for ETUARY (pirfenidone) in the PRC for IPF.
Gyre Pharmaceuticals successfully advanced Pirfenidone from research and development to commercialization in the PRC for the treatment of IPF. In addition to IPF, Pirfenidone is undergoing three additional Phase 3 clinical trials for connective tissue disease-associated interstitial lung diseases (sclerosis-related interstitial lung disease and dermatomyositis-related interstitial lung disease) and pneumoconiosis to broaden its indications and market. In May 2024, Gyre Pharmaceuticals executed a comprehensive agreement with Jiangsu Wangao Pharmaceuticals Co., Ltd. to acquire the commercial rights to nintedanib, a small-molecule drug for the treatment of IPF. With this acquisition, we acquired the other product approved for the treatment of IPF, which is currently approved globally for the treatment of IPF. Nintedanib is expected to provide patients more choices and benefits, and further enhance Gyre Pharmaceuticals’ leading position in the pulmonary fibrosis market. Gyre Pharmaceutical is planning to initiate commercialization of the nintedanib product in the PRC in 2025, which is anticipated to offset any declines in ETUARY sales as a result of the fluctuations in the Chinese economy significantly affecting demand for anti-fibrosis drugs and decreasing healthcare spending generally.
F351, our lead development candidate in both the United States and the PRC, is a structural derivative of ETUARY (Pirfenidone). It is a new oral chemical entity with an anti-fibrotic, TGF-ß1-targeting mechanism of action. Studies suggest that F351 and its major metabolites have minimal drug-drug interaction risks. We are prioritizing F351 for the treatment of liver fibrosis due to the large potential addressable market and significant unmet need.
Gyre Pharmaceuticals has completed a Phase 2 trial of F351 in the PRC for CHB-associated liver fibrosis. The Phase 2 trial showed that F351 was well-tolerated without notable toxicity and patients treated showed statistically-significant improvement of liver fibrosis, with the best efficacy results achieved at 270 mg/day dosing. Based on these results, a confirmatory Phase 3 trial is ongoing in the PRC with a primary endpoint of the reduction of the liver fibrosis score (Ishak Scoring System) by at least one stage after taking F351 in combination with Entecavir. In October 2024, the last patient completed the 52-week pivotal Phase 3 trial. Gyre Pharmaceuticals expects to report top-line data from this trial by the first quarter of 2025.
In the United States, we have completed a Phase 1 clinical trial of F351 in healthy volunteers. Following results from the PRC Phase 3 trial in CHB-associated liver fibrosis and pending approval of an IND submission, we expect to initiate a Phase 2 trial to evaluate F351 for the treatment of MASH-associated liver fibrosis in 2025. We cannot guarantee that a Phase 2 trial will be initiated or estimate the funding needed for such trial at this time, but may need to raise additional capital to fund this program.
In parallel, we are also conducting a randomized, double-blind, placebo-controlled Phase 2 clinical trial in the PRC to assess the safety and efficacy of F573, a caspase inhibitor for the treatment of acute/acute on-chronic liver failure. In addition, in May 2024, we obtained the approval from the PRC’s National Medical Products Administration (“NMPA”) for the IND to launch a new clinical trial in the PRC of another new drug candidate, F230, a selective endothelin receptor agonist for the treatment of pulmonary arterial hypertension. We are preparing for the anticipated launch of the clinical trial in the PRC. We are also evaluating F528, a novel anti-inflammation agent that targets the inhibition of multiple inflammatory cytokines, in preclinical studies as a potential first-line therapy for the treatment of chronic obstructive pulmonary disease. In June 2024, Gyre Pharmaceuticals received approval from the NMPA for avatrombopag maleate tablets for the treatment of
TABLE OF CONTENTS
thrombocytopenia (“TP”) associated with chronic liver disease (“CLD”) in adult patients undergoing elective diagnostics procedures or therapy. TP is the most common hematologic complication in patients with CLD and can be life threatening in severe cases. Avatrombopag is an oral thrombopoietin receptor agonist. Avatrombopag was approved by the U.S. Food and Drug Administration for the treatment of adults with CLD-associated TP in May 2018, and its indication was subsequently expanded to include the treatment of immune thrombocytopenia in June 2019. Gyre Pharmaceuticals acquired avatrombopag under a transfer agreement with Nanjing Healthnice Pharmaceutical Technology, Co., Ltd. (“Nanjing Healthnice”) in June 2021 and is planning to start commercializing the avatrombopag product by the first half of 2025.
A significant portion of our business is operated through Gyre Pharmaceuticals. Such structure involves unique legal and operational risks to investors in our common stock. In particular, the PRC government has significant authority to exert influence on the ability of a company with substantive operations in the PRC, such as us, to conduct its business, accept foreign investments or list on a U.S. or other foreign exchanges. For example, we face risks associated with regulatory approvals of offshore offerings, anti-monopoly regulatory actions, oversight on cybersecurity and data privacy. Such risks could result in a material change in our operations and/or the value of our common stock or could significantly limit or completely hinder our ability to offer or continue to offer our common stock to investors and cause the value of such common stock to significantly decline or become worthless. As we are a company with substantive business operations in the PRC, you should pay special attention to disclosures included in our most recent annual report on Form 10-K incorporated by reference in this prospectus and risk factors included herein.
In addition, our auditor is headquartered in mainland China, a jurisdiction where the PCAOB was unable to conduct inspections without the approval of the Chinese authorities. Trading in our common stock on the Nasdaq or over-the-counter may be prohibited, and as a result, our common stock may be delisted under the HFCAA if the PCAOB determines that it has been unable to inspect or investigate completely our auditor located in the PRC for two consecutive years. On December 16, 2021, the PCAOB issued the HFCAA Determination Report to notify the SEC of its determinations that the PCAOB was unable to inspect or investigate completely registered public accounting firms headquartered in mainland China and Hong Kong, including our auditor. On December 15, 2022, the PCAOB issued a report that vacated its December 16, 2021 determination and removed mainland China and Hong Kong from the list of jurisdictions where it is unable to inspect or investigate completely registered public accounting firms. As a result, we were not identified as a “Commission-Identified Issuer” under the HFCAA upon filing of our annual report on Form 10-K for the year ended December 31, 2023. However, whether the PCAOB will continue to be able to satisfactorily conduct inspections and investigations of PCAOB-registered public accounting firms headquartered in mainland China and Hong Kong is subject to uncertainty and depends on a number of factors out of our, and our auditor’s, control, including positions taken by authorities of the PRC.
The PCAOB is expected to continue to demand complete access to inspections and investigations against accounting firms headquartered in mainland China and Hong Kong in the future. The PCAOB is required under the HFCAA to make its determination on an annual basis with regards to its ability to inspect and investigate completely accounting firms based in the mainland China and Hong Kong. The possibility of being a “Commission-Identified Issuer” and risk of delisting could continue to adversely affect the trading price of our securities. If the PCAOB determines in the future that it no longer has full access to inspect and investigate accounting firms headquartered in mainland China and Hong Kong and we continue to use such accounting firm to conduct audit work, we would be identified as a “Commission-Identified Issuer” under the HFCAA following the filing of the annual report for the relevant fiscal year, and if we were so identified for two consecutive years, trading in our securities on U.S. markets would be prohibited under the HFCAA.
The PRC government has oversight over the conduct of our business and its laws, regulations and policies may affect our operations. The PRC government has recently published new policies that affected certain industries with respect to matters such as cybersecurity, data privacy, antitrust and competition, foreign investments, and overseas listings, and we cannot rule out the possibility that it will in the future release regulations or policies regarding our industry that could adversely affect our business, financial condition and results of operations. Furthermore, the PRC regulatory authorities have recently issued new laws and regulations to exert more oversight and control over overseas securities offerings and other capital markets activities and foreign investment in PRC-based companies. Any such action, once taken by the PRC regulatory authorities, could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and
TABLE OF CONTENTS
cause the value of such securities to significantly decline or in extreme cases, become worthless. For additional information, see “Risk Factors - Risks Related to Our Business Operations in the PRC” in our most recent annual report on Form 10-K incorporated by reference in this prospectus.
Corporate Information
We were incorporated in Delaware in 1997 as a wholly-owned subsidiary of R.J. Reynolds Tobacco Company. In August 2000, we became an independent company when we issued and sold stock to venture capital investors. On August 20, 2015, pursuant to the merger agreement between Targacept, Inc. and Catalyst Biosciences, Inc. (“Private Catalyst”), we acquired Private Catalyst and on August 20, 2015, we changed our name from Targacept, Inc. to Catalyst Biosciences, Inc. On October 30, 2023, we consummated a business combination pursuant to which we acquired an indirect controlling interest in Gyre Pharmaceuticals. At the closing, we changed our name from Catalyst Biosciences, Inc. to Gyre Therapeutics, Inc. Our principal executive offices are located at 12770 High Bluff Drive, Suite 150, San Diego, CA 92130, and our telephone number is (858) 567-7770. Our website address is www.gyretx.com. We do not incorporate the information on, or accessible through, our website into this prospectus, and you should not consider any information on, or accessible through, our website as part of this prospectus.
TABLE OF CONTENTS
Investing in our securities involves risks. You should carefully consider the risks, uncertainties and other factors described in our most recent Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that we have filed or will file with the SEC, and in other documents which are incorporated by reference into this prospectus, as well as the risk factors and other information contained below or incorporated by reference into any accompanying prospectus supplement before investing in any of our securities. Our business, financial condition, results of operations, cash flows or prospects could be materially and adversely affected by any of these risks. The risks and uncertainties described in the documents incorporated by reference herein are not the only risks and uncertainties that you may face.
For more information about our SEC filings, please see “Where You Can Find More Information” and “Incorporation of Certain Information by Reference.”
The PRC government may intervene in, influence or exert control over Gyre Pharmaceuticals’ operations at any time, which could result in an adverse change in our operations.
The PRC government has some oversight and discretion over the conduct of our business in the PRC and may intervene in, influence or exert control over our operations as the government deems appropriate to further regulatory, political and societal goals. The PRC government has recently published new policies that significantly affected certain industries, and we cannot rule out the possibility that it will in the future do the same regarding our industry, including policies that could require us to seek permission from the PRC authorities to continue to operate our business in the PRC.
The central or local governments may impose new, stricter regulations or interpretations of existing regulations that would require additional expenditures and efforts on our part to ensure our compliance with such regulations or interpretations. For instance, regulations introduced by the NMPA concerning drug inspection, investigation, evidence collection and disposal are relatively new, and because of the limited volume of published judicial decisions, which are non-binding in nature, the interpretation and enforcement of these laws and regulations are uncertain. In addition, the implementation of laws and regulations may be in part based on government policies and internal rules that are subject to the interpretation and discretion of different government agencies (some of which are not published on a timely basis or at all) that may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules until sometime after the violation. The imposition of new regulations or interpretations of existing regulations can occur quickly with little advance notice. We may incur penalties for any failure to comply with PRC laws and regulations. In addition, any litigation in the PRC, regardless of outcome, may be protracted and result in substantial costs and diversion of resources and management attention. Since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy. If we were to become subject to the direct intervention or influence of the PRC government at any time due to changes in laws or other unforeseeable reasons, it may require a material and potentially adverse change in our operations in the PRC.
Furthermore, the PRC government has indicated an intent to increase oversight and control over offerings of companies with significant operations in the PRC that are to be conducted in foreign markets. For example, in July 2021, the relevant PRC government authorities made public the Opinions on Strictly Scrutinizing Illegal Securities Activities in Accordance with the Law. These opinions emphasized the need to strengthen the administration over illegal securities activities and the supervision of overseas listings by China-based companies and proposed to take effective measures, such as promoting the construction of relevant regulatory systems to deal with the risks and incidents faced by China-based overseas-listed companies. In February 2023, the China Securities Regulatory Commission (the “CSRC”) released the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Enterprises (the “Trial Measures”), which came into effect on March 31, 2023. The Trial Measures comprehensively improve and reform the existing regulatory regime for overseas offering and listing of PRC domestic companies’ securities and regulate both direct and indirect overseas offering and listing of PRC domestic companies’ securities by adopting a filing-based regulatory regime.
In February 2023, the CSRC and other PRC governmental authorities jointly issued the Provisions on Strengthening the Confidentiality and Archives Administration of Overseas Securities Offering and Listing by Domestic Companies (the “Confidentiality Provisions”), which came into effect on March 31, 2023. According
TABLE OF CONTENTS
to the Confidentiality Provisions, PRC domestic companies that directly or indirectly conduct overseas offerings and listings shall strictly abide by the laws and regulations on confidentiality when providing or publicly disclosing, whether directly or through their overseas listed entities, materials to securities services providers. In the event such materials contain state secrets or working secrets of government agencies, PRC domestic companies shall first obtain approval from authorities, and file with the secrecy administrative department at the same level with the approving authority; in the event that such materials, if divulged, will jeopardize national security or public interest, PRC domestic companies shall comply with procedures stipulated by national regulations. Given the recent nature of the introduction of the Trial Measures and the Confidentiality Provisions, there remains significant uncertainty as to the interpretation and implementation of regulatory requirements related to overseas securities offerings and other capital markets activities.
If (i) we mistakenly conclude that certain regulatory filings, permissions and approvals are not required or (ii) applicable laws, regulations, or interpretations change and (iii) we are required to obtain such filings, permissions or approvals in the future, we may be unable to obtain them in a timely manner, or at all, and such filings, permissions or approvals may be denied or rescinded even if obtained. We may face adverse actions or sanctions by the CSRC or other PRC regulatory agencies if we are unable to comply with such requirements, which may result in fines and penalties, restrictions on our operations, having to delist from a stock exchange outside of China, the halting of securities offerings to foreign investors and other actions that could materially and adversely affect our operations and the interest of our investors.
In addition, the risks that the PRC government may intervene or influence our operations in the PRC at any time could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless.
The enacted “Holding Foreign Companies Accountable Act” and the “Accelerating Holding Foreign Companies Accountable Act” call for additional and more stringent criteria to be applied to emerging market companies upon assessing the qualification of their auditors, especially the non-U.S. auditors who are not inspected by the PCAOB. These developments could add uncertainties to the market for our common stock.
The HFCAA requires certain issuers of securities to establish that they are not owned or controlled by a foreign government. Specifically, an issuer must make this certification if the PCAOB is unable to audit specified reports because the issuer has retained a foreign public accounting firm not subject to inspection by the PCAOB. Furthermore, if the PCAOB is unable to inspect the issuer’s public accounting firm for three consecutive years, the issuer’s securities are banned from trading on a national exchange or through other methods. In December 2022, the AHFCAA amended the HFCAA by decreasing the number of non-inspection years from three to two, thus reducing the time period before our common stock may be prohibited from trading or delisted if the PCAOB were to determine that it could not inspect our auditor.
In March 2021, the SEC adopted interim final amendments to implement congressionally mandated submission and disclosure requirements of the HFCAA. The interim final amendments will apply to registrants that the SEC identifies as having filed an annual report on Forms 10-K, 20-F, 40-F or N-CSR with an audit report issued by a registered public accounting firm that is located in a foreign jurisdiction and that the PCAOB has determined it is unable to inspect or investigate completely because of a position taken by an authority in that jurisdiction. In December 2021, the SEC adopted amendments finalizing such rules to require that any such identified registrant is required to submit documentation to the SEC establishing that it is not owned or controlled by a governmental entity in that foreign jurisdiction, and is also required to disclose in the registrant’s annual report the audit arrangements of, and governmental influence on, such a registrant.
In December 2021, the PCAOB issued a Determination Report which found that the PCAOB was then unable to inspect or investigate completely registered public accounting firms headquartered in: (1) mainland China of the PRC, because of a position taken by one or more authorities in mainland China; and (2) Hong Kong, a Special Administrative Region and dependency of the PRC, because of a position taken by one or more authorities in Hong Kong. The PCAOB has made such designations as mandated under the HFCAA. Pursuant to each annual determination by the PCAOB, the SEC will, on an annual basis, identify issuers that have used non-inspected audit firms and thus are at risk of such suspensions in the future.
In August 2022, the CSRC, the Ministry of Finance of the PRC, and the PCAOB signed a Statement of Protocol (the “Protocol”), governing inspections and investigations of audit firms based in the PRC and Hong Kong. Pursuant to the Protocol, the PCAOB shall have independent discretion to select any issuer audits
TABLE OF CONTENTS
for inspection or investigation and has the unfettered ability to transfer information to the SEC. In December 2022, the PCAOB determined that the PCAOB was able to secure complete access to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong and voted to vacate its previous determinations to the contrary. However, should PRC authorities obstruct or otherwise fail to facilitate the PCAOB’s access in the future, the PCAOB will consider the need to issue a new determination. Notwithstanding the foregoing, if the PCAOB is not able to inspect and investigate completely our auditor’s work papers in China, you may be deprived of the benefits of such inspection which could result in limitation or restriction to our access to the U.S. capital markets and trading of our securities may be prohibited under the HFCAA.
Our auditor, Grant Thornton Zhitong Certified Public Accountants LLP, an independent public accounting firm registered with the PCAOB, and an auditor of publicly traded companies in the U.S., is subject to laws in the U.S. pursuant to which the PCAOB conducts regular inspections to assess its compliance with the applicable professional standards. Our auditor is headquartered in mainland China and was inspected by the PCAOB for the first time in July 2024 and was identified as a firm subject to the determinations announced by the PCAOB in December 2021. Should the PCAOB be unable to fully conduct inspection of our auditor’s work papers in mainland China, it will make it difficult to evaluate the effectiveness of our auditor’s audit procedures or equity control procedures. Investors may consequently lose confidence in our reported financial information and procedures or quality of the financial statements, which would adversely affect us and our securities. Moreover, if trading in our securities is prohibited under the HFCAA in the future because the PCAOB determines that it cannot inspect or fully investigate our auditor at such future time, if our securities were then traded on an exchange, that exchange may determine to delist our securities.
TABLE OF CONTENTS
We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Unless otherwise specified in a prospectus supplement accompanying this prospectus, the net proceeds from the sale by us of the securities to which this prospectus relates will be used for development, manufacturing and scale-up, as well as for working capital and general corporate purposes. We may also use a portion of the proceeds to license, acquire or invest in new programs or for drug development activities related to such programs, however, we have no current commitments to do so. Our expected use of proceeds from the sale of the securities offered hereby represents our current intentions based on our present plans and business condition. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the proceeds to be received from the sale of the securities offered hereby or the amounts that we will actually spend on the uses set forth above.
Pending the use of the net proceeds, we may invest the proceeds in interest-bearing, investment-grade securities, certificates of deposit or government securities. When we offer and sell the securities to which this prospectus relates, the prospectus supplement related to such offering will set forth our intended use of the proceeds, if any, received from the sale of such securities.
TABLE OF CONTENTS
We have no present intention to pay cash dividends on our common stock for the foreseeable future. Any determination to pay dividends to holders of our common stock will be at the discretion of our board of directors and will depend on many factors, including our financial condition, results of operations, liquidity, earnings, projected capital and other cash requirements, legal requirements, restrictions in the agreements governing any indebtedness we may enter into, business prospects and other factors that our board of directors deems relevant.
TABLE OF CONTENTS
This prospectus contains summary descriptions of the securities we may offer from time to time. These summary descriptions are not meant to be complete descriptions of each security. The particular terms of any security will be described in the applicable prospectus supplement.
TABLE OF CONTENTS
DESCRIPTION OF SECURITIES
The following is a summary of the material terms of our capital stock, as well as other material terms of certain provisions of Delaware law, our restated certificate of incorporation (as amended from time to time, our “certificate of incorporation”), and our amended and restated bylaws (as amended from time to time, our “bylaws”). This summary does not purport to be complete and is qualified in its entirety by the provisions of our certificate of incorporation and our bylaws. For more information on how you can obtain our certificate of incorporation and our bylaws, see the heading “Where You Can Find Additional Information.”
Our authorized capital stock consists of 400,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share.
As of September 30, 2024, 85,769,526 shares of our common stock were issued and outstanding, which excludes 7,701,462 shares issued in Gyre’s name to a stock plan administrator.
Common Stock
Our certificate of incorporation authorizes the issuance of up to 400,000,000 shares of our common stock. All outstanding shares of our common stock are validly issued, fully paid and nonassessable.
Dividends
Subject to preferential dividend rights of any other class or series of stock, the holders of shares of our common stock are entitled to receive dividends, including dividends of our stock, as and when declared by our board of directors, subject to any limitations imposed by law and to the rights of the holders, if any, of our preferred stock. On September 20, 2022, we paid a special, one-time cash dividend of approximately $45.0 million (or $1.43 per share) to our common stockholders of record as of the close of business on September 6, 2022. On January 12, 2023, we paid a special, one-time cash dividend of approximately $7.6 million (or $0.24 per share) to our common stockholders of record as of the close of business on January 5, 2023. In June 2023, we distributed $3.5 million, which reflected, in connection with an asset purchase agreement with Vertex Pharmaceuticals Inc. (“Vertex”), the hold-back amount received from Vertex less expenses and a reserve for potential tax liabilities, to holders of the contingent value rights (“CVRs”) distributed to our stockholders of record on January 5, 2023 pursuant to the Contingent Value Rights Agreement, dated December 26, 2022, as amended on March 29, 2023 (as amended, the “CVR Agreement”). As of September 30, 2024, the CVR holders have received all requisite cash payable under the CVR Agreement and there are no outstanding distributions. We do not anticipate paying periodic cash dividends on our common stock for the foreseeable future. Any future determination about the payment of dividends will be made at the discretion of our board of directors and will depend upon our earnings, if any, capital requirements, operating and financial conditions and on such other factors as the board of directors deems relevant.
Liquidation
In the event we are liquidated, dissolved or our affairs are wound up, after we pay or make adequate provision for all of our known debts and liabilities, each holder of our common stock will be entitled to share ratably in all assets that remain, subject to any rights that are granted to the holders of any class or series of preferred stock.
Voting Rights
For all matters submitted to a vote of stockholders, each holder of our common stock is entitled to one vote for each share registered in his or her name. Except as may be required by law and in connection with some significant actions, such as mergers, consolidations, or amendments to our restated certificate of incorporation that affect the rights of stockholders, holders of our common stock vote together as a single class. There is no cumulative voting in the election of our directors, which means that, subject to any rights to elect directors that are granted to the holders of any class or series of preferred stock, a plurality of the votes cast at a meeting of stockholders at which a quorum is present is sufficient to elect a director.
Other Rights and Restrictions
Subject to the preferential rights of any other class or series of stock, all shares of our common stock have equal dividend, distribution, liquidation and other rights, and have no preference, appraisal or exchange rights,
TABLE OF CONTENTS
except for any appraisal rights provided by Delaware law. Furthermore, holders of our common stock have no conversion, sinking fund or redemption rights, or preemptive rights to subscribe for any of our securities. Our restated certificate of incorporation and our bylaws do not restrict the ability of a holder of our common stock to transfer his or her shares of our common stock.
The rights, powers, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of holders of shares of any series of preferred stock which we may designate and issue in the future.
Listing
Our common stock is listed on Nasdaq under the symbol “GYRE.”
Transfer Agent and Registrar
The transfer agent for our common stock is Equiniti Trust Company, LLC. Its address is 6201 15th Avenue, Brooklyn, NY 11219.
Description of Preferred Stock
Under our restated certificate of incorporation, we have authority, subject to any limitations prescribed by law and without further stockholder approval, to issue from time to time up to 5,000,000 shares of preferred stock, par value $0.001 per share, in one or more series. On December 22, 2022, we designated 123,418 shares of our preferred stock as “Series X Convertible Preferred Stock” (hereinafter referred to as, “Convertible Preferred Stock”) pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock, filed with the Secretary of State of the State of Delaware on December 27, 2022, as amended on October 30, 2023 (as amended, “Certificate of Designation”). On October 30, 2023, we designated 811 shares of our preferred stock as Convertible Preferred Stock. As of September 30, 2024, there were no shares of preferred stock issued and outstanding.
Pursuant to our restated certificate of incorporation, we are authorized to issue “blank check” preferred stock, which may be issued from time to time in one or more series upon authorization by our board of directors. Our board of directors, without further approval of the stockholders, is authorized to fix the designation, powers, preferences, relative, participating optional or other special rights, and any qualifications, limitations and restrictions applicable to each series of the preferred stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes could, among other things, adversely affect the voting power or rights of the holders of our common stock and, under certain circumstances, make it more difficult for a third party to gain control of us, discourage bids for our common stock at a premium or otherwise adversely affect the market price of the common stock.
Series X Convertible Preferred Stock
Conversion
Under our restated certificate of incorporation, effective as of 5:00 p.m. (New York City time) on August 31, 2023 (the second business day after the date on which stockholder approval was received), each holder of Convertible Preferred Stock may, at its option, effect conversions of Convertible Preferred Stock then outstanding into approximately 10,000 of common stock, subject to certain beneficial ownership limitations, including that a holder of Convertible Preferred Stock is prohibited from converting shares of Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be initially set at 9.99% and thereafter adjusted by the holder between to a number between 4.99% and 19.99%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion.
Voting Rights
Except as otherwise provided in the Certificate of Designation or as otherwise required by the Delaware General Corporation Law (“DGCL”), Convertible Preferred Stock does not have voting rights. However, as long as any shares of Convertible Preferred Stock are outstanding, in addition to any other requirement of the DGCL or our restated certificate of incorporation, we shall not, without the affirmative vote of the holders of a majority
TABLE OF CONTENTS
of the then outstanding shares of Convertible Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to Convertible Preferred Stock or alter or amend the Certificate of Designation, amend or repeal any provision of or add any provision to, our restated certificate of incorporation or our bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of Convertible Preferred Stock, regardless of whether any of the foregoing actions shall be by means of amendment to our restated certificate of incorporation or by merger, consolidation or otherwise, (ii) issue further shares of Convertible Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Convertible Preferred Stock, (iii) at any time while at least 30% of the originally issued Convertible Preferred Stock remains issued and outstanding, consummate either: (A) any Fundamental Transaction (as defined in the Certificate of Designation) or (B) any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which our stockholders immediately before such transaction do not hold at least a majority of the capital stock of the Company immediately after such transaction, or (iv) enter into any agreement with respect to any of the foregoing.
Dividends
Holders of Convertible Preferred Stock shall be entitled to receive when, as and if dividends are declared and paid on shares of common stock, an equivalent dividend (with the same dividend declaration date and payment date), calculated on an as-converted basis without regard to the Beneficial Ownership Limitation (as defined in the Certificate of Designation); provided, however, in no event shall holders of Convertible Preferred Stock be entitled to receive (a) the “rights” distributed pursuant to the CVR Agreement or any amounts paid under the CVR Agreement, or (b) cash distributions declared by us on or prior to the closing of the transactions contemplated by the Business Combination Agreement, dated as of December 26, 2022, as amended on March 29, 2023 and August 30, 2023, by and among us, GNI USA, Inc., a Delaware corporation, GNI Group Ltd., a company incorporated under the laws of Japan with limited liability, GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability, Shanghai Genomics, Inc., a company organized under the laws of the People’s Republic of China, the Minority Holders (as defined therein) and Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares.
Liquidation
Convertible Preferred Stock ranks (i) senior to any class or series of our capital stock hereafter created specifically ranking by its terms junior to any Convertible Preferred Stock; (ii) on parity with our common stock and any class or series of our capital stock hereafter created specifically ranking by its terms on parity with Convertible Preferred Stock; and (iii) junior to (A) any class or series of our capital stock hereafter created specifically ranking by its terms senior to any Convertible Preferred Stock or (B) any “rights” distributed pursuant to the CVR Agreement or any amounts paid under the CVR Agreement, in each case, as to distributions of assets upon our liquidation, dissolution or winding up, whether voluntarily or involuntarily.
Certain Effects of Authorized but Unissued Stock
We have shares of common stock and preferred stock available for future issuance without stockholder approval, subject to any limitations imposed by the listing requirements of Nasdaq. We may issue these additional shares for a variety of corporate purposes, including future public or private offerings to raise additional capital or to facilitate corporate acquisitions or for payment as a dividend on our capital stock. The existence of unissued and unreserved preferred stock may enable our board of directors to issue shares of preferred stock with terms that could render more difficult or discourage a third-party attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of our management. In addition, if we issue preferred stock, the issuance could adversely affect the voting power of holders of common stock and the likelihood that holders of common stock will receive dividend payments or payments upon liquidation.
Anti-Takeover Effects of Provisions of Our Charter Documents
Our restated certificate of incorporation provides for our board of directors to be divided into three classes serving staggered terms. Approximately one-third of our board of directors will be elected each year. The provision for a classified board could prevent a party who acquires control of a majority of the outstanding
TABLE OF CONTENTS
voting stock from obtaining control of the board of directors until the second annual stockholders meeting following the date the acquirer obtains the controlling stock interest. The classified board provision could discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of the Company and could increase the likelihood that incumbent directors will retain their positions. Our restated certificate of incorporation provides that directors may be removed with or without cause only by the affirmative vote of the holders of at least 66 2/3% of the voting power of all outstanding stock entitled to vote in the election of directors, voting together as a single class.
Our restated certificate of incorporation requires that certain amendments to the restated certificate of incorporation and amendments by the stockholders of our bylaws require the affirmative vote of holders of at least 66 2/3% of the then outstanding stock entitled to vote generally in the election of directors, voting together as a single class. These provisions could discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of the Company and could delay changes in management.
Our bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual stockholders meeting, including proposed nominations of persons for election to our board of directors. At an annual stockholders meeting, stockholders may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors. Stockholders may also consider a proposal or nomination by a person who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given to the Secretary of the Company timely written notice, in proper form, of his or her intention to bring that business before the annual stockholders meeting. Our bylaws do not give our board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting of the stockholders. However, our bylaws may have the effect of precluding the conduct of business at a meeting if the proper procedures are not followed. These provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of the Company.
Our bylaws provide that only our board of directors, the chairperson of the board, the President or the Chief Executive Officer may call a special meeting of stockholders. Because our stockholders do not have the right to call a special meeting, a stockholder could not force stockholder consideration of a proposal over the opposition of our board of directors by calling a special meeting of stockholders prior to such time as a majority of our board of directors, the chairperson of the board, the President or the Chief Executive Officer believed the matter should be considered or until the next annual meeting provided that the requestor met the notice requirements. The restriction on the ability of stockholders to call a special meeting means that a proposal to replace the board also could be delayed until the next annual stockholders meeting.
Our restated certificate of incorporation does not allow stockholders to act by written consent without a meeting. Without the availability of stockholder’s actions by written consent, a holder controlling a majority of our capital stock would not be able to amend our bylaws or remove directors without holding a stockholders’ meeting.
Section 203 of the Delaware General Corporation Law
We are subject to the provisions of Section 203 of the DGCL (“Section 203”). Under Section 203, we would generally be prohibited from engaging in any business combination with any interested stockholder for a period of three years following the time that this stockholder became an interested stockholder unless:
• | prior to this time, our board of directors approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; |
• | upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding shares owned by persons who are directors and also officers, and by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or |
• | at or subsequent to such time, the business combination is approved by our board of directors and authorized at a special or annual stockholders meeting, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. |
TABLE OF CONTENTS
Under Section 203, a “business combination” includes:
• | any merger or consolidation involving the corporation and the interested stockholder; |
• | any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder; |
• | any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder, subject to limited exceptions; |
• | any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or |
• | the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. |
In general, Section 203 defines an interested stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by such entity or person.
Limitation of Liability and Indemnification
Our restated certificate of incorporation provides that our directors and officers shall not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director or officer, respectively, except for liability for breach of the director’s or officers’, respectively, duty of loyalty to us or our stockholders, for acts or omissions not in good faith or involving intentional misconduct or a knowing violation of law, for payment of dividends or approval of stock purchases or redemptions that are prohibited by the DGCL, or for any transaction from which the director or officer, respectively, derived an improper personal benefit. Under the DGCL, our directors and officers have a fiduciary duty to us that is not eliminated by this provision of the restated certificate of incorporation and, in appropriate circumstances, equitable remedies such as injunctive or other forms of non-monetary relief will remain available. This provision also does not affect our directors’ or officers’ responsibilities under any other laws, such as federal securities laws or state or federal environmental laws.
Section 145 of the DGCL empowers a corporation to indemnify its directors and officers against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by them in connection with any action, suit or proceeding brought by third parties by reason of the fact that they were or are directors or officers of the corporation, if they acted in good faith, in a manner they reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe that their conduct was unlawful. The DGCL provides further that the indemnification permitted thereunder shall not be deemed exclusive of any other rights to which the directors and officers may be entitled under the corporation’s bylaws, any agreement, a vote of stockholders or otherwise. Our restated certificate of incorporation provides that, to the fullest extent permitted by Section 145 of the DGCL, we shall indemnify any person who is or was a director or officer of us, or is or was serving at our request as a director, officer or trustee of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, against the expenses, liabilities or other matters referred to in or covered by Section 145 of the DGCL. Our bylaws provide that we will indemnify any person who was or is a party or threatened to be made a party to any proceeding by reason of the fact that such person is or was a director or officer of us or is or was serving at our request as a director, officer or trustee of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise to the fullest extent permitted by the DGCL.
In addition, we have entered into indemnification agreements with each of our directors and with certain of our executive officers. Pursuant to the indemnification agreements, we have agreed to indemnify and hold harmless these directors and officers to the fullest extent permitted by the DGCL. The agreements generally cover expenses that a director or officer incurs or amounts that a director or officer becomes obligated to pay because of any proceeding to which he or she is made or threatened to be made a party or participant by reason of his or her service as a current or former director, officer, employee or agent of the Company. The agreements also provide for the advancement of expenses to the directors and officers subject to specified conditions. There are certain exceptions to our obligation to indemnify the directors and officers, including any intentional malfeasance or act where the director or officer did not in good faith believe he or she was acting in our best
TABLE OF CONTENTS
interests, with respect to “short-swing” profit claims under Section 16(b) of the 1934 Act and, with certain exceptions, with respect to proceedings that he or she initiates.
Section 145 of the DGCL also empowers a corporation to purchase insurance for its officers and directors for such liabilities. We maintain liability insurance for our officers and directors.
Choice of Forum
Our bylaws require that the Court of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a claim of breach of a fiduciary duty owed by, or other wrongdoing by, any current or former director, officer, employee or stockholder to us or our stockholders; (3) any action asserting a claim against us arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, our certificate of incorporation or our bylaws (as either may be amended from time to time); (4) any action to interpret, apply, enforce or determine the validity of the certificate of incorporation or our bylaws (as either may be amended from time to time); or (5) any action asserting a claim against us governed by the internal affairs doctrine. This provision would not apply to claims brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Our bylaws provide further that the federal district courts of the United States will be the exclusive forum for the resolution of any complaint asserting a cause of action against us or any director, officer, employee or agent of us arising under the Securities Act. Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors or officers.
Debt Securities
The paragraphs below describe the general terms and provisions of the debt securities we may issue. When we offer to sell a particular series of debt securities, we will describe the specific terms of the securities in a supplement to this prospectus, including any additional covenants or changes to existing covenants relating to such series. The prospectus supplement also will indicate whether the general terms and provisions described in this prospectus apply to a particular series of debt securities. You should read the actual indenture if you do not fully understand a term or the way we use it in this prospectus.
If we issue debt securities at a discount from their principal amount, then, for purposes of calculating the aggregate initial offering price of the offered securities issued under this prospectus, we will include only the initial offering price of the debt securities and not the principal amount of the debt securities.
We have summarized below the material provisions of the indenture, or indicated which material provisions will be described in the related prospectus supplement. The prospectus supplement relating to any particular securities offered will describe the specific terms of the securities, which may be in addition to or different from the general terms summarized in this prospectus. We have included the form of the indenture as an exhibit to our registration statement of which this prospectus is a part, and it is incorporated into this prospectus by reference. Because the summary in this prospectus and in any prospectus supplement does not contain all of the information that you may find useful, you should read the documents relating to the securities that are described in this prospectus or in any applicable prospectus supplement. Please read “Where You Can Find More Information” in this prospectus to find out how you can obtain a copy of those documents. References below to an “indenture” are references to the indenture, as supplemented, under which a particular series of debt securities is issued. As used under this caption, the term “debt securities” includes the debt securities being offered by this prospectus and all other debt securities issued by us under the indenture.
TABLE OF CONTENTS
General
The indenture:
• | does not limit the amount of debt securities that we may issue; |
• | allows us to issue debt securities in one or more series; |
• | does not require us to issue all of the debt securities of a series at the same time; and |
• | allows us to reopen a series to issue additional debt securities without the consent of the holders of the debt securities of such series. |
The prospectus supplement for each offering of debt securities will provide the following terms, where applicable:
• | the title of the debt securities and whether they are senior, senior subordinated or subordinated debt securities; |
• | the aggregate principal amount of the debt securities being offered and any limit on their aggregate principal amount, and, if the series is to be issued at a discount from its face amount, the method of computing the accretion of such discount; |
• | the price at which the debt securities will be issued, expressed as a percentage of the principal and, if other than the full principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof or, if applicable, the portion of the principal amount of such debt securities that is convertible into common stock or preferred stock or the method by which any such portion shall be determined; |
• | if convertible, the terms on which such debt securities are convertible, including the initial conversion price or rate or the method of calculation, how and when the conversion price or exchange ratio may be adjusted, whether conversion or exchange is mandatory, at the option of the holder or at our option, the conversion or exchange period, and any other provision in relation thereto, and any applicable limitations on the ownership or transferability of common stock or preferred stock received on conversion; |
• | the date or dates, or the method for determining the date or dates, on which the principal of the debt securities will be payable; |
• | the fixed or variable interest rate or rates of the debt securities, or the method by which the interest rate or rates is determined; |
• | the date or dates, or the method for determining the date or dates, from which interest will accrue; |
• | the dates on which interest will be payable; |
• | the record dates for interest payment dates, or the method by which we will determine those dates; |
• | the persons to whom interest will be payable; |
• | the basis upon which interest will be calculated if other than that of a 360-day year of twelve 30-day months; |
• | Any collateral securing the performance of our obligations under the debt securities; |
• | the place or places where the principal of, premium, if any, and interest on, the debt securities will be payable; |
• | where the debt securities may be surrendered for registration of transfer or conversion or exchange; |
• | where notices or demands to or upon us in respect of the debt securities and the applicable indenture may be served; |
• | any provisions regarding our right to redeem or purchase debt securities or the right of holders to require us to redeem or purchase debt securities; |
TABLE OF CONTENTS
• | any right or obligation we have to redeem, repay or purchase the debt securities pursuant to any sinking fund or analogous provision; |
• | the currency or currencies (including any composite currency) in which the debt securities are denominated and payable if other than U.S. dollars, and the currency or currencies (including any composite currency) in which principal, premium, if any, and interest, if any, will be payable, and if such payments may be made in a currency other than that in which the debt securities are denominated, the manner for determining such payments, including the time and manner of determining the exchange rate between the currency in which such securities are denominated and the currency in which such securities or any of them may be paid, and any additions to, modifications of or deletions from the terms of the debt securities to provide for or to facilitate the issuance of debt securities denominated or payable in a currency other than U.S. dollars; |
• | whether the amount of payments of principal of, premium, if any, or interest on, the debt securities may be determined according to an index, formula or other method and how such amounts will be determined; |
• | whether the debt securities will be in registered form, bearer form or both, and the terms of these forms; |
• | whether the debt securities will be issued in whole or in part in the form of a global security and, if applicable, the identity of the depositary for such global security; |
• | any provision for electronic issuance of the debt securities or issuance of the debt securities in uncertificated form; |
• | whether and upon what terms the debt securities of such series may be defeased or discharged, if different from the provisions set forth in the indenture for the series to which the supplemental indenture or authorizing resolution relates; |
• | any provisions granting special rights to holders of securities upon the occurrence of such events as specified in the applicable prospectus supplement; |
• | any deletions from, modifications of, or additions to our events of default or covenants or other provisions set forth in the indenture for the series to which the supplemental indenture or authorizing resolution relates; and |
• | any other material terms of the debt securities, which may be different from the terms set forth in this prospectus. |
We may issue debt securities at a discount below their principal amount and provide for less than the entire principal amount thereof to be payable upon declaration of acceleration of the maturity of the debt securities. We refer to any such debt securities throughout this prospectus as “original issue discount securities.” The applicable prospectus supplement will describe the U.S. federal income tax consequences and other relevant considerations applicable to original issue discount securities.
Neither the DGCL nor our governing instruments define the term “substantially all” as it relates to the sale of assets. Additionally, Delaware cases interpreting the term “substantially all” rely upon the facts and circumstances of each particular case. Consequently, to determine whether a sale of “substantially all” of our assets has occurred, a holder of debt securities must review the financial and other information that we have disclosed to the public.
The applicable prospectus supplement will also describe any material covenants to which a series of debt securities will be subject and the applicability of those covenants to any of our subsidiaries to be restricted thereby, which are referred to herein as “restricted subsidiaries.” The applicable prospectus supplement will also describe provisions for restricted subsidiaries to cease to be restricted by those covenants.
TABLE OF CONTENTS
Events of Default
Unless the applicable prospectus supplement states otherwise, when we refer to “events of default” as defined in the indentures with respect to any series of debt securities, we mean:
• | our failure to pay interest on any debt security of such series when the same becomes due and payable and the continuance of any such failure for a period of 30 days; |
• | our failure to pay the principal or premium of any debt security of such series when the same becomes due and payable at maturity, upon acceleration, redemption or otherwise; |
• | our failure or the failure of any restricted subsidiary to comply with any of its agreements or covenants in, or provisions of, the debt securities of such series or the indenture (as they relate thereto) and such failure continues for a period of 60 days after our receipt of notice of the default from the trustee or from the holders of at least 25 percent in aggregate principal amount of the then outstanding debt securities of that series (except in the case of a default with respect to the provisions of the indenture regarding the consolidation, merger, sale, lease, conveyance or other disposition of all or substantially all of the assets of us (or any other provision specified in the applicable supplemental indenture or authorizing resolution), which will constitute an event of default with notice but without passage of time); or |
• | certain events of bankruptcy, insolvency or reorganization occur with respect to Gyre or any restricted subsidiary of Gyre that is a significant subsidiary (as defined in the indenture). |
If an event of default occurs and is continuing with respect to debt securities of any series outstanding, then the trustee or the holders of 25% or more in principal amount of the outstanding debt securities of that series will have the right to declare the principal amount of all the debt securities of that series to be due and payable immediately. However, the holders of at least a majority in principal amount of outstanding debt securities of such series may rescind and annul such declaration and its consequences, except an acceleration due to nonpayment of principal or interest on such series, if the rescission would not conflict with any judgment or decree and if all existing events of default with respect to such series have been cured or waived.
The indenture also provides that the holders of at least a majority in principal amount of the outstanding debt securities of any series, by notice to the trustee, may, on behalf of all holders, waive any existing default and its consequences with respect to such series of debt securities, other than any event of default in payment of principal or interest.
The indenture will require the trustee to give notice to the holders of debt securities within 90 days after the trustee obtains knowledge of a default that has occurred and is continuing. However, the trustee may withhold notice to the holders of any series of debt securities of any default, except a default in payment of principal or interest, if any, with respect to such series of debt securities, if the trustee considers it in the interest of the holders of such series of debt securities to do so.
The holders of a majority of the outstanding principal amount of the debt securities of any series will have the right to direct the time, method and place of conducting any proceedings for any remedy available to the trustee with respect to such series, subject to limitations specified in the indenture.
Amendment, Supplement and Waiver
Without notice to or the consent of any holder, we and the trustee may amend or supplement the indenture or the debt securities of a series:
• | to cure any ambiguity, omission, defect or inconsistency; |
• | to comply with the provisions of the indenture regarding the consolidation, merger, sale, lease, conveyance or other disposition of all or substantially all of our assets; |
• | to provide that specific provisions of the indenture shall not apply to a series of debt securities not previously issued or to make a change to specific provisions of the indenture that only applies to any series of debt securities not previously issued or to additional debt securities of a series not previously issued; |
• | to create a series and establish its terms; |
TABLE OF CONTENTS
• | to provide for uncertificated debt securities in addition to or in place of certificated debt securities; |
• | to release a guarantor in respect of any series which, in accordance with the terms of the indenture applicable to such series, ceases to be liable in respect of its guarantee; |
• | to add a guarantor subsidiary in respect of any series of debt securities; |
• | to secure any series of debt securities; |
• | to add to the covenants of Gyre for the benefit of the holders or surrender any right or power conferred upon Gyre; |
• | to appoint a successor trustee with respect to the securities; |
• | to comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under the Trust Indenture Act; |
• | to make any change that does not adversely affect the rights of holders; or |
• | to conform the provisions of the indenture to the final offering document in respect of any series of debt securities. |
The indenture will provide that we and the trustee may amend or supplement any provision of the debt securities of a series or of the indenture relating to such series with the written consent of the holders of at least a majority in principal amount of the outstanding debt securities of such series. However, without the consent of each holder of a debt security the terms of which are directly amended, supplemented or waived, an amendment, supplement or waiver may not:
• | reduce the amount of debt securities of such series whose holders must consent to an amendment, supplement or waiver; |
• | reduce the rate of or extend the time for payment of interest, including defaulted interest; |
• | reduce the principal of or extend the fixed maturity of any debt security or alter the provisions with respect to redemptions or mandatory offers to repurchase debt securities of a series in a manner adverse to holders; |
• | make any change that adversely affects any right of a holder to convert or exchange any debt security into or for shares of our common stock or other securities, cash or other property in accordance with the terms of such security; |
• | modify the ranking or priority of the debt securities of the relevant series; |
• | release any guarantor of any series from any of its obligations under its guarantee or the indenture otherwise than in accordance with the terms of the indenture; |
• | make any change to any provision of the indenture relating to the waiver of existing defaults, the rights of holders to receive payment of principal and interest on the debt securities, or to the provisions regarding amending or supplementing the indenture or the debt securities of a particular series with the written consent of the holders of such series, except to increase the percentage required for modification or waiver or to provide for consent of each affected holder of debt securities of such series; |
• | waive a continuing default or event of default in the payment of principal of or interest on the debt securities; or |
• | make any debt security payable at a place or in money other than that stated in the debt security, or impair the right of any holder of a debt security to bring suit as permitted by the indenture. |
The holders of a majority in aggregate principal amount of the outstanding debt securities of such series may, on behalf of all holders of debt securities of that series, waive any existing default under, or compliance with, any provision of the debt securities of a particular series or of the indenture relating to a particular series of debt securities, other than any event of default in payment of interest or principal.
TABLE OF CONTENTS
Defeasance
The indenture will permit us to terminate all our respective obligations under the indenture as they relate to any particular series of debt securities, other than the obligation to pay interest, if any, on and the principal of the debt securities of such series and certain other obligations, at any time by:
• | depositing in trust with the trustee, under an irrevocable trust agreement, money or government obligations in an amount sufficient to pay principal of and interest, if any, on the debt securities of such series to their maturity or redemption; and |
• | complying with other conditions, including delivery to the trustee of an opinion of counsel to the effect that holders will not recognize income, gain or loss for federal income tax purposes as a result of our exercise of such right and will be subject to federal income tax on the same amount and in the same manner and at the same times as would have been the case otherwise. |
The indenture will also permit us to terminate all of our respective obligations under the indenture as they relate to any particular series of debt securities, including the obligations to pay interest, if any, on and the principal of the debt securities of such series and certain other obligations, at any time by:
• | depositing in trust with the trustee, under an irrevocable trust agreement, money or government obligations in an amount sufficient to pay principal and interest, if any, on the debt securities of such series to their maturity or redemption; and |
• | complying with other conditions, including delivery to the trustee of an opinion of counsel to the effect that (A) we have received from, or there has been published by, the Internal Revenue Service a ruling, or (B) since the date such series of debt securities were originally issued, there has been a change in the applicable federal income tax law, in either case to the effect that, and based thereon such opinion of counsel shall state that, holders will not recognize income, gain or loss for federal income tax purposes as a result of our exercise of such right and will be subject to federal income tax on the same amount and in the same manner and at the same times as would have been the case otherwise. |
In addition, the indenture will permit us to terminate substantially all our respective obligations under the indenture as they relate to a particular series of debt securities by depositing with the trustee money or government obligations sufficient to pay all principal and interest on such series at its maturity or redemption date if the debt securities of such series will become due and payable at maturity within one year or are to be called for redemption within one year of the deposit.
Transfer and Exchange
A holder will be able to transfer or exchange debt securities only in accordance with the indenture. The registrar may require a holder, among other things, to furnish appropriate endorsements and transfer documents, and to pay any taxes and fees required by law or permitted by the indenture.
Concerning the Trustee
The indenture will contain limitations on the rights of the trustee, should it become our creditor, to obtain payment of claims in specified cases or to realize on property received in respect of any such claim as security or otherwise. The indenture will permit the trustee to engage in other transactions; however, if it acquires any conflicting interest, it must eliminate such conflict or resign.
The indenture will provide that in case an event of default occurs and is not cured, the trustee will be required, in the exercise of its power, to use the degree of care of a prudent person in similar circumstances in the conduct of such person’s own affairs. The trustee shall be under no obligation to exercise any of the rights or powers vested in it by the indenture at the request or direction of any of the holders pursuant to the indenture, unless such holders shall have offered to the trustee security or indemnity satisfactory to the trustee against the costs, expenses and liabilities which might be incurred by it in compliance with such request or direction.
No Recourse Against Others
The indenture will provide that there is no recourse under any obligation, covenant or agreement in the applicable indenture or with respect to any debt security against any of our or our successor’s past, present or future stockholders, employees, officers or directors.
TABLE OF CONTENTS
Governing Law
The laws of the State of New York will govern the indenture and the debt securities.
Warrants
We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series, from time to time. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from those securities.
If we issue warrants, they will be evidenced by warrant agreements or warrant certificates issued under one or more warrant agreements, which are contracts between us and an agent for the holders of the warrants. We urge you to read the prospectus supplement related to any series of warrants we may offer, as well as the complete warrant agreement and warrant certificate that contain the terms of the warrants. If we issue warrants, forms of warrant agreements and warrant certificates relating to warrants for the purchase of common stock, preferred stock and debt securities will be incorporated by reference into the registration statement of which this prospectus is a part from reports we would subsequently file with the SEC.
Units
We may issue units consisting of any combination of the other types of securities offered under this prospectus in one or more series. We may evidence each series of units by unit certificates that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and address of the unit agent in the applicable prospectus supplement relating to a particular series of units.
The following description, together with the additional information included in any applicable prospectus supplement, summarizes the general features of the units that we may offer under this prospectus. You should read any prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to the series of units being offered, as well as the complete unit agreements that contain the terms of the units. Specific unit agreements will contain additional important terms and provisions and we will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from another report that we file with the SEC, the form of each unit agreement relating to units offered under this prospectus.
If we offer any units, certain terms of that series of units will be described in the applicable prospectus supplement, including, without limitation, the following, as applicable:
• | the title of the series of units; |
• | identification and description of the separate constituent securities comprising the units; |
• | the price or prices at which the units will be issued; |
• | the date, if any, on and after which the constituent securities comprising the units will be separately transferable; |
• | a discussion of certain U.S. federal income tax considerations applicable to the units; and |
• | any other terms of the units and their constituent securities. |
TABLE OF CONTENTS
We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions:
• | at a fixed price or prices, which may be changed; |
• | at market prices prevailing at the time of sale; |
• | at prices related to such prevailing market prices; or |
We may also sell equity securities covered by this registration statement in an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either:
• | on or through the facilities of Nasdaq or any other securities exchange or quotation or trading service on which such securities may be listed, quoted or traded at the time of sale; and/or |
• | to or through a market maker otherwise than on Nasdaq or such other securities exchanges or quotation or trading services. |
Such at the market offerings, if any, may be conducted by underwriters acting as principal or agent.
A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities, including, to the extent applicable:
• | the name or names of any underwriters, dealers or agents, if any; |
• | the purchase price of the securities and the proceeds we will receive from the sale; |
• | any options under which underwriters may purchase additional securities from us; |
• | any agency fees or underwriting discounts and other items constituting agents’ or underwriters’ compensation; |
• | any public offering price; |
• | any discounts or concessions allowed or re-allowed or paid to dealers; and |
• | any securities exchange or market on which the securities may be listed. |
Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement.
If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement. Any public offering price and any discounts or concessions allowed or re-allowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship.
We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities, and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment.
TABLE OF CONTENTS
We may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.
We may provide agents and underwriters with indemnification against civil liabilities related to offerings pursuant to this prospectus, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business.
All securities we offer, other than our shares of common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities.
Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. These transactions may be effected on any exchange or over-the-counter market or otherwise.
Any underwriters who are qualified market makers on Nasdaq may engage in passive market making transactions in the securities on Nasdaq in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker’s bid, however, the passive market maker’s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.
TABLE OF CONTENTS
Certain legal matters, including the legality of the securities offered, will be passed upon for us by Gibson, Dunn & Crutcher LLP, San Francisco, California. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.
The audited consolidated financial statements of Gyre Therapeutics, Inc. for the years ended December 31, 2023 and December 31, 2022 incorporated by reference in this prospectus and elsewhere in the registration statement have been so incorporated by reference in reliance upon the report of Grant Thornton Zhitong Certified Public Accountants LLP, independent registered public accountants, upon the authority of said firm as experts in accounting and auditing.
The consolidated balance sheets of Catalyst Biosciences, Inc. as of December 31, 2022 and 2021, and the related consolidated statements of operations, comprehensive loss, redeemable convertible preferred stock and stockholders' equity (deficit), and cash flows for each of the years then ended, have been audited by EisnerAmper LLP, independent registered public accounting firm, as stated in their report which is incorporated herein by reference, which report includes an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue as a going concern. Such financial statements have been incorporated herein by reference in reliance on the report of such firm given upon their authority as experts in accounting and auditing.
TABLE OF CONTENTS
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and special reports, proxy statements and other information with the SEC, and we have filed with the SEC a registration statement on Form S-3 under the Securities Act with respect to the securities offered by this prospectus. This prospectus, which forms part of the registration statement, does not contain all of the information included in the registration statement, including its exhibits and schedules. For further information about us and the securities described in this prospectus, you should refer to the registration statement, its exhibits and schedules and our reports, proxies, information statements and other information filed with the SEC.
Our filings are available to the public on the Internet, through a database maintained by the SEC at www.sec.gov. We also maintain a website at www.gyretx.com. We have included our website address for the information of prospective investors and do not intend it to be an active link to our website. Information contained on our website does not constitute a part of this prospectus or any applicable prospectus supplement (or any document incorporated by reference herein or therein).
TABLE OF CONTENTS
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
The SEC allows us to incorporate by reference much of the information we file with the SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus.
Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement until the offering of the securities under the registration statement is terminated or completed, except that we are not incorporating by reference any information furnished (and not filed) with the SEC, including any information furnished pursuant to Items 2.02 or 7.01 of Form 8-K or related exhibits furnished pursuant to Item 9.01 of Form 8-K:
• | our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 27, 2024 (including the portions of our Definitive Proxy Statement on Schedule 14A filed on April 29, 2024 incorporated by reference therein) and our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 30, 2023; |
• | our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023, September 30, 2023, March 31, 2024, June 30, 2024 and September 30, 2024, filed with the SEC on May 15, 2023, August 14, 2023, October 26, 2023, May 13, 2024, August 13, 2024 and November 13, 2024, respectively; |
• | our Current Reports on Form 8-K and Form 8-K/A, as applicable, filed with the SEC on January 12, 2024, January 19, 2024, March 21, 2024 (excluding Items 7.01 and 9.01), March 26, 2024, May 8, 2024 (excluding Items 7.01 and 9.01), May 30, 2024 (excluding Items 7.01 and 9.01), June 17, 2024, July 5, 2024, and August 8, 2024 (excluding Items 7.01 and 9.01); and |
• | the description of our common stock attached as Exhibit 4.1 to our Annual Report on Form 10-K, for the year ended December 31, 2023, filed with the SEC on March 27, 2024, including any amendment or report filed for the purpose of updating such description. |
We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02, Item 7.01 or Item 9.01 of Form 8-K and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i) after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, and (ii) after the date of this prospectus but prior to the termination of the offering. These documents include, without limitation, Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, as well as proxy statements.
You may request a copy of these filings, at no cost, by contacting us, either orally or in writing, at the following:
Gyre Therapeutics, Inc.
12770 High Bluff Drive
Suite 150
San Diego, California 92130
(858) 567-7770
We maintain a website at www.gyretx.com. Information about us, including our reports filed with the SEC, is available through that site. Such reports are accessible at no charge through our website and are made available as soon as reasonably practicable after such material is filed with or furnished to the SEC. Our website and the information contained on that website, or connected to that website, are not incorporated by reference in this prospectus.
You may read and copy any materials we file with the SEC at the SEC’s website mentioned under the heading “Where You Can Find More Information.” The information on the SEC’s website is not incorporated by reference in this prospectus.
TABLE OF CONTENTS
PART II
INFORMATION NOT REQUIRED IN THE PROSPECTUS
Item 14.
| Other Expenses of Issuance and Distribution |
The following table sets forth an estimate of the fees and expenses, other than the underwriting discounts and commissions, payable by the registrant in connection with the issuance and distribution of the securities being registered. All the amounts shown are estimates, except for the SEC registration fee and FINRA filing fee.
| | | |
SEC registration fee* | | | $825.00 |
FINRA filing fee | | | 23,000.00 |
Printing and engraving expenses | | | ** |
Legal fees and expenses | | | ** |
Accounting fees and expenses | | | ** |
Transfer agent and registrar fees and expenses | | | ** |
Miscellaneous fees and expenses | | | ** |
Total | | | $** |
| | | |
*
| Excludes registration fee offsets pursuant to Rule 457(p) of the Securities Act. |
**
| These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be estimated at this time. |
Item 15.
| Indemnification of Directors and Officers |
The company is a Delaware corporation. Section 145(a) of the Delaware General Corporation Law (the “DGCL”) provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, other than an action by or in the right of the corporation, by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.
Section 145(b) of the DGCL provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that such person acted in any of the capacities set forth above, against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in, or not opposed to, the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation, unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine, upon application, that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the court shall deem proper.
Further subsections of DGCL Section 145 provide that:
(1)
| to the extent a present or former director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (i) and (ii) of Section 145 or in the defense of any claim, issue or matter therein, such person shall be indemnified against expenses, including attorneys’ fees, actually and reasonably incurred by such person in connection therewith; |
TABLE OF CONTENTS
(2)
| the indemnification and advancement of expenses provided for pursuant to Section 145 shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any bylaw, agreement, vote of shareholders or disinterested directors or otherwise; and |
(3)
| the corporation shall have the power to purchase and maintain insurance of behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person’s status as such, whether or not the corporation would have the power to indemnify such person against such liability under Section 145. |
As used in this Item 14, the term “proceeding” means any threatened, pending or completed action, suit or proceeding, whether or not by or in the right of the company, and whether civil, criminal, administrative, investigative or otherwise.
Section 145 of the DGCL makes provision for the indemnification of officers and directors in terms sufficiently broad to indemnify officers and directors of the company under certain circumstances from liabilities (including reimbursement for expenses incurred) arising under the Securities Act. The company’s Second Amended and Restated Certificate of Incorporation and Second Amended and Restated Bylaws provide, in effect, that, to the fullest extent and under the circumstances permitted by Section 145 of the DGCL, the company will indemnify any and all of its officers and directors. The company has entered into indemnification agreements with its officers and directors. The company may, in its discretion, similarly indemnify its employees and agents. The company’s Second Amended and Restated Certificate of Incorporation also relieves the company’s directors from monetary damages to the company or its shareholders for breach of such director’s fiduciary duty as a director to the fullest extent permitted by the DGCL. Under Section 102(b)(7) of the DGCL, a corporation may relieve its directors from personal liability to such corporation or its shareholders for monetary damages for any breach of their fiduciary duty as directors except (i) for a breach of the duty of loyalty, (ii) for failure to act in good faith, (iii) for intentional misconduct or knowing violation of law, (iv) for willful or negligent violations of certain provisions in the DGCL imposing certain requirements with respect to stock repurchases, redemptions and dividends or (v) for any transactions from which the director derived an improper personal benefit.
The company has purchased insurance policies that, within the limits and subject to the terms and conditions thereof, cover certain expenses and liabilities that may be incurred by directors and officers in connection with proceedings that may be brought against them as a result of an act or omission committed or suffered while acting as a director or officer of the company.
The underwriting agreements that we may enter into may provide for the indemnification by the underwriters of us and our officers and directors for certain liabilities, including liabilities arising under the Securities Act, and afford certain rights of contribution with respect thereto.
TABLE OF CONTENTS
A list of exhibits filed with this registration statement on Form S-3 is set forth on the Exhibit Index and is incorporated herein by reference.
| | | |
1.1* | | | Form of Underwriting Agreement. |
| | | |
3.1* | | | Restated Certificate of Incorporation of the Company. |
| | | |
| | | Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.3 to the Company’s Form 8-K filed on October 30, 2023). |
| | | |
| | | Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, filed with the Delaware Secretary of State on April 10, 2017 (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K on August 13, 2017). |
| | | |
| | | Certificate of Elimination of Series A Preferred Stock, filed with the Delaware Secretary of State on March 25, 2024 (incorporated by reference to Exhibit 3.6(b) to the Company’s Form 10-K on March 17, 2024). |
| | | |
| | | Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock, filed with the Delaware Secretary of State on December 27, 2022 (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K on December 27, 2022). |
| | | |
| | | Amendment to Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock, filed with the Delaware Secretary of State on October 30, 2023 (incorporated by reference to Exhibit 3.2 to the Company’s Form 8-K on October 30, 2023). |
| | | |
| | | Certificate of Designation of Preferences, Rights and Limitations of Series Y Preferred Stock, filed with the Delaware Secretary of State on June 20, 2023, with respect to the Series Y Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K on June 20, 2023). |
| | | |
| | | Certificate of Elimination of Series Y Preferred Stock, filed with the Delaware Secretary of State on August 31, 2023 (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K on August 31, 2023). |
| | | |
| | | Warrant to Purchase Stock of Catalyst Biosciences, Inc., issued to Silicon Valley Bank on March 3, 2005 (incorporated by reference to Exhibit 4.3 to the Company’s Form 10-K filed on March 9, 2016). |
| | | |
| | | Form of Warrant to Purchase Stock of Catalyst Biosciences, Inc., issued to purchasers of convertible promissory notes (incorporated by reference to Exhibit 4.5 to the Company’s Form 10-K filed on March 9, 2016). |
| | | |
| | | Form of Warrant to Purchase Series X Convertible Preferred Stock (incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K filed on October 30, 2023). |
| | | |
| | | Form of Debt Indenture. |
| | | |
4.5* | | | Form of Debt Securities. |
| | | |
4.6* | | | Form of Warrant Agreement and Warrant Certificate. |
| | | |
| | | |
TABLE OF CONTENTS
| | | |
4.7* | | | Form of Unit Agreement and Unit Certificate. |
| | | |
| | | Opinion of Gibson, Dunn & Crutcher LLP, relating to base prospectus. |
| | | |
| | | Consent of Grant Thornton Zhitong Certified Public Accountants LLP, Independent Registered Public Accounting Firm. |
| | | |
| | | Consent of EisnerAmper LLP. |
| | | |
| | | Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1 hereto). |
| | | |
| | | Power of Attorney (included on the signature pages to the registration statement). |
| | | |
25.1** | | | Statement of Eligibility of Trustee under the Indenture. |
| | | |
| | | Unaudited pro forma condensed combined statement of operations of Catalyst Biosciences, Inc. for the year ended December 31, 2023. |
| | | |
| | | Filing Fee Table. |
| | | |
*
| To be filed, if necessary, by amendment or as an exhibit to a document to be incorporated or deemed to be incorporated by reference in this registration statement, including a Current Report on Form 8-K. |
**
| To be filed in accordance with the requirements of Section 305(b)(2) of the Trust Indenture Act of 1939, as amended, and the applicable rules thereunder. |
The undersigned registrant hereby undertakes:
(a) (1)
| To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: |
(i)
| to include any prospectus required by Section 10(a)(3) of the Securities Act; |
(ii)
| to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and |
(iii)
| to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; |
provided, however, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.
TABLE OF CONTENTS
(2)
| That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
(3)
| To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. |
(4)
| That, for the purpose of determining liability under the Securities Act to any purchaser: |
(i)
| Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and |
(ii)
| Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. |
(5)
| That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: |
(i)
| Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; |
(ii)
| Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; |
(iii)
| The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and |
(iv)
| Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. |
(6)
| The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
TABLE OF CONTENTS
(7)
| Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. |
(8)
| That, for purposes of determining any liability under the Securities Act, (i) the information omitted from the form of prospectus filed as part of the registration statement in reliance upon Rule 430A and contained in the form of prospectus filed by the registrant pursuant to Rule 424(b)(l) or (4) or 497(h) under the Securities Act shall be deemed to be a part of the registration statement as of the time it was declared effective; and (ii) each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
(9)
| To file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust Indenture Act in accordance with the rules and regulations prescribed by the Commission under Section 305(b)(2) of the Trust Indenture Act. |
TABLE OF CONTENTS
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on November 14, 2024.
| | | |
| | | Gyre Therapeutics, Inc. |
| | | | | | |
| | | By: | | | /s/ Han Ying |
| | | | | | Han Ying, Ph.D. |
| | | | | | Chief Executive Officer |
| | | | | | |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Han Ying, Ph.D. and Ruoyu Chen, and each of them, as true and lawful attorneys-in-fact and agents, with full powers of substitution and resubstitution, for them and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement (or any registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, and generally to do all such things in their names and behalf in their capacities as officers and directors to enable the Gyre Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933 and all requirements of the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.
| | | | | | |
| | | | | | |
/s/ Han Ying, Ph.D. | | | Chief Executive Officer, Director
(Principal Executive Officer) | | | November 14, 2024 |
Han Ying, Ph.D. | |
| | | | | | |
/s/ Ruoyu Chen | | | Chief Financial Officer
(Principal Financial and Accounting Officer) | | | November 14, 2024 |
Ruoyu Chen | |
| | | | | | |
/s/ Ying Luo, Ph.D. | | | Chairman of the Board of Directors | | | November 14, 2024 |
Ying Luo, Ph.D. | |
| | | | | | |
/s/ Songjiang Ma | | | President and Director | | | November 14, 2024 |
Songjiang Ma | |
| | | | | | |
/s/ Gordon G. Carmichael | | | Director | | | November 14, 2024 |
Gordon G. Carmichael | |
| | | | | | |
/s/ Thomas Eastling | | | Director | | | November 14, 2024 |
Thomas Eastling | |
| | | | | | |
/s/ David Epstein, Ph.D. | | | Director | | | November 14, 2024 |
David Epstein, Ph.D. | |
| | | | | | |
/s/ Rodney L. Nussbaum | | | Director | | | November 14, 2024 |
Rodney L. Nussbaum | |
| | | | | | |
/s/ Renate Parry, Ph.D. | | | Director | | | November 14, 2024 |
Renate Parry, Ph.D. | |
| |
Exhibit
4.4
GYRE
THERAPEUTICS, INC.
Debt
Securities
Indenture
Dated
as of , 202
[ ],
as
Trustee
CROSS-REFERENCE
TABLE
This
Cross-Reference Table is not a part of the Indenture
| TIA Section |
|
Indenture Section |
| 310(a)(1) |
|
7.10 |
| (a)(2) |
|
7.10 |
| (a)(3) |
|
N.A. |
| (a)(4) |
|
N.A. |
| (b) |
|
7.08; 7.10; 12.02 |
| |
|
| 311(a) |
|
7.11 |
| (b) |
|
7.11 |
| (c) |
|
N.A. |
| |
|
| 312(a) |
|
2.05 |
| (b) |
|
12.03 |
| (c) |
|
12.03 |
| |
|
| 313(a) |
|
7.06 |
| (b)(1) |
|
N.A. |
| (b)(2) |
|
7.06 |
| (c) |
|
12.02 |
| (d) |
|
7.06 |
| |
|
| 314(a) |
|
4.03; 12.02 |
| (b) |
|
N.A. |
| (c)(1) |
|
12.04 |
| (c)(2) |
|
12.04 |
| (c)(3) |
|
N.A. |
| (d) |
|
N.A. |
| (e) |
|
12.05 |
| |
|
| 315(a) |
|
7.01(b) |
| (b) |
|
7.05; 12.02 |
| (c) |
|
7.01(a) |
| (d) |
|
7.01(c) |
| (e) |
|
6.11 |
| |
|
| 316(a)(last sentence) |
|
12.06 |
| (a)(1)(A) |
|
6.05 |
| (a)(1)(B) |
|
6.04 |
| (a)(2) |
|
N.A. |
| (b) |
|
6.07 |
| |
|
| 317(a)(1) |
|
6.08 |
| (a)(2) |
|
6.09 |
| (b)d |
|
2.04 |
| |
|
| 318(a) |
|
12.01 |
N.A.
means Not Applicable.
TABLE
OF CONTENTS
This
Table of Contents is not a part of the Indenture
ARTICLE
ONE
DEFINITIONS
AND INCORPORATION BY REFERENCE
| |
|
|
|
|
| Section 1.01 |
|
Definitions |
|
1 |
| Section 1.02 |
|
Other Definitions |
|
4 |
| Section 1.03 |
|
Incorporation by Reference of Trust Indenture Act |
|
4 |
| Section 1.04 |
|
Rules of Construction |
|
4 |
| |
|
ARTICLE
TWO
|
| |
| THE SECURITIES |
| |
|
|
| Section 2.01 |
|
Form and Dating |
|
5 |
| Section 2.02 |
|
Execution and Authentication |
|
6 |
| Section 2.03 |
|
Registrar and Paying Agent |
|
6 |
| Section 2.04 |
|
Paying Agent to Hold Money in Trust |
|
7 |
| Section 2.05 |
|
Securityholder Lists |
|
7 |
| Section 2.06 |
|
Transfer and Exchange |
|
7 |
| Section 2.07 |
|
Replacement Securities |
|
7 |
| Section 2.08 |
|
Outstanding Securities |
|
8 |
| Section 2.09 |
|
Temporary Securities |
|
8 |
| Section 2.10 |
|
Cancellation |
|
8 |
| Section 2.11 |
|
Defaulted Interest |
|
8 |
| Section 2.12 |
|
Treasury Securities |
|
9 |
| Section 2.13 |
|
CUSIP/ISIN Numbers |
|
9 |
| Section 2.14 |
|
Deposit of Moneys |
|
9 |
| Section 2.15 |
|
Book-Entry Provisions for Global Security |
|
9 |
| Section 2.16 |
|
No Duty to Monitor |
|
10 |
| |
|
|
|
|
|
ARTICLE THREE
REDEMPTION
|
| |
|
|
| Section 3.01 |
|
Notices to Trustee |
|
11 |
| Section 3.02 |
|
Selection of Securities to be Redeemed |
|
11 |
| Section 3.03 |
|
Notice of Redemption |
|
11 |
| Section 3.04 |
|
Effect of Notice of Redemption |
|
12 |
| Section 3.05 |
|
Deposit of Redemption Price |
|
12 |
| Section 3.06 |
|
Securities Redeemed in Part |
|
12 |
| |
|
ARTICLE FOUR
|
| |
| COVENANTS |
| |
|
|
| Section 4.01 |
|
Payment of Securities |
|
12 |
| Section 4.02 |
|
Maintenance of Office or Agency |
|
13 |
| Section 4.03 |
|
Reports |
|
13 |
| Section 4.04 |
|
Compliance Certificate |
|
13 |
| Section 4.05 |
|
Waiver of Stay, Extension or Usury Laws |
|
13 |
| |
|
ARTICLE FIVE
|
| |
| SUCCESSOR CORPORATION |
| |
|
|
| Section 5.01 |
|
When Company May Merge, etc. |
|
13 |
| |
|
ARTICLE SIX
|
| |
| DEFAULTS AND REMEDIES |
| |
|
|
| Section 6.01 |
|
Events of Default |
|
14 |
| Section 6.02 |
|
Acceleration |
|
15 |
| Section 6.03 |
|
Other Remedies |
|
15 |
| Section 6.04 |
|
Waiver of Existing Defaults |
|
15 |
| Section 6.05 |
|
Control by Majority |
|
15 |
| Section 6.06 |
|
Limitation on Suits |
|
15 |
| Section 6.07 |
|
Rights of Holders to Receive Payment and Convert |
|
16 |
| Section 6.08 |
|
Collection Suit by Trustee |
|
16 |
| Section 6.09 |
|
Trustee May File Proofs of Claim |
|
16 |
| Section 6.10 |
|
Priorities |
|
16 |
| Section 6.11 |
|
Undertaking for Costs |
|
17 |
| |
|
|
|
|
|
ARTICLE SEVEN
|
| |
| TRUSTEE |
| |
|
|
| Section 7.01 |
|
Duties of Trustee |
|
17 |
| Section 7.02 |
|
Rights of Trustee |
|
18 |
| Section 7.03 |
|
Individual Rights of Trustee |
|
19 |
| Section 7.04 |
|
Trustee’s Disclaimer |
|
19 |
| Section 7.05 |
|
Notice of Defaults |
|
19 |
| Section 7.06 |
|
Reports by Trustee to Holders |
|
19 |
| Section 7.07 |
|
Compensation and Indemnity |
|
19 |
| Section 7.08 |
|
Replacement of Trustee |
|
20 |
| Section 7.09 |
|
Successor Trustee by Merger, etc. |
|
20 |
| Section 7.10 |
|
Eligibility; Disqualification |
|
21 |
| Section 7.11 |
|
Preferential Collection of Claims Against Company |
|
21 |
| |
|
ARTICLE EIGHT
|
| |
| DISCHARGE OF INDENTURE |
| |
|
|
| Section 8.01 |
|
Defeasance upon Deposit of Moneys or Government Obligations |
|
21 |
| Section 8.02 |
|
Survival of the Company’s Obligations |
|
23 |
| Section 8.03 |
|
Application of Trust Money |
|
23 |
| Section 8.04 |
|
Repayment to the Company |
|
23 |
| Section 8.05 |
|
Reinstatement |
|
23 |
| |
|
|
|
|
| ARTICLE NINE |
| |
| RESERVED |
| |
| ARTICLE TEN |
| |
| AMENDMENTS, SUPPLEMENTS AND WAIVERS |
| |
|
|
| Section 10.01 |
|
Without Consent of Holders |
|
24 |
| Section 10.02 |
|
With Consent of Holders |
|
24 |
| Section 10.03 |
|
Compliance with Trust Indenture Act |
|
25 |
| Section 10.04 |
|
Revocation and Effect of Consents |
|
25 |
| Section 10.05 |
|
Notation on or Exchange of Securities |
|
26 |
| Section 10.06 |
|
Trustee to Sign Amendments, etc. |
|
26 |
| |
|
ARTICLE ELEVEN
|
| |
| SECURITIES IN FOREIGN CURRENCIES |
| |
|
|
| Section 11.01 |
|
Applicability of Article |
|
26 |
| |
| ARTICLE TWELVE |
| |
| MISCELLANEOUS |
| |
|
|
| Section 12.01 |
|
Trust Indenture Act Controls |
|
27 |
| Section 12.02 |
|
Notices |
|
27 |
| Section 12.03 |
|
Communications by Holders with Other Holders |
|
27 |
| Section 12.04 |
|
Certificate and Opinion as to Conditions Precedent |
|
27 |
| Section 12.05 |
|
Statements Required in Certificate or Opinion |
|
28 |
| Section 12.06 |
|
Rules by Trustee and Agents |
|
28 |
| Section 12.07 |
|
Legal Holidays |
|
28 |
| Section 12.08 |
|
Governing Law |
|
28 |
| Section 12.09 |
|
No Adverse Interpretation of Other Agreements |
|
28 |
| Section 12.10 |
|
No Recourse Against Others |
|
28 |
| Section 12.11 |
|
Successors and Assigns |
|
29 |
| Section 12.12 |
|
Duplicate Originals |
|
29 |
| Section 12.13 |
|
Severability |
|
29 |
| Section 12.14 |
|
Waiver of Jury Trial |
|
29 |
| |
|
| SIGNATURES |
|
30 |
| |
|
| EXHIBIT A – Form of Security |
|
31 |
INDENTURE
dated as of , 202 , (the “Base Indenture”), by and among GYRE THERAPEUTICS, INC., a Delaware corporation
(the “Company”) and [ ], as trustee (the “Trustee”).
Each
party agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders of the Company’s
debt securities issued under this Base Indenture:
ARTICLE
ONE
DEFINITIONS
AND INCORPORATION BY REFERENCE
Section
1.01 Definitions.
“Affiliate”
means, when used with reference to a specified person, any Person directly or indirectly controlling or controlled by or under
direct or indirect common control with the Person specified.
“Agent”
means any Registrar, Paying Agent or co-Registrar or agent for service of notices and demands.
“Authorizing
Resolution” means a resolution adopted by the Board of Directors or by an Officer or committee of Officers pursuant
to Board delegation authorizing a Series of Securities.
“Bankruptcy
Law” means Title 11 of the United States Code, as amended, or any similar federal or state law for the relief of debtors.
“Board
of Directors” means the Board of Directors of the Company or any duly authorized committee thereof.
“Capital
Stock” means, with respect to any Person, any and all shares, interests, participations or other equivalents (however
designated) of or in such Person’s capital stock or other equity interests.
“Company”
means the party named as such in this Indenture until a successor replaces it pursuant to the Indenture and thereafter means the
successor.
“control”
means, when used with respect to any Person, the power to direct the management and policies of such Person, directly or indirectly,
whether through the ownership of voting securities, by contract or otherwise; and the terms “controlling” and
“controlled” have meanings correlative to the foregoing.
“Default”
means any event, act or condition that is, or after notice or the passage of time or both would be, an Event of Default.
“Definitive
Security” means a certificated Security registered in the name of the Securityholder thereof.
“Depositary”
means, with respect to Securities of any Series which the Company shall determine will be issued in whole or in part as a Global
Security, DTC, another clearing agency, or any successor registered as a clearing agency under the Exchange Act, and any other
applicable U.S. or foreign statute or regulation, which, in each case, shall be designated by the Company pursuant to Section
2.01.
“Dollars”
and “$” mean United States Dollars.
“DTC”
means The Depository Trust Company, New York, New York.
“Exchange
Act” means the Securities Exchange Act of 1934, as amended.
“Foreign
Currency” means any currency, currency unit or composite currency, including, without limitation, the Euro, issued by
the government of one or more countries other than the United States of America or by any recognized confederation or association
of such governments.
“GAAP”
means generally accepted accounting principles set forth in the accounting standards codification of the Financial Accounting
Standards Board or in such other statements by such or any other entity as may be approved by a significant segment of the accounting
profession of the United States, as in effect on the date of this Base Indenture.
“Global
Security” means, with respect to any Series of Securities, a Security executed by the Company and delivered by the Trustee
to the Depositary or pursuant to the Depositary’s instruction, all in accordance with the Indenture, which shall be registered
in the name of the Depositary or its nominee.
“Government
Obligations” means securities which are (i) direct obligations of the United States or the other government or governments
in the confederation which issued the Foreign Currency in which the principal of or any interest on the Security of the applicable
Series shall be payable, in each case for the payment of which its full faith and credit is pledged or (ii) obligations of a Person
controlled or supervised by and acting as an agency or instrumentality of the United States or such other government or governments,
in each case the payment of which is unconditionally guaranteed as a full faith and credit obligation by the United States or
such other government or governments, which, in either case are not callable or redeemable at the option of the issuer or issuers
thereof, and shall also include a depositary receipt issued by a bank or trust company as custodian with respect to any such Government
Obligations or a specific payment of interest on or principal of any such Government Obligation held by such custodian for the
account of the holder of a depositary receipt; provided that (except as required by law) such custodian is not authorized
to make any deduction from the amount payable to the holder of such depositary receipt from any amount received by the custodian
in respect of the Government Obligation or the specific payment of interest on or principal of the Government Obligation evidenced
by such depositary receipt.
“Holder”
or “Securityholder” means the Person in whose name a Security is registered on the Registrar’s books.
“Indenture”
means this Base Indenture as amended or supplemented from time to time, including pursuant to any Authorizing Resolution or supplemental
indenture pertaining to any Series, and including, for all purposes of this instrument and any such Authorizing Resolution or
supplemental indenture, the provisions of the TIA that are deemed to be a part of and govern this Base Indenture and any such
Authorizing Resolution or supplemental indenture, respectively.
“Issue
Date” means, with respect to any Series of Securities, the date on which the Securities of such Series are originally
issued under this Indenture.
“NYUCC”
means the New York Uniform Commercial Code, as in effect from time to time.
“Officer”
means the Chairman of the Board, the President, any Vice President, the Treasurer, the Controller or the Secretary of the Company.
“Officers’
Certificate” means a certificate signed by two Officers or by an Officer and an Assistant Treasurer or an Assistant
Secretary of the Company.
“Opinion
of Counsel” means a written opinion, in form and substance reasonably satisfactory to the Trustee, from legal counsel.
The counsel may be an employee of or counsel to the Company. Each such opinion shall include the statements provided for in Section
12.05 if and to the extent required by the provisions of such Section.
“Person”
means any individual, corporation, partnership, limited liability company, joint venture, incorporated or unincorporated association,
joint stock company, trust, unincorporated organization or government or any agency or political subdivision thereof.
“principal”
of a debt security means the principal of the security plus, when appropriate, the premium, if any, on the security.
“Property”
of any Person means all types of real, personal, tangible, intangible or mixed property owned by such Person, whether or not included
in the most recent consolidated balance sheet of such Person and its Subsidiaries under GAAP.
“SEC”
means the Securities and Exchange Commission or any successor agency performing the duties now assigned to it under the TIA.
“Securities”
means any Securities that are issued under this Base Indenture.
“Securities
Act” means the Securities Act of 1933, as amended.
“Series”
means a series of Securities established under this Base Indenture.
“Significant
Subsidiary” means any Subsidiary of the Company which would constitute a “significant subsidiary” as defined
in Rule 1-02 of Regulation S-X under the Securities Act and the Exchange Act.
“Subsidiary”
of any Person means any corporation or other entity of which a majority of the Capital Stock having ordinary voting power to elect
a majority of the board of directors of such entity or other persons performing similar functions is at the time directly or indirectly
owned or controlled by such Person.
“TIA”
means the Trust Indenture Act of 1939, as in effect from time to time, except as otherwise provided herein.
“Trustee”
means the party named as such in this Base Indenture until a successor replaces it pursuant to this Base Indenture and thereafter
means the successor serving hereunder; provided, however, that if at any time there is more than one such Person,
“Trustee” as used with respect to the Securities of any Series shall mean only the Trustee with respect to Securities
of that Series.
“Trust
Officer” means, when used with respect to the Trustee, any officer within the corporate trust department of the Trustee,
including any vice president, assistant vice president, assistant secretary, senior associate, associate, trust officer or any
other officer of the Trustee who customarily performs functions similar to those performed by the Persons who at the time shall
be such officers or to whom any corporate trust matter is referred because of such person’s knowledge of and familiarity
with the particular subject and who shall have direct responsibility for the administration of this Indenture.
“United
States” means the United States of America.
Section
1.02 Other Definitions.
| |
|
|
|
|
| Term |
|
Defined in Section |
|
| Agent Members |
|
|
2.15 |
|
| Base Indenture |
|
|
Preamble |
|
| Business Day |
|
|
12.07 |
|
| Covenant Defeasance |
|
|
8.01 |
|
| Custodian |
|
|
6.01 |
|
| Event of Default |
|
|
6.01 |
|
| Legal Defeasance |
|
|
8.01 |
|
| Legal Holiday |
|
|
12.07 |
|
| Paying Agent |
|
|
2.03 |
|
| Payment Default |
|
|
6.01 |
|
| Registrar |
|
|
2.03 |
|
| Security Register |
|
|
2.03 |
|
| Successor |
|
|
5.01 |
|
Section
1.03 Incorporation by Reference of Trust Indenture Act.
Whenever
this Indenture refers to a provision of the TIA, the provision is incorporated by reference in and made a part of this Indenture.
The following TIA terms used in this Indenture have the following meanings:
“Commission”
means the SEC.
“indenture
securities” means the Securities of a particular Series.
“indenture
security holder” means a Securityholder.
“indenture
to be qualified” means this Indenture.
“indenture
trustee” or “institutional trustee” means the Trustee.
“obligor”
on the indenture securities means the Company or any other obligor on the Securities of a Series.
All
other TIA terms used in this Indenture that are defined by the TIA, defined by TIA reference to another statute or defined by
SEC rule have the meanings so assigned to them.
Section
1.04 Rules of Construction.
Unless
the context otherwise requires:
| |
(1) |
a term has the meaning assigned to it herein; |
| |
(2) |
an accounting term not otherwise defined has the meaning assigned to it in accordance with GAAP and all accounting
determinations shall be made in accordance with GAAP; |
| |
(3) |
“or” is not exclusive and “including” means “including without limitation”; |
| |
(4) |
words in the singular include the plural, and in the plural include the singular; |
| |
(5) |
“herein,” “hereof” and “hereunder,” and other words of similar import, refer to this Indenture as a whole (including any
Authorizing Resolution or supplemental indenture relating to the relevant Series) and not to any particular Article, Section or other subdivision; |
| |
(6) |
all exhibits are incorporated by reference herein and expressly made a part of this Indenture; and |
| |
(7) |
any transaction or event shall be considered “permitted by” or made “in accordance with” or “in compliance with” this
Indenture or any particular provision thereof if such transaction or event is not expressly prohibited by this Indenture or such provision, as the case may be. |
ARTICLE
TWO
THE
SECURITIES
Section
2.01 Form and Dating.
The
aggregate principal amount of Securities that may be issued under this Base Indenture is unlimited. The Securities may be issued
from time to time in one or more Series. Each Series shall be created by an Authorizing Resolution or a supplemental indenture
that establishes the terms of the Series, which may include the following:
| |
(1) |
the title of the Series (which shall distinguish the Securities of such Series from all other Securities); |
| |
(2) |
the aggregate principal amount (or any limit on the aggregate principal amount) of the Series and, if any Securities of a
Series are to be issued at a discount from their face amount, the method of computing the accretion of such discount; |
| |
(3) |
the interest rate or method of calculation of the interest rate; |
| |
(4) |
the date from which interest will accrue; |
| |
(5) |
the record dates for interest payable on Securities of the Series; |
| |
(6) |
the dates when, places where and manner in which principal and interest are payable; |
| |
(7) |
the Registrar and Paying Agent; |
| |
(8) |
the terms of any mandatory (including any sinking fund requirements) or optional redemption by the Company; |
| |
(9) |
the terms of any redemption at the option of Holders; |
| |
(10) |
the permissible denominations in which Securities of such Series are issuable, if different from $2,000 and multiples of
$1,000 in excess thereof; |
| |
(11) |
whether Securities of such Series will be issued in registered or bearer form and the terms of any such forms of Securities;
|
| |
(12) |
whether the Securities of the Series shall be issued in whole or in part in the form of a Global Security or Securities, the
terms and conditions, if different from those contained in this Base Indenture, upon which such Global Security or Securities may be exchanged in whole or in part for Definitive Securities; the Depositary for such Global Security or Securities;
and the form of any legend or legends, if any, to be borne by any such Global Security or Securities in addition to or in lieu of the legends referred to in Section 2.15; |
| |
(13) |
the currency or currencies (including any composite currency) in which principal or interest or both may be paid; |
| |
(14) |
if payments of principal or interest may be made in a currency other than that in which Securities of such Series are
denominated, the manner for determining such payments, including the time and manner of determining the exchange rate between the currency in which such Securities are denominated and the currency in which such Securities or any of them may be
paid, and any deletions from or modifications of or additions to the terms of this Indenture to provide for or to facilitate the issuance of Securities denominated or payable, at the election of the Company or a Holder thereof or otherwise, in
a Foreign Currency; |
| |
(15) |
provisions for electronic issuance of Securities or issuance of Securities of such Series in uncertificated form; |
| |
(16) |
any Events of Default, covenants and/or defined terms in addition to or in lieu of those set forth in this Base Indenture; |
| |
(17) |
whether and upon what terms Securities of such Series may be defeased or discharged if different from the provisions set
forth in this Base Indenture; |
| |
(18) |
the form of the Securities of such Series, which, unless the Authorizing Resolution or supplemental indenture otherwise
provides, shall be in the form of Exhibit A; |
| |
(19) |
any terms that may be required by or advisable under applicable law; |
| |
(20) |
the percentage of the principal amount of the Securities of such Series which is payable if the maturity of the Securities of
such Series is accelerated in the case of Securities issued at a discount from their face amount; |
| |
(21) |
whether Securities of such Series will or will not have the benefit of guarantees and the Company’s Subsidiaries that will be
the initial guarantors of such Series and, if applicable, the terms and conditions upon which such guarantees may be subordinated to other indebtedness of the respective guarantors; |
| |
(22) |
whether the Securities of such Series are senior or subordinated debt securities, and if subordinated debt securities, the
terms of such subordination; |
| |
(23) |
whether the Securities of the Series will be convertible into or exchangeable for other Securities, common shares or other
securities of any kind of the Company or another obligor, and, if so, the terms and conditions upon which such Securities will be so convertible or exchangeable, including the initial conversion or exchange price or rate or the method of
calculation, how and when the conversion price or exchange ratio may be adjusted, whether conversion or exchange is mandatory, at the option of the holder or at the Company’s option, the conversion or exchange period, and any other provision in
relation thereto; and |
| |
(24) |
any other terms in addition to or different from those contained in this Base Indenture applicable to such Series. |
All
Securities of one Series need not be issued at the same time and, unless otherwise provided, a Series may be reopened for issuances
of additional Securities of such Series pursuant to an Authorizing Resolution, an Officers’ Certificate or in any indenture
supplemental hereto.
The
creation and issuance of a Series and the authentication and delivery thereof are not subject to any conditions precedent.
Section
2.02 Execution and Authentication.
One
Officer shall sign the Securities for the Company by manual or facsimile signature.
If
an Officer whose signature is on a Security no longer holds that office at the time the Trustee authenticates the Security, the
Security shall nevertheless be valid.
A
Security shall not be valid until the Trustee manually signs the certificate of authentication on the Security. The signature
shall be conclusive evidence that the Security has been authenticated under this Base Indenture.
At
any time and from time to time after the execution and delivery of this Indenture, the Company may deliver Securities of any series
executed by the Company to the Trustee for authentication. Each Security shall be dated the date of its authentication. The Trustee
shall authenticate Securities for original issue upon receipt of, and shall be fully protected in relying upon:
(a)
An order to the Trustee signed by an officer of the Company directing the Trustee to authenticate the Securities;
(b)
a copy of the resolution or resolutions of the Board of Directors in or pursuant to which the terms and form of the Securities
were established, certified by the Secretary or an Assistant Secretary of the Company to have been duly adopted by the Board of
Directors and to be in full force and effect as of the date of such certificate, and if the terms and form of such Securities
are established by an Officers’ Certificate pursuant to general authorization of the Board of Directors, such Officers’
Certificate;
(c)
an Officers’ Certificate of the Company delivered in accordance with Section 12.04; and
(d)
an Opinion of Counsel delivered in accordance with Section 12.04.
The
Trustee shall have the right to decline to authenticate and deliver any Securities under this Section if the Trustee, being advised
by counsel, determines that such action may not lawfully be taken or if the Trustee in good faith shall determine that such action
would expose the Trustee to personal liability to existing Holders.
Section
2.03 Registrar and Paying Agent.
The
Company shall maintain an office or agency where Securities may be presented for registration of transfer or where Securities
of a Series that are convertible or exchangeable may be surrendered for conversion or exchange (“Registrar”),
an office or agency where Securities may be presented for payment (“Paying Agent”) and an office or agency
where notices and demands to or upon the Company in respect of the Securities and this Indenture may be served. The Registrar
shall keep a register of the Securities and of their transfer and exchange (the “Security Register”). The Company
may have one or more co-Registrars and one or more additional paying agents. The term “Paying Agent” includes any
additional paying agent.
The
Company shall enter into an appropriate agency agreement with any Agent not a party to this Base Indenture. The agreement shall
implement the provisions of this Indenture that relate to such Agent. The Company shall promptly notify the Trustee in writing
of the name and address of any such Agent and the Trustee shall have the right to inspect the Securities Register at all reasonable
times to obtain copies thereof, and the Trustee shall have the right to rely upon such register as to the names and addresses
of the Holders and the principal amounts and certificate numbers thereof. If the Company fails to maintain a Registrar or Paying
Agent or fails to give the foregoing notice, the Trustee shall act as such.
The
Company initially appoints the Trustee as Registrar and Paying Agent.
Section
2.04 Paying Agent to Hold Money in Trust.
Each
Paying Agent shall hold in trust for the benefit of Securityholders and the Trustee all money held by the Paying Agent for the
payment of principal of or interest on the Securities, and shall notify the Trustee of any default by the Company in making any
such payment. If the Company or a Subsidiary acts as Paying Agent, it shall segregate the money and hold it as a separate trust
fund. The Company at any time may require a Paying Agent to pay all money held by it to the Trustee. Upon doing so the Paying
Agent shall have no further liability for the money.
Section
2.05 Securityholder Lists.
The
Trustee shall preserve in as current a form as is reasonably practicable the most recent list available to it of the names and
addresses of Securityholders. If the Trustee is not the Registrar, the Company shall furnish to the Trustee at least five (5)
Business Days before each semiannual interest payment date and at such other times as the Trustee may request in writing a list
in such form and as of such date as the Trustee may reasonably require of the names and addresses of Securityholders.
Section
2.06 Transfer and Exchange.
Where
a Security is presented to the Registrar or a co-Registrar with a request to register a transfer, the Registrar shall register
the transfer as requested if the requirements of Section 8-401(a) of the NYUCC are met and the other provisions of this Section
2.06 are satisfied. Where Securities are presented to the Registrar or a co-Registrar with a request to exchange them for
an equal principal amount of Securities of other denominations, the Registrar shall make the exchange as requested if the same
requirements are met. To permit transfers and exchanges, the Trustee shall authenticate Securities at the Registrar’s request.
The Registrar need not transfer or exchange any Security selected for redemption or repurchase, except the unredeemed or repurchased
part thereof if the Security is redeemed or repurchased in part, or transfer or exchange any Securities for a period of 15 days
before a selection of Securities to be redeemed or repurchased. Any exchange or transfer shall be without charge, except that
the Company may require payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation
thereto except in the case of exchanges pursuant to 2.09, 3.06, or 10.05 not involving any transfer.
Any
Holder of a Global Security shall, by acceptance of such Global Security, agree that transfers of beneficial interests in such
Global Security may be effected only through a book entry system maintained by the Holder of such Global Security (or its agent),
and that ownership of a beneficial interest in the Security shall be required to be reflected in a book entry.
Section
2.07 Replacement Securities.
If
the Holder of a Security claims that the Security has been lost, destroyed, mutilated or wrongfully taken, the Company shall issue
and execute a replacement security and, upon written request of any Officer of the Company, the Trustee shall authenticate such
replacement Security, provided, in the case of a lost, destroyed or wrongfully taken Security, that the requirements of
Section 8-405 of the NYUCC are met. If any such lost, destroyed, mutilated or wrongfully taken Security shall have matured or
shall be about to mature, the Company may, instead of issuing a substitute Security therefor, pay such Security without requiring
(except in the case of a mutilated Security) the surrender thereof. An indemnity bond must be sufficient in the judgment of the
Company and the Trustee to protect the Company, the Trustee and any Agent from any loss which any of them may suffer if a Security
is replaced, including the acquisition of such Security by a bona fide purchaser. The Company and the Trustee may charge for its
expenses in replacing a Security.
Section
2.08 Outstanding Securities.
Securities
outstanding at any time are all Securities authenticated by the Trustee except for those cancelled by it and those described in
this Section. A Security does not cease to be outstanding because the Company or one of its Affiliates holds the Security.
If
a Security is replaced pursuant to Section 2.07, it ceases to be outstanding unless the Trustee receives proof satisfactory
to it that the replaced Security is held by a “protected purchaser” (as such term is defined in the NYUCC).
If
the Paying Agent holds on a redemption date, purchase date or maturity date money sufficient to pay Securities payable on that
date, then on and after that date such Securities cease to be outstanding and interest on them ceases to accrue.
Subject
to the foregoing provisions of this Section, each Security delivered under this Indenture upon registration of transfer of or
in exchange for or in lieu of any other Security shall carry the rights to interest accrued and unpaid, and to accrue, which were
carried by such other Security.
Section
2.09 Temporary Securities.
Until
Definitive Securities are ready for delivery, the Company may prepare and the Trustee shall authenticate temporary Securities.
Temporary Securities shall be substantially in the form of Definitive Securities but may have variations that the Company considers
appropriate for temporary Securities. Without unreasonable delay, the Company shall prepare and, upon surrender for cancellation
of the temporary Security, the Company shall execute and the Trustee shall authenticate Definitive Securities in exchange for
temporary Securities. Until so exchanged, the temporary Securities shall in all respects be entitled to the same benefits under
this Indenture as Definitive Securities authenticated and delivered hereunder.
Section
2.10 Cancellation.
The
Company at any time may deliver Securities to the Trustee for cancellation. The Registrar and Paying Agent shall forward to the
Trustee any Securities surrendered to them for registration of transfer, exchange, redemption, purchase or payment. The Trustee
and no one else shall cancel and dispose of such cancelled or tendered securities, or retain in accordance with its standard retention
policy, all Securities surrendered for registration of transfer, exchange, redemption, purchase, payment or cancellation. Unless
the Authorizing Resolution or supplemental indenture so provides, the Company may not issue new Securities to replace Securities
that it has previously paid or delivered to the Trustee for cancellation.
Section
2.11 Defaulted Interest.
If
the Company defaults in a payment of interest on the Securities of any Series, it shall pay the defaulted interest plus
any interest payable on the defaulted interest to the persons who are Securityholders of such Series on a subsequent special record
date. The Company shall fix such special record date and a payment date which shall be reasonably satisfactory to the Trustee.
At least 15 days before such special record date, the Company shall mail to each Securityholder of the relevant Series a notice
that states the record date, the payment date and the amount of defaulted interest to be paid. On or before the date such notice
is mailed, the Company shall deposit with the Paying Agent money sufficient to pay the amount of defaulted interest to be so paid.
The Company may pay defaulted interest in any other lawful manner if, after notice given by the Company to the Trustee of the
proposed payment, such manner of payment shall be deemed practicable by the Trustee.
Section
2.12 Treasury Securities.
In
determining whether the Holders of the required principal amount of Securities of a Series have concurred in any direction, waiver,
consent or notice, Securities owned by the Company or any of its Affiliates shall be considered as though they are not outstanding,
except that for the purposes of determining whether the Trustee shall be protected in relying on any such direction, waiver or
consent, only Securities which a Trust Officer of the Trustee actually knows are so owned shall be so considered.
Section
2.13 CUSIP/ISIN Numbers.
The
Company in issuing the Securities of any Series may use a “CUSIP” and/or “ISIN” or other similar number,
and if so, the Trustee shall use the CUSIP and/or ISIN or other similar number in notices of redemption or exchange as a convenience
to Holders of such Securities; provided that no representation is hereby deemed to be made by the Trustee as to the correctness
or accuracy of any such CUSIP and/or ISIN or other similar number printed in the notice or on such Securities, and that reliance
may be placed only on the other identification numbers printed on such Securities. The Company shall promptly notify the Trustee
of any change in any CUSIP and/or ISIN or other similar number.
Section
2.14 Deposit of Moneys.
Prior
to 11:00 a.m., New York City time, on each interest payment date and maturity date with respect to each Series of Securities,
the Company shall have deposited with the Paying Agent in immediately available funds money in the applicable currency sufficient
to make cash payments due on such interest payment date or maturity date, as the case may be, in a timely manner which permits
the Paying Agent to remit payment to the Holders of such Series on such interest payment date or maturity date, as the case may
be.
Section
2.15 Book-Entry Provisions for Global Security.
(a)
Any Global Security of a Series initially shall (i) be registered in the name of the Depositary or the nominee of such Depositary,
(ii) be delivered to the Trustee as custodian for such Depositary and (iii) bear any required legends.
Members
of, or participants in, the Depositary (“Agent Members”) shall have no rights under this Indenture with respect
to any Global Security held on their behalf by the Depositary, or the Trustee as its custodian, or under the Global Security,
and the Depositary may be treated by the Company, the Trustee and any agent of the Company or the Trustee as the absolute owner
of the Global Security for all purposes whatsoever. Notwithstanding the foregoing, nothing herein shall prevent the Company, the
Trustee or any agent of the Company or the Trustee from giving effect to any written certification, proxy or other authorization
furnished by the Depositary or impair, as between the Depositary and its Agent Members, the operation of customary practices governing
the exercise of the rights of a Holder of any Security.
(b)
Transfers of any Global Security shall be limited to transfers in whole, but not in part, to the Depositary, its successors or
their respective nominees. Interests of beneficial owners in the Global Security may be transferred or exchanged for Definitive
Securities in accordance with the rules and procedures of the Depositary. In addition, Definitive Securities shall be transferred
to all beneficial owners in exchange for their beneficial interests in a Global Security if (i) the Depositary notifies the Company
that it is unwilling or unable to continue as Depositary for the Global Security or the Depositary has ceased to be a “clearing
agency” registered under the Exchange Act, and a successor depository is not appointed by the Company within 90 days of
such notice, or (ii) the Company elects, at any time in its sole discretion, to discontinue use of the system of book entry transfer
through any Depositary. Any Security that is held in the form of a Global Security and that is exchanged pursuant to clause (i)
above shall be so exchanged in whole and not in part, and any Security that is held in the form of a Global Security and that
is exchanged pursuant to clause (ii) above may be exchanged in whole or from time to time in part as directed by the Company.
(c)
In connection with any transfer or exchange of a portion of the beneficial interest in any Global Security to beneficial owners
pursuant to paragraph (b), the Registrar shall (if one or more Definitive Securities are to be issued) reflect on its books
and records the date and a decrease in the principal amount of the Global Security in an amount equal to the principal amount
of the beneficial interest in the Global Security to be transferred, and the Company shall execute, and the Trustee shall authenticate
and deliver, one or more Definitive Securities of like Series and amount.
(d)
In connection with the transfer of an entire Global Security to beneficial owners pursuant to paragraph (b), the Global
Security shall be deemed to be surrendered to the Trustee for cancellation, and the Company shall execute, and the Trustee shall
authenticate and deliver, to each beneficial owner identified by the Depositary in exchange for its beneficial interest in the
Global Security, an equal aggregate principal amount of Definitive Securities of the same Series in authorized denominations.
(e)
The Holder of any Global Security may grant proxies and otherwise authorize any person, including Agent Members and persons that
may hold interests through Agent Members, to take any action which a Holder is entitled to take under this Indenture or the Securities
of such Series.
(f)
Unless otherwise provided in the Authorizing Resolution or supplemental indenture for a particular Series of Securities, each
Global Security of such Series shall bear legends in substantially the following forms:
“THIS
GLOBAL SECURITY IS HELD BY THE DEPOSITARY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY) OR ITS NOMINEE IN CUSTODY FOR
THE BENEFIT OF THE HOLDERS OF BENEFICIAL INTERESTS HEREIN, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANCES EXCEPT
THAT (I) THE TRUSTEE MAY MAKE ANY SUCH NOTATIONS HEREON AS MAY BE REQUIRED PURSUANT TO THE INDENTURE, (II) THIS GLOBAL SECURITY
MAY BE EXCHANGED IN WHOLE BUT NOT IN PART PURSUANT TO SECTION 2.06 AND SECTION 2.15 OF THE INDENTURE, (III) THIS GLOBAL SECURITY
MAY BE DELIVERED TO THE TRUSTEE FOR CANCELLATION PURSUANT TO THE INDENTURE AND (IV) THIS GLOBAL SECURITY MAY BE TRANSFERRED TO
A SUCCESSOR DEPOSITARY WITH THE PRIOR WRITTEN CONSENT OF THE COMPANY.”
“UNLESS
AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS
A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR TO ANOTHER NOMINEE
OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY.
UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”),
TO ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF
CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE &
CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF
FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST
HEREIN.”
Section
2.16 No Duty to Monitor.
The
Trustee shall have no obligation or duty to monitor, determine or inquire as to compliance with any restrictions on transfer imposed
under this Indenture or under applicable law with respect to any transfer of any interest in any Security (including any transfers
between or among Agent Members or beneficial owners of interests in any Global Security) other than to require delivery of such
certificates and other documentation or evidence as are expressly required by, and to do so if and when expressly required by
the terms of, this Indenture, and to examine the same to determine substantial compliance as to form with the express requirements
hereof.
Neither
the Trustee nor any Agent shall have any responsibility for any actions taken or not taken by the Depositary.
ARTICLE
THREE
REDEMPTION
Section
3.01 Notices to Trustee.
Securities
of a Series that are redeemable prior to maturity shall be redeemable in accordance with their terms and, unless the Authorizing
Resolution or supplemental indenture provides otherwise, in accordance with this Article Three.
If
the Company wants to redeem Securities pursuant to Paragraph 4 of the Securities, it shall notify the Trustee in writing
of the redemption date and the principal amount of Securities to be redeemed. Any such notice may be cancelled at any time prior
to notice of such redemption being mailed to Holders. Any such cancelled notice shall be void and of no effect.
If
the Company wants to credit any Securities previously redeemed, retired or acquired against any redemption pursuant to Paragraph
5 of the Securities, it shall notify the Trustee of the amount of the credit and it shall deliver any Securities not previously
delivered to the Trustee for cancellation with such notice.
The
Company shall give each notice provided for in this Section 3.01 at least 30 days before the notice of any such redemption
is to be delivered to Holders (unless a shorter notice shall be satisfactory to the Trustee).
Section
3.02 Selection of Securities to be Redeemed.
If
fewer than all of the Securities of a Series are to be redeemed, the Trustee (or depository, as applicable) shall select the Securities
to be redeemed by lot, pro rata, or such other method the Trustee (or depository, as applicable) considers fair and appropriate
and in a manner that complies with applicable requirements of the Depositary. The Trustee (or depository, as applicable) shall
make the selection from Securities outstanding not previously called for redemption and shall promptly notify the Company of the
serial numbers or other identifying attributes of the Securities so selected. The Trustee (or depository, as applicable) may select
for redemption portions of the principal of Securities that have denominations larger than the minimum denomination for the Series.
Securities and portions of them it selects shall be in amounts equal to a permissible denomination for the Series. Provisions
of this Indenture that apply to Securities called for redemption also apply to portions of Securities called for redemption.
Unless
otherwise provided in the Authorizing Resolution or supplemental indenture relating to a Series, if any Security selected for
partial redemption is converted into or exchanged for the Company’s Capital Stock or other securities, cash or other property
in part before termination of the conversion or exchange right with respect to the portion of the Security so selected, the converted
portion of such Security shall be deemed (so far as may be) to be the portion selected for redemption. Securities which have been
converted or exchanged during a selection of Securities to be redeemed shall be treated by the Trustee as outstanding for the
purpose of such selection.
Section
3.03 Notice of Redemption.
At
least 30 days but not more than 60 days before a redemption date, the Company shall mail a notice of redemption by first-class
mail, postage prepaid, to each Holder of Securities to be redeemed.
The
notice shall identify the Securities to be redeemed and shall state:
| |
(2) |
the redemption price or the formula pursuant to which such price will be calculated; |
| |
(3) |
if any Security is being redeemed in part, the portion of the principal amount of such Security to be redeemed and that,
after the redemption date, upon surrender of such Security, a new Security or Securities in principal amount equal to the unredeemed portion shall be issued upon cancellation of the original Security; |
| |
(4) |
in the case of Securities of a Series that are convertible or exchangeable into shares of the Company’s Capital Stock or
other securities, cash or other property, the conversion or exchange price or rate, the date or dates on which the right to convert or exchange the principal of the Securities of such Series to be redeemed will commence or terminate and the
place or places where such Securities may be surrendered for conversion or exchange; |
| |
(5) |
the name and address of the Paying Agent; |
| |
(6) |
that Securities called for redemption must be surrendered to the Paying Agent to collect the redemption price; |
| |
(7) |
that interest on Securities called for redemption ceases to accrue on and after the redemption date; |
| |
(8) |
that the Securities are being redeemed pursuant to the mandatory redemption or the optional redemption provisions, as
applicable; and |
| |
(9) |
the CUSIP number and/or ISIN or other similar number used to identify the Securities, that no representation is hereby deemed
to be made be made by the Trustee as to the correctness or accuracy of any such CUSIP and/or ISIN or other similar number printed in the notice or on such Securities, and that reliance may be placed only on the other identification numbers
printed on such Securities. |
At
the Company’s request, the Trustee shall give the notice of redemption in the Company’s name and at its expense; provided,
however, that the Company shall deliver to the Trustee at least 15 days prior to the date on which notice of redemption
is to be mailed or such shorter period as may be satisfactory to the Trustee, an Officers’ Certificate requesting that the
Trustee give such notice and setting forth the information to be stated in such notice as provided in the preceding paragraph.
Section
3.04 Effect of Notice of Redemption.
Once
notice of redemption is mailed, Securities called for redemption become due and payable on the redemption date and at the redemption
price as set forth in the notice of redemption, which notice, and which obligation to redeem such Securities, may, at the Company’s
discretion, be subject to one or more conditions precedent as set forth in such notice. Upon surrender to the Paying Agent, such
Securities shall be paid at the redemption price, plus accrued and unpaid interest to the redemption date.
Section
3.05 Deposit of Redemption Price.
On
or before the redemption date, the Company shall deposit with the Paying Agent immediately available funds in the applicable currency
sufficient to pay the redemption price of and accrued interest on all Securities to be redeemed on that date.
Section
3.06 Securities Redeemed in Part.
Upon
surrender of a Security that is redeemed in part, the Company shall execute and the Trustee shall authenticate for each Holder
a new Security of the same Series equal in principal amount to the unredeemed portion of the Security surrendered.
ARTICLE
FOUR
COVENANTS
Section
4.01 Payment of Securities.
The
Company shall pay the principal of, premium, if any, and interest on a Series on the dates, in the currency and in the manner
provided in the Securities of the Series. An installment of principal, premium, if any, or interest shall be considered paid on
the date it is due if the Paying Agent holds on that date money in the applicable currency designated for and sufficient to pay
the installment.
Section
4.02 Maintenance of Office or Agency.
The
Company shall maintain the office or agency required under Section 2.03. The Company shall give prior written notice to
the Trustee of the location, and any change in the location, of such office or agency. If at any time the Company shall fail to
maintain any such required office or agency or shall fail to furnish the Trustee with the address thereof, such presentations,
surrenders, notices and demands may be made or served at the address of the Trustee.
Section
4.03 Reports.
At
any time when the Company is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act, the Company shall
file with the Trustee, within fifteen (15) days after it actually files the same with the SEC (regardless of when the same is
required to be filed with the SEC), each annual, quarterly or current report, information or proxy statement other report which
the Company is required to file with the SEC pursuant to Section 13 or 15(d) of the Exchange Act; provided, however,
that the Company shall not be required to file or deliver to the Trustee any material for which the Company has sought and received,
or is seeking, confidential treatment by the SEC; and, provided further, that the Company shall be deemed to have filed
such information with the Trustee if the Company has filed such information on the SEC’s EDGAR system (or any successor
system) and such information is publicly available. The Company also shall comply with the other provisions of TIA Section 314(a).
The Trustee does not have the duty to review such information, documents or reports, is not considered to have notice of the content
of such information, documents or reports and does not have a duty to verify the accuracy of such information, documents or reports.
Section
4.04 Compliance Certificate.
The
Company shall deliver to the Trustee within 120 days after the end of each fiscal year of the Company an Officers’ Certificate
stating whether or not the signers know of any continuing Default by the Company in performing any of its obligations under this
Indenture. If they do know of such a Default, the certificate shall describe the Default. In addition, the Company will notify
the Trustee within 5 business days upon the Company’s knowledge of a Default.
Section
4.05 Waiver of Stay, Extension or Usury Laws.
The
Company covenants (to the extent that it may lawfully do so) that it will not at any time insist upon, plead, or in any manner
whatsoever claim or take the benefit or advantage of, any stay or extension law or any usury law or other law that would prohibit
or forgive the Company from paying all or any portion of the principal of or interest on the Securities of any Series as contemplated
herein, wherever enacted, now or at any time hereafter in force, or which may affect the covenants or the performance of this
Indenture; and (to the extent that it may lawfully do so) the Company expressly waives all benefit or advantage of any such law,
and covenants that it will not hinder, delay or impede the execution of any power herein granted to the Trustee, but will suffer
and permit the execution of every such power as though no such law had been enacted.
ARTICLE
FIVE
SUCCESSOR
CORPORATION
Section
5.01 When Company May Merge, etc.
The
Company will not consolidate or merge with or into, or sell, lease, convey or otherwise dispose of all or substantially all of
its assets (including by way of liquidation or dissolution), to any Person (in each case other than in a transaction in which
the Company is the survivor of a consolidation or merger, or the transferee in a sale, lease, conveyance or other disposition)
unless:
| |
(1) |
the Person formed by or surviving such consolidation or merger (if other than the Company), or to which such sale, lease,
conveyance or other disposition will be made (collectively, the “Successor”) assumes by supplemental indenture in a form reasonably satisfactory to the Trustee all of the obligations of the Company under the Securities, as the case may
be, and the Indenture, and |
| |
(2) |
immediately after giving effect to such transaction, no Default or Event of Default has occurred and is continuing. |
The
foregoing provisions shall not apply to a transaction the purpose of which is to change the state of incorporation of the Company.
Upon
any such consolidation, merger, sale, lease, conveyance or other disposition, the Successor will be substituted for the Company
under the Indenture. The Successor may then exercise every power and right of the Company under this Indenture, and except in
the case of a lease, the Company will be released from all of its liabilities and obligations in respect of the Securities and
the Indenture. If the Company leases all or substantially all of its assets, the Company will not be released from its obligations
to pay the principal of and interest, if any, on the Securities.
ARTICLE
SIX
DEFAULTS
AND REMEDIES
Section
6.01 Events of Default.
An
“Event of Default” with respect to a Series occurs upon the occurrence of any of the following:
| |
(1) |
the failure by the Company to pay interest on any Security of such Series when the same becomes due and payable and the
continuance of any such failure for a period of 30 days; |
| |
(2) |
the failure by the Company to pay the principal of any Security of such Series when the same becomes due and payable at
maturity, upon acceleration, redemption or otherwise; |
| |
(3) |
the failure by the Company to comply with any of its agreements or covenants in, or provisions of, the Securities of such
Series or this Indenture (as they relate thereto) and such failure continues for the period and after the notice specified below (except in the case of a default with respect to Article Five (or any other provision specified in the applicable
supplemental indenture or Authorizing Resolution), which will constitute an Event of Default with notice but without passage of time); |
| |
(4) |
the Company or any Subsidiary that is a Significant Subsidiary pursuant to or within the meaning of any Bankruptcy Law: |
| |
(A) |
commences a voluntary case, |
| |
(B) |
consents to the entry of an order for relief against it in an involuntary case, |
| |
(C) |
consents to the appointment of a Custodian of it or for all or substantially all of its Property, or |
| |
(D) |
makes a general assignment for the benefit of its creditors; |
| |
(5) |
a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that: |
| |
(A) |
is for relief against the Company or any Subsidiary that is a Significant Subsidiary as debtor in an involuntary case, |
| |
(B) |
appoints a Custodian of the Company or any Subsidiary that is a Significant Subsidiary or a Custodian for all or
substantially all of the Property of the Company, or |
| |
(C) |
orders the liquidation of the Company or any Subsidiary that is a Significant Subsidiary, and the order or decree remains
unstayed and in effect for 60 days. |
A
Default as described in subclause (3) above will not be deemed an Event of Default until the Trustee notifies the Company,
or the Holders of at least 25 percent in principal amount of the then outstanding Securities of the applicable Series notify the
Company and the Trustee, of the Default and (except in the case of a default with respect to Article Five (or any other
provision specified in the applicable supplemental indenture or Authorizing Resolution)) the Company does not cure the Default
within 60 days after receipt of the notice. The notice must specify the Default, demand that it be remedied and state that the
notice is a “Notice of Default.” If such a Default is cured within such time period, it ceases to exist, without any
action by the Trustee or any other Person.
The
term “Custodian” means any receiver, trustee, assignee, liquidator, custodian or similar official under any
Bankruptcy Law.
Section
6.02 Acceleration.
If
an Event of Default (other than an Event of Default with respect to the Company resulting from subclause (4) or (5)
above), shall have occurred and be continuing under the Indenture, the Trustee by notice to the Company, or the Holders of
at least 25 percent in principal amount of the Securities of the applicable Series then outstanding by notice to the Company and
the Trustee, may declare all Securities of such Series to be due and payable immediately. Upon such declaration of acceleration,
the amounts due and payable on the Securities of such Series will be due and payable immediately. If an Event of Default with
respect to the Company specified in subclauses (4) or (5) above occurs, all amounts due and payable on the Securities
of such Series will ipso facto become and be immediately due and payable without any declaration, notice or other act on the part
of the Trustee and the Company or any Holder.
Holders
of a majority in principal amount of the then outstanding Securities of such Series may rescind an acceleration with respect to
such Series and its consequence (except an acceleration due to nonpayment of principal or interest) if the rescission would not
conflict with any judgment or decree and if all existing Events of Default (other than the non-payment of accelerated principal)
have been cured or waived.
No
such rescission shall extend to or shall affect any subsequent Event of Default, or shall impair any right or power consequent
thereon.
Section
6.03 Other Remedies.
If
an Event of Default on a Series occurs and is continuing, the Trustee may pursue any available remedy by proceeding at law or
in equity to collect the payment of principal of or interest on the Series or to enforce the performance of any provision in the
Securities or this Indenture applicable to the Series.
The
Trustee may maintain a proceeding even if it does not possess any of the Securities or does not produce any of them in the proceeding.
A delay or omission by the Trustee or any Securityholder in exercising any right or remedy accruing upon an Event of Default shall
not impair the right or remedy or constitute a waiver of or acquiescence in the Event of Default. No remedy is exclusive of any
other remedy. All available remedies are cumulative.
Section
6.04 Waiver of Existing Defaults.
Subject
to Section 10.02, the Holders of a majority in principal amount of the outstanding Securities of a Series on behalf of
all the Holders of the Series by notice to the Trustee may waive an existing Default on such Series and its consequences. When
a Default is waived, it is cured and stops continuing, and any Event of Default arising therefrom shall be deemed to have been
cured; but no such waiver shall extend to any subsequent or other Default or impair any right consequent thereon.
Section
6.05 Control by Majority.
The
Holders of a majority in principal amount of the outstanding Securities of a Series may direct the time, method and place of conducting
any proceeding for any remedy available to the Trustee or exercising any trust or power conferred on it with respect to such Series.
The Trustee, however, may refuse to follow any direction (i) that conflicts with law or this Indenture, (ii) that, subject to
Section 7.01, the Trustee determines is unduly prejudicial to the rights of other Securityholders, (iii) that would involve
the Trustee in personal liability, if there shall be reasonable grounds for believing that adequate indemnity against such liability
is not reasonably assured to it, or (iv) if the Trustee shall not have been provided with indemnity satisfactory to it.
Section
6.06 Limitation on Suits.
A
Securityholder of a Series may not pursue any remedy with respect to this Indenture or the Securities of a Series unless:
| |
(1) |
the Holder gives to the Trustee written notice of a continuing Event of Default on the Series; |
| |
(2) |
the Holders of at least 25% in principal amount of the outstanding Securities of the Series make a written request to the
Trustee to pursue the remedy; |
| |
(3) |
such Holder or Holders offer to the Trustee indemnity satisfactory to the Trustee against any loss, liability or expense; |
| |
(4) |
the Trustee does not comply with the request within 60 days after receipt of the request and the offer of indemnity; and |
| |
(5) |
no written request inconsistent with such written request shall have been given to the Trustee pursuant to this Section
6.06. |
A
Securityholder may not use this Indenture to prejudice the rights of another Holder of Securities of the same Series or to obtain
a preference or priority over another Holder of Securities of the same Series (it being understood that the Trustee does not have
an affirmative duty to ascertain whether or not such actions or forbearances by such Holder are unduly prejudicial to another
Holder).
Section
6.07 Rights of Holders to Receive Payment and Convert.
Notwithstanding
any other provision of this Indenture, the right of any Holder to receive payment of principal of, premium, if any, and interest
on any Security, on or after the respective due dates expressed in the Security, or to bring suit for the enforcement of any such
payment on or after such respective dates, is absolute and unconditional and shall not be impaired or affected without the consent
of the Holder. Notwithstanding anything to the contrary in this Indenture or the Securities, the right of any Holder of Securities
to convert such Securities in accordance with this Indenture, or to bring suit for the enforcement of such right, shall not be
impaired or affected without the consent of the Holder.
Section
6.08 Collection Suit by Trustee.
If
an Event of Default in payment of interest or principal specified in Section 6.01(1) or (2) occurs and is continuing,
the Trustee may recover judgment in its own name and as trustee of an express trust against the Company for the whole amount of
principal and interest remaining unpaid.
Section
6.09 Trustee May File Proofs of Claim.
The
Trustee may file such proofs of claim and other papers or documents as may be necessary or advisable in order to have the claims
of the Trustee (including any claim for the reasonable compensation, expenses, disbursements, and advances of the Trustee, its
agents and counsel) and the Securityholders allowed in any judicial proceedings relative to the Company or its creditors or Property,
and unless prohibited by applicable law or regulation, may vote on behalf of the Holders in any election of a Custodian, and shall
be entitled and empowered to collect and receive any moneys or other Property payable or deliverable on any such claims and to
distribute the same and any Custodian in any such judicial proceeding is hereby authorized by each Securityholder to make such
payments to the Trustee. Nothing herein shall be deemed to authorize the Trustee to authorize or consent to or vote for or accept
or adopt on behalf of any Securityholder any plan of reorganization, arrangement, adjustment or composition affecting the Securities
or the rights of any Holder or to authorize the Trustee to vote in respect of the claim of any Securityholder except as aforesaid
for the election of the Custodian.
Section
6.10 Priorities.
If
the Trustee collects any money pursuant to this Article with respect to Securities of any Series, it shall pay out the money in
the following order:
| First: |
to the Trustee for amounts due under Section 7.07; |
| Second: |
to Securityholders of the Series for amounts due and unpaid on the Series for principal and interest, ratably, without preference or priority of
any kind, according to the amounts due and payable on the Series for principal and interest, respectively; and |
| Third: |
to the Company or as a court of competent jurisdiction shall direct. |
The
Trustee may fix a record date and payment date for any payment to Securityholders pursuant to this Section 6.10.
Section
6.11 Undertaking for Costs.
In
any suit for the enforcement of any right or remedy under this Indenture or in any suit against the Trustee for any action taken
or omitted by it as Trustee, a court in its discretion may require the filing by any party litigant in the suit of an undertaking
to pay the costs of the suit, and the court in its discretion may assess reasonable costs, including reasonable attorneys’
fees and expenses, against any party litigant in the suit, having the due regard to the merits and good faith of the claims or
defenses made by the party litigant. This Section does not apply to a suit by the Trustee, a suit by a Holder pursuant to Section
6.07 or a suit by Holders of more than 10% in principal amount of the Series.
ARTICLE
SEVEN
TRUSTEE
Section
7.01 Duties of Trustee.
(a)
If an Event of Default has occurred and is continuing with respect to Securities of any Series, the Trustee shall, prior to the
receipt of directions from the Holders of a majority in principal amount of the Securities of the Series, exercise its rights
and powers and use the same degree of care and skill in their exercise as a prudent man would exercise or use under the circumstances
in the conduct of his own affairs.
(b)
Except during the continuance of an Event of Default:
(1)
The Trustee need perform only those duties that are specifically set forth in this Indenture and no others and no implied covenants
or obligations shall be read into this Indenture against the Trustee.
(2)
In the absence of bad faith on its part, the Trustee may conclusively rely, as to the truth of the statements and the correctness
of the opinions expressed therein, upon certificates or opinions furnished to the Trustee and conforming to the requirements of
this Indenture. The Trustee, however, in the case of certificates or opinions specifically required by any provision hereof to
be furnished to it, shall examine the certificates and opinions to determine whether or not they conform to the requirements of
this Indenture but need not confirm or investigate the accuracy of mathematical calculations or other facts or matters stated
therein.
(c)
The Trustee may not be relieved from liability for its own negligent action, its own negligent failure to act or its own willful
misconduct, except that:
(1)
This paragraph does not limit the effect of paragraph (b) of this Section.
(2)
The Trustee shall not be liable for any error of judgment made in good faith by a Trust Officer, unless it is proved that the
Trustee was negligent in ascertaining the pertinent facts.
(3)
The Trustee shall not be liable with respect to any action it takes or omits to take in good faith in accordance with a direction
received by it pursuant to Section 6.05 or any other direction of the Holders permitted hereunder.
(d)
Every provision of this Indenture that in any way relates to the Trustee is subject to paragraphs (a), (b) and (c)
of this Section.
(e)
The Trustee may refuse to perform any duty or exercise any right or power unless it receives indemnity satisfactory to it against
any loss, liability or expense.
(f)
The Trustee shall not be liable for interest on any money received by it except as the Trustee may agree with the Company. Money
held in trust by the Trustee need not be segregated from other funds except to the extent required by law.
(g)
None of the provisions contained in this Indenture shall require the Trustee to expend or risk its own funds or otherwise incur
financial liability in the performance of any of its duties or in the exercise of any of its rights or powers, if there shall
be reasonable grounds for believing that the repayment of such funds or adequate indemnity against such liability is not reasonably
assured to it.
Section
7.02 Rights of Trustee.
Subject
to Section 7.01:
(a)
The Trustee may conclusively rely and shall be fully protected in acting or refraining from acting on any document, resolution,
certificate, instrument, report, or direction believed by it to be genuine and to have been signed or presented by the proper
person. The Trustee need not investigate any fact or matter stated in the document, resolution, certificate, instrument, report,
or direction.
(b)
Before the Trustee acts or refrains from acting, it may require an Officers’ Certificate or an Opinion of Counsel or both,
which shall conform to Sections 12.04 and 12.05 hereof and containing such other statements as the Trustee reasonably
deems necessary to perform its duties hereunder. The Trustee shall not be liable for any action it takes or omits to take in good
faith in reliance on the Officers’ Certificate, Opinion of Counsel or any other direction of the Company permitted hereunder.
(c)
The Trustee may act through agents and shall not be responsible for the misconduct or negligence of any agent appointed with due
care.
(d)
The Trustee shall not be liable for any action taken, suffered or omitted by it in good faith and believed by it to be authorized
or within the discretion or rights or powers conferred upon it by this Indenture.
(e)
The Trustee may consult with counsel of its selection, and the advice of such counsel or any Opinion of Counsel as to matters
of law shall be full and complete authorization and protection in respect of any action taken, omitted or suffered by it hereunder
in good faith and in accordance with the advice or opinion of such counsel.
(f)
Unless otherwise specifically provided in the Indenture, any demand, request, direction or notice from the Company shall be sufficient
if signed by an Officer of the Company.
(g)
For all purposes under this Indenture, the Trustee shall not be deemed to have notice or knowledge of any Event of Default unless
written notice of any Event of Default is received by the Trustee at its address specified in Section 12.02 hereof and
such notice references the Securities generally, the Company and this Indenture.
(h)
The Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the request
or direction of any of the Holders pursuant to this Indenture, unless such Holders shall have offered to the Trustee security
or indemnity reasonably satisfactory to the Trustee against the costs, expenses and liabilities which might be incurred by it
in compliance with such request or direction.
(i)
The Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement,
instrument, opinion, report, notice, request, direction, consent, order, bond, debenture, note, other evidence of indebtedness
or other paper or document, but the Trustee, in its discretion, may make such further inquiry or investigation into such facts
or matters as it may see fit, and, if the Trustee shall determine to make such further inquiry or investigation, it shall be entitled
to examine the books, records and premises of the Company, personally or by agent or attorney at the sole cost of the Company
and shall incur no liability or additional liability of any kind by reason of such inquiry or investigation.
(j)
In no event shall the Trustee be responsible or liable for special, indirect, or consequential loss or damage of any kind whatsoever
(including, but not limited to, loss of profit) irrespective of whether the Trustee has been advised of the likelihood of such
loss or damage and regardless of the form of action.
(k)
The rights, privileges, protections, immunities and benefits given to the Trustee, including, without limitation, its right to
be indemnified, are extended to, and shall be enforceable by, the Trustee in each of its capacities hereunder, and each agent,
custodian and other Person employed to act hereunder.
(l)
The Trustee may request that the Company deliver a certificate setting forth the names of individuals and/or titles of officers
authorized at such time to take specified actions pursuant to this Indenture.
(m)
In no event shall the Trustee be responsible or liable for any failure or delay in the performance of its obligations hereunder
arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages,
accidents, acts of war or terrorism, civil or military disturbances, nuclear or natural catastrophes or acts of God, and interruptions,
loss or malfunctions of utilities, communications or computer (software and hardware) services; it being understood that the Trustee
shall use reasonable efforts which are consistent with accepted practices in the banking industry to resume performance as soon
as practicable under the circumstances.
Section
7.03 Individual Rights of Trustee.
The
Trustee in its individual or any other capacity may become the owner or pledgee of Securities and may otherwise deal with the
Company or its affiliates with the same rights it would have if it were not Trustee. Any Agent may do the same with like rights.
The Trustee, however, must comply with Sections 7.10 and 7.11.
Section
7.04 Trustee’s Disclaimer.
The
Trustee makes no representation as to the validity or adequacy of this Indenture, the Securities or of any prospectus used to
sell the Securities of any Series; it shall not be accountable for the Company’s use of the proceeds from the Securities;
it shall not be accountable for any money paid to the Company, or upon the Company’s direction, if made under and in accordance
with any provision of this Indenture; it shall not be responsible for the use or application of any money received by any Paying
Agent other than the Trustee; and it shall not be responsible for any statement of the Company in this Indenture or in the Securities
other than its certificate of authentication.
Section
7.05 Notice of Defaults.
If
a Default on a Series occurs and is continuing and if it is known to the Trustee, the Trustee shall deliver to each Securityholder
of the Series notice of the Default (which shall specify any uncured Default known to it) within 90 days after the Trustee obtains
such knowledge. Except in the case of a default in payment of principal of or interest on a Series, the Trustee may withhold the
notice if and so long as the board of directors of the Trustee, the executive or any trust committee of such directors and/or
responsible officers of the Trustee in good faith determine(s) that withholding the notice is in the interests of Holders of the
Series.
Section
7.06 Reports by Trustee to Holders.
Within
60 days after each May 15 beginning with the May 15 following the date of this Base Indenture, the Trustee shall mail to each
Securityholder a brief report dated as of such May 15 that complies with TIA § 313(a) (but if no event described in TIA §
313(1) through (8) has occurred within the twelve months preceding the reporting date no report in relation thereto need be transmitted).
The Trustee also shall comply with TIA § 313(b).
A
copy of each report at the time of its mailing to Securityholders shall be delivered to the Company and filed by the Trustee with
the SEC and each national securities exchange on which the Securities are listed. The Company agrees to notify the Trustee of
each national securities exchange on which the Securities are listed.
Section
7.07 Compensation and Indemnity.
The
Company shall pay to the Trustee from time to time reasonable compensation for its services subject to any written agreement between
the Trustee and the Company (which compensation shall not be limited by any provision of law in regard to the compensation of
a trustee of an express trust). The Company shall reimburse the Trustee upon request for all reasonable out-of-pocket expenses
incurred by it. Such expenses shall include the reasonable compensation and expenses of the Trustee’s agents and counsel.
The Company shall indemnify the Trustee, its officers, directors, employees and agents and hold it harmless against any loss,
liability or expense incurred or made by or on behalf of it in connection with the administration of this Indenture or the trust
hereunder and its duties hereunder including the costs and expenses of defending itself against or investigating any claim in
the premises. The Trustee shall notify the Company promptly of any claim of which it has received written notice and for which
it may seek indemnity. The Company need not reimburse any expense or indemnify against any loss or liability incurred by the Trustee
through the Trustee’s, or its officers’, directors’, or employees’ negligence or willful misconduct.
Unless
otherwise provided in any supplemental indenture or Authorizing Resolution relating to any Series, to ensure the Company’s
payment obligations in this Section, the Trustee shall have a claim prior to the Securities of all Series on all money or Property
held or collected by the Trustee, except that held in trust to pay principal of or interest on particular Securities. When the
Trustee incurs expenses or renders services in connection with an Event of Default specified in Section 6.01 or in connection
with Article Six hereof, the expenses (including the reasonable fees and expenses of its counsel) and the compensation
for services in connection therewith are to constitute expenses of administration under any Bankruptcy Law. Section 7.07 shall
survive the discharge of the Indenture or resignation of Trustee.
Section
7.08 Replacement of Trustee.
The
Trustee may resign with respect to Securities of any or all Series by so notifying the Company. The Holders of a majority in principal
amount of the outstanding Securities (or of the relevant Series) may remove the Trustee by so notifying the removed Trustee in
writing and may appoint a successor trustee with the Company’s consent. Such resignation or removal shall not take effect
until the appointment by the Securityholders of the relevant Series or the Company as hereinafter provided of a successor trustee
and the acceptance of such appointment by such successor trustee. The Company may remove the Trustee and any Securityholder may
petition any court of competent jurisdiction for the removal of the Trustee and the appointment of a successor trustee for any
or no reason, including if:
| |
(1) |
the Trustee fails to comply with Section 7.10 after written request by the Company or any bona fide Securityholder
who has been a Securityholder for at least six months; |
| |
(2) |
the Trustee is adjudged a bankrupt or an insolvent; |
| |
(3) |
a receiver or other public officer takes charge of the Trustee or its Property; or |
| |
(4) |
the Trustee becomes incapable of acting. |
If
the Trustee resigns or is removed or if a vacancy exists in the office of Trustee for any reason, the Company shall promptly appoint
a successor trustee with respect to the Securities of the relevant Series. If a successor trustee does not take office within
30 days after the retiring Trustee resigns or is removed, the retiring Trustee at the expense of the Company, the Company or any
Holder may petition any court of competent jurisdiction for the appointment of a successor trustee.
A
successor trustee shall deliver a written acceptance of its appointment to the retiring Trustee and to the Company. Immediately
after that, the retiring Trustee shall, upon payment of its charges hereunder, transfer all Property held by it as Trustee to
the successor trustee, the resignation or removal of the retiring Trustee shall become effective, and the successor trustee shall
have all the rights, powers and duties of the Trustee under this Indenture. A successor trustee shall mail notice of its succession
to each Securityholder.
Section
7.09 Successor Trustee by Merger, etc.
If
the Trustee consolidates with, merges with or into or converts into, or transfers all or substantially all of its corporate trust
business to, another corporation, the successor corporation without any further act shall be the successor trustee.
Section
7.10 Eligibility; Disqualification.
This
Indenture shall always have a Trustee who satisfies the requirements of TIA § 310(a)(1). The Trustee shall have a combined
capital and surplus of at least $10,000,000 as set forth in its most recent published annual report of condition. The Trustee
shall comply with TIA § 310(b).
Section
7.11 Preferential Collection of Claims Against Company.
The
Trustee shall comply with TIA § 311(a), excluding any creditor relationship listed in TIA § 311(b). A Trustee who has
resigned or been removed shall be subject to TIA § 311(a) to the extent indicated therein.
ARTICLE
EIGHT
DISCHARGE
OF INDENTURE
Section
8.01 Defeasance upon Deposit of Moneys or Government Obligations.
(a)
The Company may, at its option and at any time, elect to have either paragraph (b) or paragraph (c) below be applied
to the outstanding Securities of any Series upon compliance with the applicable conditions set forth in paragraph (d).
(b)
Upon the Company’s exercise under paragraph (a) of the option applicable to this paragraph (b) with respect
to any Series, the Company shall be deemed to have been released and discharged from its obligations with respect to the outstanding
Securities of the Series on the date the applicable conditions set forth below are satisfied (hereinafter, “Legal Defeasance”).
For this purpose, such Legal Defeasance means that the Company shall be deemed to have paid and discharged the entire indebtedness
represented by the outstanding Securities of a Series, which shall thereafter be deemed to be “outstanding” only for
the purposes of the Sections and matters under this Indenture referred to in (i) and (ii) below, and the Company shall be deemed
to have satisfied all its other obligations under such Securities and this Indenture insofar as such Securities are concerned,
except for the following which shall survive until otherwise terminated or discharged hereunder: (i) the rights of Holders of
outstanding Securities of a Series to receive solely from the trust fund described in paragraph (d) below and as more fully
set forth in such paragraph, payments in respect of the principal of and interest on such Securities when such payments are due
and (ii) obligations listed in Section 8.02, subject to compliance with this Section 8.01. The Company may exercise
its option under this paragraph (b) with respect to a Series notwithstanding the prior exercise of its option under paragraph
(c) below with respect to the Securities of the Series.
(c)
Upon the Company’s exercise under paragraph (a) of the option applicable to this paragraph (c) with respect
to a Series, the Company shall be released and discharged from the obligations under any covenant contained in Article Five,
Sections 4.03 and any other covenant contained in or referenced in the Authorizing Resolution or supplemental indenture
relating to such Series (to the extent such release and discharge shall not be prohibited thereby), on and after the date the
conditions set forth below are satisfied (hereinafter, “Covenant Defeasance”), and the Securities of such Series
shall thereafter be deemed to be not “outstanding” for the purpose of any direction, waiver, consent or declaration
or act of Holders (and the consequences of any thereof) in connection with such covenants, but shall continue to be deemed “outstanding”
for all other purposes hereunder. For this purpose, such Covenant Defeasance means that, with respect to the outstanding Securities
of a Series, the Company may omit to comply with and shall have no liability in respect of any term, condition or limitation set
forth in the covenants described in the preceding sentence, whether directly or indirectly, by reason of any reference elsewhere
herein to any such covenant or by reason of any reference in any such covenant to any other provision herein or in any other document
and such omission to comply shall not constitute a Default or an Event of Default under Section 6.01(3) or otherwise, but,
except as specified above, the remainder of this Indenture and such Securities shall be unaffected thereby.
(d)
The following shall be the conditions to application of either paragraph (b) or paragraph (c) above to the outstanding
Securities of the applicable Series:
(1)
The Company shall have irrevocably deposited in trust with the Trustee (or another qualifying trustee), pursuant to an irrevocable
trust and security agreement in form and substance reasonably satisfactory to the Trustee, money in the currency in which the
Securities of such Series are payable or Government Obligations or a combination thereof in such amounts and at such times as
are sufficient, in the opinion of a nationally recognized firm of independent public accountants, to pay the principal of and
interest on the outstanding Securities of such Series to maturity or redemption; provided, however, that the Trustee (or
other qualifying trustee) shall have received an irrevocable written order from the Company instructing the Trustee (or other
qualifying trustee) to apply such money or the proceeds of such Government Obligations to said payments with respect to the Securities
of such Series to maturity or redemption;
(2)
No Default or Event of Default (other than a Default or Event of Default resulting from non-compliance with any covenant from
which the Company is released upon effectiveness of such Legal Defeasance or Covenant Defeasance pursuant to paragraph (b)
or (c) hereof, as applicable) shall have occurred and be continuing on the date of such deposit or result therefrom;
(3)
(i) In the event the Company elects paragraph (b) hereof, the Company shall deliver to the Trustee an Opinion of Counsel
in the United States, in form and substance reasonably satisfactory to the Trustee, to the effect that (A) the Company has received
from, or there has been published by, the Internal Revenue Service a ruling or (B) since the Issue Date pertaining to such Series,
there has been a change in the applicable federal income tax law, in either case to the effect that, and based thereon such Opinion
of Counsel shall state that, or (ii) in the event the Company elects paragraph (c) hereof, the Company shall deliver to
the Trustee an Opinion of Counsel in the United States, in form and substance reasonably satisfactory to the Trustee, to the effect
that, in the case of clauses (i) and (ii), and subject to customary assumptions and exclusions, Holders of the Securities
of such Series will not recognize income, gain or loss for federal income tax purposes as a result of such deposit and the defeasance
contemplated hereby and will be subject to federal income tax in the same amounts and in the same manner and at the same times
as would have been the case if such deposit and defeasance had not occurred;
(4)
The Company shall have delivered to the Trustee an Officers’ Certificate, stating that the deposit under clause (1)
was not made by the Company with the intent of preferring the Holders of the Securities of such Series over any other creditors
of the Company or with the intent of defeating, hindering, delaying or defrauding any other creditors of the Company or others;
(5)
The Company shall have delivered to the Trustee an Opinion of Counsel (subject to customary assumptions and qualifications) to
the effect that, assuming no intervening bankruptcy of the Company between the date of deposit and the 91st day following the
deposit and assuming that no Holder is an “insider” of the Company under applicable Bankruptcy Law, after the 91st
day following the deposit, the trust funds shall not be subject to the effect of Section 547 of the United States Bankruptcy Code
or any analogous New York State law provision; and
(6)
The Company has delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel, each stating that all conditions
precedent specified herein relating to the defeasance contemplated by this Section 8.01 have been complied with.
In
the event all or any portion of the Securities of a Series are to be redeemed through such irrevocable trust, the Company must
make arrangements satisfactory to the Trustee, at the time of such deposit, for the giving of the notice of such redemption or
redemptions by the Trustee in the name and at the expense of the Company.
(e)
In addition to the Company’s rights above under this Section 8.01, the Company may terminate all of its obligations
under this Indenture with respect to a Series, when:
(1)
All Securities of such Series theretofore authenticated and delivered (other than Securities which have been destroyed, lost or
stolen and which have been replaced or paid as provided in Section 2.07 and Securities for whose payment money has theretofore
been deposited in trust or segregated and held in trust by the Company and thereafter repaid to the Company or discharged from
such trust) have been delivered to the Trustee for cancellation or all such Securities not theretofore delivered to the Trustee
for cancellation (A) have become due and payable, (B) will become due and payable at maturity within one year or (C) are to be
called for redemption within one year under arrangements satisfactory to the Trustee for the giving of notice of redemption by
the Trustee in the name, and at the expense, of the Company, and in each such case, the Company has irrevocably deposited or caused
to be deposited with the Trustee (or another qualifying trustee) as trust funds in trust solely for that purpose an amount of
money in the currency in which the Securities of such Series are payable or Government Obligations or a combination thereof sufficient,
in the opinion of a nationally recognized firm of independent public accountants, to pay and discharge the entire indebtedness
on the Securities of such Series not theretofore delivered to the Trustee for cancellation, for principal of and interest on the
Securities of such Series, on the date of such deposit or to the maturity or redemption date, as the case may be;
(2)
The Company has paid or caused to be paid all other sums payable hereunder by the Company;
(3)
The Company has delivered irrevocable instructions to the Trustee (or such other qualifying trustee), to apply the deposited money
toward the payment of the Securities of such Series at maturity or redemption, as the case may be; and
(4)
The Company has delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel, stating that all conditions
precedent specified in this Section 8.01(e) relating to the satisfaction and discharge of this Indenture have been complied
with.
Section
8.02 Survival of the Company’s Obligations.
Notwithstanding
the satisfaction and discharge of this Indenture under Section 8.01, the Company’s obligations in Paragraph 8
of the Securities and Sections 2.03 through 2.07, 4.01, 7.07, 7.08, 8.04 and 8.05,
however, shall survive until the Securities of an applicable Series are no longer outstanding. Thereafter, the Company’s
obligations in Paragraph 8 of the Securities of such Series and Sections 7.07, 8.04 and 8.05 shall
survive (as they relate to such Series) such satisfaction and discharge.
Section
8.03 Application of Trust Money.
The
Trustee shall hold in trust money or Government Obligations deposited with it pursuant to Section 8.01. It shall apply
the deposited money and the money from Government Obligations in accordance with this Indenture to the payment of principal of
and interest on the Securities of the defeased Series.
Section
8.04 Repayment to the Company.
The
Trustee and the Paying Agent shall promptly pay to the Company upon request any excess money or securities held by them at any
time. The Trustee and the Paying Agent shall pay to the Company upon request any money held by them for the payment of principal
or interest that remains unclaimed for two years, provided, however, that the Trustee or such Paying Agent, before being
required to make any such repayment, may at the expense of the Company cause to be published once in a newspaper of general circulation
in the City of New York or mail to each such Holder notice that such money remains unclaimed and that, after a date specified
therein, which shall not be less than 30 days from the date of such publication or mailing, any unclaimed balance of such money
then remaining will be repaid to the Company. After payment to the Company, Securityholders entitled to the money must look to
the Company for payment as general creditors unless applicable abandoned property law designates another person and all liability
of the Trustee or such Paying Agent with respect to such money shall cease.
Section
8.05 Reinstatement.
If
the Trustee is unable to apply any money or Government Obligations in accordance with Section 8.01 by reason of any legal
proceeding or by reason of any order or judgment of any court or governmental authority enjoining, restraining or otherwise prohibiting
such application, the Company’s obligations under this Indenture and the Securities relating to the Series shall be revived
and reinstated as though no deposit had occurred pursuant to Section 8.01 until such time as the Trustee is permitted to
apply all such money or Government Obligations in accordance with Section 8.01; provided, however, that (a)
if the Company has made any payment of interest on or principal of any Securities of the Series because of the reinstatement of
its obligations hereunder, the Company shall be subrogated to the rights of the Holders of such Securities to receive such payment
from the money or Government Obligations held by the Trustee and (b) unless otherwise required by any legal proceeding or any
order or judgment of any court or governmental authority, the Trustee shall return all such money or Government Obligations to
the Company promptly after receiving a written request therefor at any time, if such reinstatement of the Company’s obligations
has occurred and continues to be in effect.
ARTICLE
NINE
RESERVED
ARTICLE
TEN
AMENDMENTS,
SUPPLEMENTS AND WAIVERS
Section
10.01 Without Consent of Holders.
The
Company and the Trustee may amend or supplement this Indenture or the Securities of a Series without notice to or consent of any
Securityholder of such Series:
| |
(1) |
to cure any ambiguity, omission, defect or inconsistency; |
| |
(2) |
to comply with Article Five; |
| |
(3) |
to provide that specific provisions of this Indenture shall not apply to a Series not previously issued or to make a change
to specific provisions of this Indenture that only applies to any Series not previously issued or to additional Securities of a Series not previously issued; |
| |
(4) |
to create a Series and establish its terms; |
| |
(5) |
to provide for uncertificated Securities in addition to or in place of certificated Securities; |
| |
(6) |
to release a guarantor in respect of any Series which, in accordance with the terms of this Indenture applicable to the
particular Series, ceases to be liable in respect of its guarantee; |
| |
(7) |
to add a guarantor in respect of any Series; |
| |
(8) |
to secure any Series; |
| |
(9) |
to add to the covenants of the Company for the benefit of the Holders or surrender any right or power conferred upon the
Company; |
| |
(10) |
to appoint a successor trustee with respect to the Securities; |
| |
(11) |
to comply with requirements of the SEC in order to effect or maintain the qualification of this Indenture under the TIA; |
| |
(12) |
to make any other change that does not adversely affect the rights of Securityholders; and |
| |
(13) |
to conform the provisions of the Indenture to the final offering memorandum or prospectus in respect of any Series. |
After
an amendment under this Section 10.01 becomes effective, the Company shall mail notice of such amendment to the Securityholders.
Section
10.02 With Consent of Holders.
The
Company and the Trustee may amend or supplement any provision of the Securities of a Series or of this Indenture relating to such
Series without notice to any Securityholder of such Series but with the written consent of the Holders of at least a majority
in principal amount of the outstanding Securities of such Series (including consents obtained in connection with a purchase of,
or tender offer or exchange offer for, Securities of such Series). Each such Series shall vote as a separate class. The Holders
of a majority in principal amount of the outstanding Securities of any Series may waive compliance by the Company with any provision
of the Securities of such Series or of this Indenture relating to such Series without notice to any Securityholder (including
any waiver granted in connection with a purchase of, or tender offer or exchange offer for, Securities of such Series). Without
the consent of each Holder of a Security the terms of which are directly amended, supplemented or waived, however, an amendment,
supplement or waiver, including a waiver pursuant to Section 6.04, may not (with respect to any Securities of such Series
held by a non-consenting Holder):
(1)
reduce the amount of Securities of the relevant Series whose Holders must consent to an amendment, supplement or waiver;
(2)
reduce the rate of or extend the time for payment of interest, including defaulted interest, on any Security;
(3)
reduce the principal of or extend the fixed maturity of any Security or alter the provisions (including related definitions) with
respect to redemption of any Security pursuant to Article Three hereof or with respect to any obligations on the part of
the Company to offer to purchase or to redeem Securities of a Series pursuant to the Authorizing Resolution or supplemental indenture
pertaining to such Series in a manner adverse to Holders;
(4)
make any change that adversely affects any right of a Holder to convert or exchange any Security into or for shares of the Company’s
Capital Stock or other securities, cash or other property in accordance with the terms of such Security;
(5)
modify the ranking or priority of the Securities of the relevant Series or any guarantee thereof;
(6)
release any guarantor of any Series from any of its obligations under its guarantee or this Indenture otherwise than in accordance
with the terms of this Indenture;
(7)
make any change in Sections 6.04, 6.07 or this Section 10.02, except to increase the percentage required
for modification or waiver or to provide for consent of each affected Holder of Securities of such Series;
(8)
waive a continuing Default or Event of Default in the payment of the principal of or interest on any Security; or
(9)
make any Security payable at a place or in money other than that stated in the Security, or impair the right of any Securityholder
to bring suit as permitted by Section 6.07.
An
amendment of a provision included solely for the benefit of one or more Series does not affect the interests of Securityholders
of any other Series.
It
shall not be necessary for the consent of the Holders under this Section to approve the particular form of any proposed supplement,
but it shall be sufficient if such consent approves the substance thereof.
Section
10.03 Compliance with Trust Indenture Act.
Every
amendment to or supplement of this Indenture or any Securities shall comply with the TIA as then in effect.
Section
10.04 Revocation and Effect of Consents.
A
consent to an amendment, supplement or waiver by a Holder shall bind the Holder and every subsequent Holder of a Security or portion
of a Security that evidences the same debt as the consenting Holder’s Security, even if notation of the consent is not made
on any Security. Unless otherwise provided in the consent or the consent solicitation statement or other document describing the
terms of the consent, any Holder or subsequent Holder may revoke the consent as to its Security or portion of a Security. Any
revocation of a consent by the Holder of a Security or any such subsequent Holder shall be effective only if the Trustee receives
the notice of revocation before the date on which the Trustee receives an Officers’ Certificate from the Company certifying
that the requisite number of consents have been received.
The
Company may, but shall not be obligated to, fix a record date for the purpose of determining the Holders of Securities of any
Series entitled to consent to any amendment, supplement or waiver, which record date shall be at least 10 days prior to the first
solicitation of such consent. If a record date is fixed, and if Holders otherwise have a right to revoke their consent under the
consent or the consent solicitation statement or other document describing the terms of the consent, then notwithstanding the
second to last sentence of the immediately preceding paragraph, those Persons who were Holders at such record date (or their duly
designated proxies), and only those Persons, shall be entitled to revoke any consent previously given, whether or not such Persons
continue to be Holders after such record date. No such consent shall be valid or effective for more than 90 days after such record
date.
An
amendment, supplement or waiver with respect to a Series becomes effective upon the (i) receipt by the Company or the Trustee
of the requisite consents, (ii) satisfaction of any conditions to effectiveness as set forth in this Indenture or any indenture
supplemental hereto containing such amendment, supplement or waiver and (iii) execution of such amendment, supplement or waiver
(or the related supplemental indenture) by the Company and the Trustee. After an amendment, supplement or waiver with respect
to a Series becomes effective, it shall bind every Holder of such Series, unless it makes a change described in any of clauses
(1) through (9) of Section 10.02, in which case, the amendment, supplement or waiver shall bind a Holder of
a Security of such Series only if it has consented to such amendment, supplement or waiver and every subsequent Holder of a Security
or portion of a Security that evidences the same debt as the consenting Holder’s Security; provided that no such
waiver shall impair or affect the right of any Holder to receive payment of principal of and interest on a Security, on or after
the respective due dates expressed in such Security, or to bring suit for the enforcement of any such payment on or after such
respective dates without the consent of such Holder.
Section
10.05 Notation on or Exchange of Securities.
If
an amendment, supplement or waiver changes the terms of a Security, the Company may require the Holder of the Security to deliver
it to the Trustee, at which time the Trustee shall place an appropriate notation on the Security about the changed terms and return
it to the Holder. Alternatively, if the Company or the Trustee so determines, the Company in exchange for the Security shall issue
and the Trustee shall authenticate a new Security that reflects the changed terms.
Section
10.06 Trustee to Sign Amendments, etc.
Subject
to Section 7.02(b), the Trustee shall sign any amendment, supplement or waiver authorized pursuant to this Article if the
amendment, supplement or waiver does not adversely affect the rights, duties, liabilities or immunities of the Trustee. If it
does, the Trustee may but need not sign it. In signing or refusing to sign such amendment or supplemental indenture, the Trustee
shall be provided with and shall be fully protected in relying upon, an Officers’ Certificate and an Opinion of Counsel
as conclusive evidence that such amendment, supplement or waiver is authorized or permitted by this Indenture, and (solely with
respect to such Opinion of Counsel) that it will be valid and binding upon the Company and enforceable in accordance with its
terms.
ARTICLE
ELEVEN
SECURITIES
IN FOREIGN CURRENCIES
Section
11.01 Applicability of Article.
Whenever
this Indenture provides for (i) any action by, or the determination of any of the rights of, Holders of Securities of any Series
in which not all of such Securities are denominated in the same currency, or (ii) any distribution to Holders of Securities, in
the absence of any provision to the contrary pursuant to this Indenture or the Securities of any particular Series, any amount
in respect of any Security denominated in a Foreign Currency shall be treated for any such action or distribution as that amount
of Dollars that could be obtained for such amount on such reasonable basis of exchange and as of the record date with respect
to Securities of such Series (if any) for such action, determination of rights or distribution (or, if there shall be no applicable
record date, such other date reasonably proximate to the date of such action, determination of rights or distribution) as the
Company may specify in a written notice to the Trustee or, in the absence of such written notice, as the Trustee may determine.
ARTICLE
TWELVE
MISCELLANEOUS
Section
12.01 Trust Indenture Act Controls.
If
any provision of this Indenture limits, qualifies or conflicts with another provision which is required to be included in this
Indenture by the TIA, the required provision shall control.
Section
12.02 Notices.
Any
order, consent, notice or communication shall be sufficiently given if in writing and delivered in person or mailed by first class
mail, postage prepaid, addressed as follows:
if
to the Company:
[
]
if
to the Trustee:
[
]
The
Company or the Trustee by notice to the other may designate additional or different addresses for subsequent notices or communications.
Any
notice or communication mailed to a Securityholder shall be mailed to him by first class mail at his address as it appears on
the registration books of the Registrar and shall be sufficiently given to him if so mailed within the time prescribed.
Failure
to mail a notice or communication to a Securityholder or any defect in it shall not affect its sufficiency with respect to other
Securityholders. If a notice or communication is mailed in the manner provided above, it is duly given, whether or not the addressee
receives it except that notice to the Trustee shall only be effective upon receipt thereof by the Trustee.
If
the Company mails notice or communications to the Securityholders, it shall mail a copy to the Trustee at the same time.
In
addition to the foregoing, the Trustee agrees to accept and act upon notice, instructions or directions pursuant to this Indenture
sent by unsecured e-mail, facsimile transmission or other similar unsecured electronic methods. If the party elects to give the
Trustee e-mail or facsimile instructions (or instructions by a similar electronic method) and the Trustee in its discretion elects
to act upon such instructions, the Trustee’s understanding of such instructions shall be deemed controlling. The Trustee
shall not be liable for any losses, costs or expenses arising directly or indirectly from the Trustee’s reliance upon and
compliance with such instructions notwithstanding such instructions conflict or are inconsistent with a subsequent written instruction.
The party providing electronic instructions agrees to assume all risks arising out of the use of such electronic methods to submit
instructions and directions to the Trustee, including without limitation the risk of the Trustee acting on unauthorized instructions,
and the risk of interception and misuse by third parties.
Section
12.03 Communications by Holders with Other Holders.
Securityholders
may communicate pursuant to TIA § 312(b) with other Securityholders with respect to their rights under this Indenture or
the Securities. The Company, the Trustee, the Registrar and anyone else shall have the protection of TIA § 312(c).
Section
12.04 Certificate and Opinion as to Conditions Precedent.
Upon
any request or application by the Company to the Trustee to take any action under this Indenture, the Company shall furnish to
the Trustee:
| |
(1) |
an Officers’ Certificate (which shall include the statements set forth in Section 12.05) stating that, in the opinion
of the signers, all conditions precedent, if any, provided for in this Indenture relating to the proposed action have been complied with; and |
| |
(2) |
an Opinion of Counsel (which shall include the statements set forth in Section 12.05) stating that, in the opinion of
such counsel, all such conditions precedent, if any, provided for in this Indenture relating to the proposed action or inaction, have been complied with. |
Any
Officers’ Certificate may be based, and may state that it is so based, insofar as it relates to legal matters, upon a certificate
or opinion of, or representations by, internal or external legal counsel. Any Opinion of Counsel may be based, and may state that
it is so based, insofar as it relates to factual matters, upon a certificate or opinion of, or representations by, an Officer
or Officers of the Company or any guarantor stating that the information with respect to such factual matters is known to the
Company or such guarantor, unless such counsel knows that the certificate or opinion or representations with respect to such matters
are erroneous.
Section
12.05 Statements Required in Certificate or Opinion.
Each
certificate or opinion with respect to compliance with a condition or covenant provided for in this Indenture shall include:
| |
(1) |
a statement that the person making such certificate or opinion has read such covenant or condition; |
| |
(2) |
a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions
contained in such certificate or opinion are based; |
| |
(3) |
a statement that, in the opinion of such person, he has made such examination or investigation as is necessary to enable him
to express an informed opinion as to whether or not such covenant or condition has been complied with; and |
| |
(4) |
a statement as to whether or not, in the opinion of such person, such condition or covenant has been complied with. |
Section
12.06 Rules by Trustee and Agents.
The
Trustee may make reasonable rules for action by or a meeting of Securityholders. The Registrar or Paying Agent may make reasonable
rules for its functions.
Section
12.07 Legal Holidays.
A
“Legal Holiday” is a Saturday, a Sunday, a legal holiday or a day on which banking institutions in New York,
New York are not required to be open. If a payment date is a Legal Holiday, payment may be made on the next succeeding day that
is not a Legal Holiday, and no interest shall accrue for the intervening period. If this Indenture provides for a time period
that ends or requires performance of any non-payment obligation by a day that is not a Business Day, then such time period shall
instead be deemed to end on, and such obligation shall instead be performed by, the next succeeding Business Day. A “Business
Day” is any day other than a Legal Holiday.
Section
12.08 Governing Law.
The
laws of the State of New York shall govern this Indenture and the Securities of each Series.
Section
12.09 No Adverse Interpretation of Other Agreements.
This
Indenture may not be used to interpret another indenture, loan or debt agreement of the Company or a Subsidiary. Any such indenture,
loan or debt agreement may not be used to interpret this Indenture.
Section
12.10 No Recourse Against Others.
All
liability described in Paragraph 12 of the Securities of any director, officer, employee or stockholder, as such, of the
Company is, to the fullest extent permitted by applicable law, waived and released.
Section
12.11 Successors and Assigns.
All
covenants and agreements of the Company in this Indenture and the Securities shall bind its successors and assigns. All agreements
of the Trustee in this Indenture shall bind its successors and assigns.
Section
12.12 Duplicate Originals.
The
parties may sign any number of copies of this Indenture. Each signed copy shall be an original, but all of them together represent
the same agreement.
Section
12.13 Severability.
In
case any one or more of the provisions contained in this Indenture or in the Securities of a Series shall for any reason be held
to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other
provisions of this Indenture or of such Securities.
Section
12.14 Waiver of Jury Trial.
EACH
OF THE COMPANY AND THE TRUSTEE HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT
TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE SECURITIES OR THE TRANSACTION CONTEMPLATED
HEREBY.
SIGNATURES
IN
WITNESS WHEREOF, the parties have caused this Indenture to be duly executed, all as of the date first above written.
| |
|
|
| |
GYRE THERAPEUTICS, INC. |
| |
|
|
| |
By: |
|
| |
Name: |
|
| |
Title: |
|
| |
|
| |
[ ], as Trustee |
| |
|
|
| |
By: |
|
| |
Name: |
|
| |
Title: |
|
EXHIBIT
A
[Title
of Security]
GYRE
THERAPEUTICS, INC.
a
Delaware corporation
promises
to pay to or registered assigns the principal sum of [Dollars]* on .
Interest
Payment Dates: and
Record
Dates: and
Authenticated:
Dated:
| |
|
|
| |
GYRE THERAPEUTICS, INC. |
| |
|
|
| |
By: |
|
| |
Name: |
|
| |
Title: |
|
[
],
as
Trustee, certifies that this is one of the Securities
referred
to in the within mentioned Indenture.
|
*
|
Or
other currency. Insert corresponding provisions on reverse side of Security in respect of foreign currency denomination or interest
payment requirement.
|
GYRE
THERAPEUTICS, INC.
[Title
of Security]
GYRE
THERAPEUTICS, INC., a Delaware corporation (together with its successors and assigns, the “Company”), issued
this Security under an Indenture dated as of (as amended, modified or supplemented from time to time in accordance therewith,
the “Base Indenture”), as supplemented by the Supplemental Indenture dated as of (the “Supplemental
Indenture” and together with the Base Indenture, the “Indenture”), by and among the Company and [ ],
as trustee (in such capacity, the “Trustee”), to which reference is hereby made for a statement of the respective
rights, obligations, duties and immunities thereunder of the Company, the Trustee and the Holders and of the terms upon which
the Securities are, and are to be, authorized and delivered. All terms used in this Security that are defined in the Indenture
shall have the meanings assigned to them therein.
1.
Interest. The Company promises to pay interest on the principal amount of this Security at the rate per annum shown
above. The Company will pay interest semiannually on and of each year, commencing , , until the principal is paid
or made available for payment. Interest on the Securities will accrue from the most recent date to which interest has been paid
or duly provided for or, if no interest has been paid, from . Interest will be computed on the basis of a 360-day year of
twelve 30-day months.
2.
Method of Payment. The Company will pay interest on the Securities (except defaulted interest, if any, which will be
paid on such special payment date to Holders of record on such special record date as may be fixed by the Company) to the persons
who are registered Holders of Securities at the close of business on the [Insert record dates] immediately preceding the interest
payment date. Holders must surrender Securities to a Paying Agent to collect principal payments. The Company will pay principal
and interest in money of [Insert applicable country or currency] that at the time of payment is legal tender for payment of public
and private debts.
3.
Paying Agent and Registrar. Initially, the Trustee will act as Paying Agent and Registrar. The Company may change or
appoint any Paying Agent, Registrar or co-Registrar without notice. The Company or any of its Subsidiaries or any of their Affiliates
may act as Paying Agent, Registrar or co-Registrar.
4.
Optional Redemption.2 The Company may redeem the Securities at any time on or after , in whole or in part, at the following redemption prices (expressed as a percentage of their principal amount) together with
interest accrued and unpaid to the date fixed for redemption:
| |
|
|
|
If
redeemed during the twelve-month period
commencing
on and ending on in each of
the
following years
|
|
Percentage |
| |
|
|
[Insert
provisions relating to redemption at option of Holders, if any]
Notice
of redemption will be mailed at least 30 days but not more than 60 days before the redemption date to each Holder of Securities
to be redeemed at its registered address. Securities in denominations larger than 3 may be redeemed in part. On
and after the redemption date interest ceases to accrue on Securities or portions of them called for redemption, provided
that if the Company shall default in the payment of such Securities at the redemption price together with accrued interest, interest
shall continue to accrue at the rate borne by the Securities.
5. Mandatory
Redemption.4 The Company shall redeem [ ]% of the
aggregate principal amount of Securities originally issued under the Indenture on each of
[ ], which
redemptions are calculated to retire [ ]% of the Securities originally
issued prior to maturity. Such redemptions shall be made at a redemption price equal to 100% of the principal amount thereof,
together with accrued interest to the redemption date. The Company may reduce the principal amount of Securities to be
redeemed pursuant to this Paragraph 5 by the principal amount of any Securities previously redeemed, retired or
acquired, otherwise than pursuant to this Paragraph 5, that the Company has delivered to the Trustee for
cancellation and not previously credited to the Company’s obligations under this Paragraph 5. Each such Security
shall be received and credited for such purpose by the Trustee at the redemption price and the amount of such mandatory
redemption payment shall be reduced accordingly.
2
If applicable
3
Insert applicable denominations and multiples.
4
If applicable.
6.
Denominations, Transfer, Exchange. The Securities are in registered form only without coupons in denominations of 5
and integral multiples of in excess thereof.6 A Holder may transfer or exchange Securities by presentation
of such Securities to the Registrar or a co-Registrar with a request to register the transfer or to exchange them for an equal
principal amount of Securities of other denominations. The Registrar may require a Holder, among other things, to furnish appropriate
endorsements and transfer documents and to pay any taxes and fees required by law or permitted by the Indenture. The Registrar
need not transfer or exchange any Security selected for redemption or purchase, except the unredeemed or unpurchased part thereof
if the Security is redeemed or purchased in part, or transfer or exchange any Securities for a period of 15 days before a selection
of Securities to be redeemed or purchased.
7.
Persons Deemed Owners. The registered Holder of this Security shall be treated as the owner of it for all purposes.
8.
Unclaimed Money. Subject to any applicable abandoned property law, the Trustee and the Paying Agent shall pay to the
Company upon written request any money held by them for the payment of principal or interest that remains unclaimed for two years,
and thereafter, Holders entitled to the money must look to the Company for payment as general creditors.
9.
Amendment, Supplement, Waiver. Subject to certain exceptions, the Indenture or the Securities of a Series may be amended
or supplemented with the consent of the Holders of at least a majority in principal amount of the outstanding Securities of such
Series and any past default or compliance with any provision relating to any Series of the Securities may be waived in a particular
instance with the consent of the Holders of a majority in principal amount of the outstanding Securities of such Series.7
Without the consent of any Securityholder, the Company and the Trustee may amend or supplement the Indenture or the Securities
in certain respects as specified in the Indenture.
10.
Successor Corporation. When a successor corporation assumes all the obligations of its predecessor under the Securities
and the Indenture, the predecessor corporation will be released from those obligations.
11.
Trustee Dealings With Company. Subject to certain limitations imposed by the TIA, the Trustee under the Indenture,
in its individual or any other capacity, may make loans to, accept deposits from, and perform services for the Company or its
affiliates, and may otherwise deal with the Company or its affiliates, as if it were not Trustee, including owning or pledging
the Securities.
12.
No Recourse Against Others. A director, officer, employee or stockholder, as such, of the Company shall not have any
liability for any obligations of the Company under the Securities or the Indenture or for any claim based on, in respect of or
by reason of, such obligations or their creation. Each Holder by accepting a Security waives and releases all such liability.
The waiver and release are part of the consideration for the issue of the Securities. The waiver may not be effective to waive
liabilities under the federal securities laws.
13.
Discharge of Indenture. The Indenture contains certain provisions pertaining to defeasance and discharge, which provisions
shall for all purposes have the same effect as if set forth herein.
5
Insert applicable denominations and multiples.
6
Insert applicable denominations and multiples.
7
If different terms apply, insert a brief summary thereof.
14.
Authentication. This Security shall not be valid until an authorized signatory of the Trustee signs the certificate
of authentication on the other side of this Security.
15.
Abbreviations. Customary abbreviations may be used in the name of a Holder or an assignee, such as: TEN COM (= tenants
in common), TEN ENT (= tenants by the entireties), JT TEN (= joint tenants with right of survivorship and not as tenants in common),
CUST (= custodian), and U/G/M/A (= Uniform Gift to Minors Act).
16.
GOVERNING LAW. THIS SECURITY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.
17.
CUSIP and ISIN Numbers. Pursuant to a recommendation promulgated by the Committee on Uniform Security Identification
Procedures, the Company has caused CUSIP and ISIN numbers to be printed on the Securities and has directed the Trustee to use
CUSIP and ISIN numbers in notices of repurchase as a convenience to Holders. No representation is made as to the accuracy of such
numbers either as printed on the Securities or as contained in any notice of repurchase and reliance may be placed only on the
other identification numbers placed thereon.
18.
Copies. The Company will furnish to any Holder upon written request and without charge a copy of the Indenture and
the applicable Authorizing Resolution or supplemental indenture. Requests may be made to: Gyre Therapeutics, Inc., [ ],
Attention: [Chief Financial Officer].
ASSIGNMENT
FORM
If
you the Holder want to assign this Security, fill in the form below:
I
or we assign and transfer this Security to (insert assignee’s social security or tax ID number)
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| (Print or type assignee’s name, address, and zip code) |
and
irrevocably appoint agent to transfer this Security on the books of the Company. The agent may substitute another to act for him.
| Date: |
|
|
|
|
|
|
| |
|
|
|
|
|
Your
signature
(Sign
exactly as your name appears on the other side
of
this Security)
|
| |
|
|
| Signature Guarantee: |
|
|
|
|
Exhibit 5.1
|
|
Gibson, Dunn & Crutcher LLP
One Embarcadero Center
San Francisco, CA 94111-3715
Tel 415.393.8200
gibsondunn.com
|
|
November 14, 2024
|
Client: 21582-00005
|
Gyre Therapeutics, Inc.
12770 High Bluff Drive, Suite 150
San Diego, CA 92130
|
Re:
|
Gyre Therapeutics, Inc.
|
Registration Statement on Form S-3
Ladies and Gentlemen:
We have acted as counsel to Gyre Therapeutics, Inc., a Delaware corporation (the “Company”), in connection with the preparation and filing with the Securities and Exchange Commission (the
“Commission”) of a Registration Statement on Form S-3 (the “Registration Statement”) under the Securities Act of 1933, as amended (the “Securities Act”), relating to the registration under the Securities Act and the proposed
issuance and sale from time to time pursuant to Rule 415 under the Securities Act, together or separately and in one or more series (if applicable) of:
(i) the Company’s debt securities (the “Debt Securities”);
(ii) shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”);
(iii) shares of the Company’s preferred stock, par value $0.001 per share (the “Preferred Stock”);
(iv) warrants for the purchase of Debt Securities, Common Stock, and Preferred Stock (the “Warrants”); and
(v) units of the Company comprised of any combination of Debt Securities, Common Stock, Preferred Stock, and Warrants (the “Units”).
The Debt Securities, Common Stock, Preferred Stock, Warrants, and Units are collectively referred to herein as the “Securities.” The Debt Securities are to be issued under an indenture
substantially in the form attached to the Registration Statement (the “Base Indenture”).
In arriving at the opinions expressed below, we have examined originals, or copies certified or otherwise identified to our satisfaction as being true and complete copies of the originals, of the
form of the Base Indenture, form of the Debt Securities, specimen Common Stock certificates, and such other documents, corporate records, certificates of officers of the Company and of public officials and other instruments as we have deemed
necessary or advisable to enable us to render these opinions. In our examination, we have assumed the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as
originals and the conformity to original documents of all documents submitted to us as copies. As to any facts material to these opinions, we have relied to the extent we deemed appropriate and without independent investigation upon statements and
representations of officers and other representatives of the Company and others.
We have assumed without independent investigation that:
(i) at the time any Securities are sold pursuant to the Registration Statement (the “Relevant Time”), the Registration Statement and any supplements and amendments
thereto (including post-effective amendments) will be effective and will comply with all applicable laws;
(ii) at the Relevant Time, a prospectus supplement will have been prepared and filed with the Commission describing the Securities offered thereby and all related
documentation and will comply with all applicable laws;
(iii) all Securities will be issued and sold in the manner stated in the Registration Statement and the applicable prospectus supplement;
(iv) at the Relevant Time, all corporate or other action required to be taken by the Company to duly authorize each proposed issuance of Securities and any related
documentation (including (i) the due reservation of any shares of Common Stock or Preferred Stock for issuance upon exercise, conversion or exchange of any Securities for Common Stock or Preferred Stock (a “Convertible Security”), and (ii)
the execution (in the case of certificated Securities), delivery and performance of the Securities and any related documentation referred to in paragraphs 1 through 5 below) shall have been duly completed and shall remain in full force and effect;
(v) upon issuance of any Common Stock or Preferred Stock, including upon exercise, conversion or exchange of any Convertible Security, the total number of shares of Common
Stock or Preferred Stock issued and outstanding will not exceed the total number of shares of Common Stock or Preferred Stock, as applicable, that the Company is then authorized to issue under its certificate of incorporation and other relevant
documents;
(vi) in the case of Debt Securities, at the Relevant Time, the relevant trustee shall have been qualified under the Trust Indenture
Act of 1939, as amended (the “TIA”), a Statement of Eligibility of the Trustee on Form T-1 shall have been properly filed with the Commission and the relevant Base Indenture shall have been duly executed and delivered by the Company and all
other parties thereto and duly qualified under the TIA;
(vii) at the Relevant Time, a definitive purchase, underwriting or similar agreement and any other necessary agreement with respect to any Securities offered or issued will
have been duly authorized by all necessary corporate or other action of the Company duly executed and delivered by the Company or any relevant trust and the other parties thereto.
Based on the foregoing and in reliance thereon, and subject to the assumptions, exceptions, qualifications and limitations set forth herein, we are of the opinion that:
| |
1.
|
With respect to any Debt Securities when:
|
| |
a.
|
the terms and conditions of such Debt Securities have been duly established by supplemental indenture or officers’ certificate in accordance with the terms and conditions of the
relevant Base Indenture,
|
| |
b.
|
any such supplemental indenture has been duly executed and delivered by the Company and the relevant trustee (together with the relevant Base Indenture, the “Indenture”), and
|
| |
c.
|
such Debt Securities have been executed (in the case of certificated Debt Securities), delivered and authenticated in accordance with the terms of the applicable Indenture and issued
and sold for the consideration set forth in the applicable definitive purchase, underwriting or similar agreement,
|
such Debt Securities will be legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms.
| |
2.
|
With respect to any shares of Preferred Stock, when:
|
| |
a.
|
the certificate of designations relating to such Preferred Stock has been duly executed and filed with the Office of the Secretary of State of the State of Delaware,
|
| |
b.
|
such shares have been issued either (i) in accordance with the applicable definitive purchase, underwriting or similar agreement and for the consideration therefor provided for therein
or (ii) upon exercise, conversion or exchange of any Convertible Security and for any additional consideration specified in such Convertible Security or the instrument governing such Convertible Security providing for such conversion or
exercise, which consideration (including any consideration paid for such Convertible Security), on a per-share basis, shall in either event not be less than the par value of the Preferred Stock, and
|
| |
c.
|
any such Convertible Security was previously validly issued and is fully paid an non-assessable (in the case of an equity Security) or is a legal, valid and binding obligation of the
Company, enforceable against the Company in accordance with its terms,
|
such shares of Preferred Stock will be validly issued, fully paid and non-assessable.
| |
3.
|
With respect to shares of Common Stock, when:
|
| |
a.
|
such shares of Common Stock have been duly executed (in the case of certificated shares) and delivered either (i) in accordance with the applicable definitive purchase, underwriting or
similar agreement for the consideration provided for therein, or (ii) upon conversion or exercise of any Convertible Security, in accordance with the terms of such Convertible Security or the instrument governing such Convertible Security
providing for such conversion or exercise, and for any additional consideration specified therein, which consideration (including any consideration paid for such Convertible Security), on a per-share basis, shall in either event not be
less than the par value of the Common Stock, and
|
| |
b.
|
any such Convertible Security was previously validly issued and is fully paid and non-assessable (in the case of an equity Security) or is a legal, valid and binding obligation of the
Company, enforceable against the Company in accordance with its terms,
|
such shares of Common Stock will be validly issued, fully paid and non-assessable.
| |
4.
|
With respect to any Warrants, when:
|
| |
a.
|
the warrant agreement relating to such Warrants (the “Warrant Agreement”), if any, has been duly executed and delivered by the Company and each other party thereto,
|
| |
b.
|
the terms of the Warrants have been established in accordance with the Warrant Agreement, if any, and the applicable definitive purchase, underwriting or similar agreement, and
|
| |
c.
|
the Warrants have been duly executed (in the case of certificated Warrants) and delivered in accordance with the Warrant Agreement, if any, and the applicable definitive purchase,
underwriting or similar agreement for the consideration provided for therein,
|
such Warrants will be legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms.
| |
5.
|
With respect to any Units, when:
|
| |
a.
|
the unit agreement relating to the Units (the “Unit Agreement”), if any, has been duly executed and delivered by the Company and each other party thereto,
|
| |
b.
|
the terms of the Units have been duly established in accordance with the Unit Agreement, if any, and the applicable definitive purchase, underwriting or similar agreement, and
|
| |
c.
|
the Units have been duly executed (in the case of certificated Units) and delivered in accordance with the Unit Agreement, if any, and the applicable definitive purchase, underwriting
or similar agreement for the consideration provided for therein,
|
the Units will be legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms.
The opinions expressed above are subject to the following exceptions, qualifications, limitations and assumptions:
A. We render no opinion herein as to matters involving the laws of any jurisdiction other than the State of New York and the United States of America and, for purposes of
paragraphs 2 and 3 above, the Delaware General Corporation Law. We are not admitted to practice in the State of Delaware; however, we are generally familiar with the Delaware General Corporation Law as currently in effect and have made such
inquiries as we consider necessary to render the opinions contained in paragraphs 2 and 3 above. This opinion is limited to the effect of the current state of the laws of the State of New York, the United States of America and, to the limited
extent set forth above, the laws of the State of Delaware and the facts as they currently exist. We assume no obligation to revise or supplement this opinion in the event of future changes in such laws or the
interpretations thereof or such facts.
B. The opinions above with respect to the Indenture, the Debt Securities, the Warrants, the Warrant Agreement, the Units and the Unit Agreement (collectively, the “Documents”)
are each subject to (i) the effect of any bankruptcy, insolvency, reorganization, moratorium, arrangement or similar laws affecting the rights and remedies of creditors’ generally, including without limitation the effect of statutory or other laws
regarding fraudulent transfers or preferential transfers, and (ii) general principles of equity, including without limitation concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability of specific
performance, injunctive relief or other equitable remedies regardless of whether enforceability is considered in a proceeding in equity or at law.
C. We express no opinion regarding the effectiveness of (i) any waiver of stay, extension or usury laws; (ii) provisions relating to indemnification, exculpation or
contribution, to the extent such provisions may be held unenforceable as contrary to public policy or federal or state securities laws; (iii) any provision in any Document waiving the right to object to venue
in any court; (iv) any agreement to submit to the jurisdiction of any Federal court; or (v) any waiver of the right to jury trial.
D. To the extent relevant to our opinions in paragraphs 4 and 5 and not covered by our opinions in paragraphs 1, 2, and 3, we have assumed that any securities underlying,
comprising or issuable upon exchange, conversion or exercise of any Warrants or Units are validly issued, fully paid and non-assessable (in the case of an equity security) or a legal, valid and binding obligation of the issuer thereof, enforceable
against such issuer in accordance with its terms.
You have informed us that you intend to issue Securities from time to time on a delayed or continuous basis, and we understand that prior to issuing any Securities pursuant to the Registration
Statement (i) you will advise us in writing of the terms thereof, and (ii) you will afford us an opportunity to (x) review the operative documents pursuant to which such Securities are to be issued or sold (including the applicable offering
documents), and (y) file such supplement or amendment to this opinion (if any) as we may reasonably consider necessary or appropriate.
We consent to the filing of this opinion as an exhibit to the Registration Statement, and we further consent to the use of our name under the caption “Legal Matters” in the Registration Statement
and the prospectus that forms a part thereof. In giving these consents, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the
Commission promulgated thereunder.
Very truly yours,
/S/ GIBSON, DUNN & CRUTCHER LLP
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We have issued our report dated March 27, 2024, with respect to the consolidated financial statements included in the Annual Report of Gyre Therapeutics, Inc. on Form 10-K for the year ended December 31, 2023, which is
incorporated by reference in this Registration Statement. We consent to the incorporation by reference of the said report in this Registration Statement, and the use of our name as it appears under the caption “Experts”.
/s/ Grant Thornton Zhitong Certified Public Accountants LLP
Beijing, China
November 14, 2024
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in this Registration Statement of Gyre Therapeutics, Inc. on Form S-3 to be filed on or about November 14, 2024 of our report dated March 30, 2023, on
our audits of the financial statements of Catalyst Biosciences, Inc. (the “Company”) as of December 31, 2022 and 2021 and for each of the years then ended, which report was included in the Annual Report on Form 10-K filed March 30, 2023. Our report
includes an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue as a going concern. We also consent to the reference to our firm under the caption “Experts” in this Registration Statement.
EISNERAMPER LLP
Philadelphia, Pennsylvania
November 14, 2024
Exhibit 99.1
UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION
On October 30, 2023, Gyre Therapeutics, Inc. (the “Company” or “Gyre”, previously known as Catalyst Biosciences, Inc. or “Catalyst”) consummated the transactions (the “Contributions”) contemplated by the Business
Combination Agreement as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “Annual Report”), which were accounted for as a reverse asset acquisition and a purchase of noncontrolling interest in
accordance with United States generally accepted accounting principles (“GAAP”). Continent Pharmaceuticals Inc. (“CPI”) was treated as the accounting acquirer of the reverse asset acquisition and is presented as the predecessor for post-acquisition
financial reporting purposes.
Pursuant to Article 11 of Regulation S-X, the Company prepared the following unaudited pro forma condensed combined financial information and the accompanying notes, reflecting the combined financial results of
operations of Catalyst and CPI for the year ended December 31, 2023, assuming that the Contributions took place as of January 1, 2023.
The unaudited pro forma condensed combined financial information, including the notes thereto, should be read in conjunction with the following historical financial statements and the accompanying notes:
|
• |
the historical unaudited condensed financial statements of Catalyst as of and for the nine months ended September 30, 2023, included in Catalyst’s Quarterly Report on Form 10-Q (the “10-Q”) filed with the SEC on October 26, 2023 and
incorporated by reference; and
|
|
• |
the Annual Report filed with the SEC on March 27, 2024 and incorporated by reference.
|
Unaudited Pro Forma Condensed Combined Statement of Operations
For the Year Ended December 31, 2023
(in thousands, except per share data)
| |
|
|
|
|
Catalyst
Prior to the Contributions
|
|
|
Transaction Accounting Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses (income):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling and marketing expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquired in-process research and development
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GNI cost-sharing reimbursement
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss (gain) on disposal of assets, net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest and other income (expense), net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in fair value of warrant liability
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision for income taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to noncontrolling interest
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to common stockholders
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share attributable to common stockholders:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in calculating net loss per share attributable to common stockholders:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
|
1. |
Basis of Pro Forma Presentation
|
The unaudited pro forma condensed combined financial information was prepared in accordance with U.S. GAAP and pursuant to Article 11 of Regulation S-X. The unaudited pro forma condensed combined statement of
operations for the year ended December 31, 2023, gives effect to the Contributions as if they had been consummated on January 1, 2023, and has aggregated:
|
a) |
Catalyst’s operations for the nine months ended September 30, 2023 from the 10-Q, and
|
|
b) |
the Company’s consolidated operations from the Annual Report, which includes CPI’s operations for the year ended December 2023, and Gyre’s operations post-merger from October 30, 2023 to December 31, 2023.
|
The Company determined that there were no significant transactions within Catalyst from October 1 to October 30, 2023. The acquired assets and assumed liabilities upon closing of the Contributions were mainly
in-process research and development (“IPR&D”), in addition to the working capital. Therefore, no pro forma adjustments, other than weighted average shares outstanding and loss per share, were deemed necessary.
(A) The weighted average shares outstanding for the period has been calculated as if the Contributions occurred on January 1, 2023, including:
|
(1) |
the weighted average shares outstanding for common stock deemed issued to Catalyst upon closing of the Contributions, for the period from October 1 to October 30, 2023, adjusted for the 1-for-15 reverse stock split completed on October
30, 2023 (the “Reverse Stock Split”);
|
|
(2) |
the weighted average shares outstanding for common stock issued to certain minority shareholders upon the closing of the Contributions, for the period from October 1 to October 30, 2023, as adjusted for the Reverse Stock Split.
|
The Company’s Series A Convertible Preferred Stock, stock options and warrants are determined to be anti-dilutive and, therefore, were excluded from the diluted loss per share attributable to common stock calculation
because including them would have been anti-dilutive.
Calculation of Filing Fee Tables
Form S-3
(Form Type)
Gyre Therapeutics, Inc.
(Exact Name of Registrant as Specified in its
Charter)
Table 1: Newly Registered and Carry Forward Securities
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Security
Type
|
Security
Class
Title
|
Fee
Calculation
or Carry
Forward
Rule
|
Amount
Registered
|
Proposed
Maximum
Offering
Price Per
Unit
|
Maximum
Aggregate
Offering
Price
|
Fee
Rate
|
Amount of
Registration
Fee
|
Carry
Forward
Form
Type
|
Carry
Forward
File
Number
|
Carry
Forward
Initial
effective
date
|
Filing Fee
Previously
Paid In
Connection
with Unsold
Securities to
be Carried
Forward
|
|
Newly Registered Securities
|
|
Fees to Be Paid
|
Equity
|
Common stock, $0.001
par value per share(1)
|
Rule 457(o)
|
(1)
|
(2)
|
(3)
|
|
|
|
|
|
|
|
Fees to Be Paid
|
Equity
|
Preferred stock, $0.001 par value per share(1)
|
Rule 457(o)
|
(1)
|
(2)
|
(3)
|
|
|
|
|
|
|
|
Fees to Be Paid
|
Debt
|
Debt Securities
|
Rule 457(o)
|
(1)
|
(2)
|
(3)
|
|
|
|
|
|
|
|
Fees to Be Paid
|
Other
|
Warrants(1)
|
Rule 457(o)
|
(1)
|
(2)
|
(3)
|
|
|
|
|
|
|
|
Fees to Be Paid
|
Other
|
Units(1)
|
Rule 457(o)
|
(1)
|
(2)
|
(3)
|
|
|
|
|
|
|
|
Fees to Be Paid
|
Unallocated (Universal)
Shelf
|
Unallocated (Universal)
Shelf
|
Rule 457(o)
|
(1)
|
(2)
|
$150,000,000
|
0.00015310
|
$22,965.00
|
|
|
|
|
| |
Total Offering Amounts
|
|
$150,000,000
|
|
$22,965.00
|
|
|
|
|
| |
Total Fees Previously Paid
|
|
|
|
|
|
|
|
|
| |
Total Fee Offsets
|
|
|
|
$22,140.00
|
|
|
|
|
| |
Net Fee Due
|
|
|
|
$825.00
|
|
|
|
|
Table 2: Fee Offset Claims and Sources
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Registrant
or Filer
Name
|
Form
or
Filing
Type
|
File
Number
|
Initial
Filing
Date
|
Filing
Date
|
Fee
Offset
Claimed
|
Security
Type
Associated
with Fee
Offset
Claimed
|
Security
Title
Associated
with Fee
Offset
Claimed
|
Unsold
Securities
Associated
with Fee
Offset
Claimed
|
Unsold
Aggregate
Offering
Amount
Associated
with Fee
Offset
Claimed
|
Fee
Paid
with
Fee
Offset
Source
|
|
Rule 457(p)
|
|
Fee Offset Claims
|
Catalyst Biosciences, Inc.
|
S-3
|
333-253874
|
March 4, 2021
|
|
$16,365.00(4)
|
Unallocated (Universal Shelf)
|
Unallocated (Universal Shelf)
|
|
$150,000,000
|
|
|
Fee Offset Sources
|
Catalyst Biosciences, Inc.
|
S-3
|
333-253874
|
|
March 4, 2021
|
|
|
|
|
|
$16,365.00(4)
|
|
Fee Offset Claims
|
Gyre Therapeutics, Inc.
|
S-3
|
333-279822
|
May 30, 2024
|
|
$5,775.00(5)
|
Unallocated (Universal Shelf)
|
Unallocated (Universal Shelf)
|
(5)
|
$150,000,000
|
|
|
Fee Offset Sources
|
Gyre Therapeutics, Inc.
|
S-3
|
333-279822
|
|
May 30, 2024
|
|
|
|
|
|
$5,775.00(5)
|
|
(1)
|
The amount to be registered consists of up to $150,000,000 of an indeterminate amount of common stock, preferred stock, debt securities, warrants and/or units. There is
also being registered hereunder such currently indeterminate number of (i) shares of common stock or other securities of the registrant as may be issued upon conversion of, or in exchange for, convertible or exchangeable debt securities
and/or preferred stock registered hereby, or (ii) shares of preferred stock, common stock, debt securities or units as may be issued upon exercise of warrants registered hereby, as the case may be. Any securities registered hereunder may be
sold separately or as units with the other securities registered hereunder.
|
|
(2)
|
The proposed maximum aggregate offering price per unit will be determined from time to time by the registrant in connection with the issuance by the registrant of the
securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act of 1933, as amended (the “Securities Act”).
|
|
(3)
|
Estimated solely for purposes of computing the registration fee pursuant to Rule 457(o) under the Securities Act. In no event will the aggregate offering price of all
securities sold by the registrant from time to time pursuant to this registration statement exceed $150,000,000. No separate consideration will be received for (i) common stock or other securities of the registrant that may be issued upon
conversion of, or in exchange for, convertible or exchangeable debt securities and/or preferred stock registered hereby, or (ii) preferred stock, common stock, debt securities or units that may be issued upon exercise of warrants registered
hereby, as the case may be.
|
| |
|
|
(4)
|
The registrant (formerly known as “Catalyst Biosciences, Inc.”) has previously registered the offer and sale of up to $150,000,000 of securities pursuant to a
registration statement on Form S-3 (File No. 333-253874), which was initially filed with the Securities and Exchange Commission (the “SEC”) on March 4, 2021 and became effective on May 3, 2021 (the “May 2021 Registration Statement”). In
connection with the filing of the May 2021 Registration Statement, the registrant made a contemporaneous fee payment in the amount of $16,365.00. Of the $150,000,000 of securities registered under the May 2021 Registration Statement,
$150,000,000 of securities remains unsold (the “Unsold Securities”). Pursuant to Rule 457(p) under the Securities Act, the registration fee of $16,365.00 that has already been paid and remains unused with respect to the Unsold Securities is
hereby offset against the registration fee of $22,140.00 due for this offering. The offering that includes the Unsold Securities under the May 2021 Registration Statement is hereby terminated.
|
| |
|
|
(5)
|
The registrant paid a registration fee of $5,775.00 in connection with the registration of $150,000,000 of securities pursuant to a registration statement on Form S-3
(File No. 333-279822), which was initially filed with the SEC on May 30, 2024 (the “May 2024 Registration Statement”). The May 2024 Registration Statement was not declared effective by the SEC, and no securities were issued or sold
thereunder. The May 2024 Registration Statement was withdrawn by filing a Form RW on July 12, 2024. In accordance with Rule 457(p) under the Securities Act, the total amount of the registration fee due upon the initial filing of this
Registration Statement is offset by $5,775.00.
|
Gyre Therapeutics (NASDAQ:GYRE)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Gyre Therapeutics (NASDAQ:GYRE)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
